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University, Melbourne, Australia and Dr. G. V. Madhava Sharma, FNASc, Chief Scientist, 
Organic and Biomolecular Chemistry Division, CSIR-Indian Institute of Chemical 
Technology, Hyderabad, India for their guidance, constant encouragement and valuable 
suggestions throughout this course, which greatly enhanced my interest in the frontier area of 
science, their remarkable scientific abilities, hardworking, affectionate and friendly nature is 
always an inspiration for me towards achieving a good career. I am very much thankful for 
their unflinching support, affection, which helped me a lot in exploring my abilities and made 
it possible for me to carry out the present work which otherwise, would be very difficult. 
 
I take this opportunity to reveal my gratitude, regards and sincere thanks to Professor Suresh 
Bhargava and Dr. Lakshmi Kantham, who has given me the opportunity to join in this 
privileged RMIT-IICT programme 
 
It gives me immense pleasure to express my heartfelt thanks to Dr. Steven Priver for his 
support at RMIT University. 
 
It is indeed a privilege to associate myself with Dr. P. Radha Krishna, he deserves much 
more than a mere thanks for his support throughout my doctoral period. 
 
It gives me a great pleasure to express my thanks to collaborators Mr. B. Sudheer, Dr. R. S. 
Prakasham, Dr. Ramesh Ummaneni, Associate professor. Sanjay V. Malhotra, Dr Arumugam 
Nagalingam, Dr. Kathleen M. Cunningham, Associate professor Dipali Sharma, Mrs Sefaa Al 
Aryahi and Professor Peter McIntyre for their support throughout my work period. 
 
I take this opportunity to reveal my gratitude, regards and sincere thanks to my teachers Prof. 
Y. Jaya Prakash, Prof. Kondal Rao, Dr.Udaya Kumari, Dr. Sridevi, Mrs Malathi and Mrs 
VI 
 
Saritha whose inspiring teaching motivated me to this stage of education of doctoral research 
work. 
 
I am thankful to my senior colleagues  Dr. Venkat Reddy, Dr. T. Sridhar, Dr. A. Bhasker, Dr. 
A. Sreenivas, Dr. T. Anupama,  Dr. Venkata Ramana Doddi,  Dr. Sudhir Kashyap, Dr. D. 
Harinadachary, Dr. K. Rajender Reddy, Mrs. K. Anitha, Dr. A. Rajesh, Mrs. B. Veena, Dr. D. 
V. Ramana, Mr. P. V. Arun Kumar, Mr. K. Ramesh, Dr. T. Prashanth, Mr. G. Raju, Mr. N. 
Santhosh Reddy, Dr. B. Karunaker Reddy, Dr. P. Srinivas, Mr. B. Sudhakar, Dr. G. 
Venkateshwarlu, Mr. G.Srikanth, Mr. G. Anjaiah, Mr. M. Hanuma Sharma, Mr. H. 
Ravindranath, Mr. G. Sridhar, Mr. A. Ramesh, Mr. N. Rajesh, Mr. S. Prabhakar, Mrs. CH. 
Sravanthi, Mr. Nagaraju and Mr. Satyanarayana have rendered their assistance whenever 
needed without a selfish cause. 
 
It gives me a great pleasure to express my thanks to my colleagues at IICT, Mr. N. Ashok, 
Mr. Prasanna Kumar, V. Jayaram, M. Shiva Krishna, B. Venkataiah, M. Mahesh M. Ashok, 
Mr. M. Somanath, K. Mohan Rao and Mr. K. Dileep. 
 
It gives me a great pleasure to express my thanks to my friends at (RMIT-IICT) Dr. Srinivas 
reddy, Dr. Jampaiah, Dr. Praveen Kumar, Dr Hitesh Kulhari, Mr Srinivas, Mr Vijay, Ms 
Radha kumara and Mrs Shantipriya for their support throughout my PhD 
 
I am glad to express my thanks to my school friends Mr. V. Ashok, Mr. B. Mahesh, Mr. M. 
Raghu, Mr. E. Bhanuchander, Mr. P. Shivanand, Mr. A. Rajshekar reddy, Mr. G. Rajesh, Mr.  
B. Naveen, Mr. M. Bharath, Mr. P. Raghavenra prasad, Mr. S. Bharath, Mr. M. Manoj and 
Mr.  N. Naveen 
 
I would like to thank my colleagues at RMIT Mrs Anuradha, Ms Anushri, Mrs Hema patil, 
Dr. Deepa, Dr. Shalini Singh, Mr Christopher Plummer, Mr Aaron, Mr Duong Le and Mr 
Sam Jackson for their help and encouragement during the period of my research. 
 
I would like to thank the staff at IICT - Mr Ratan lal, Mr Naveen, Mohammad, Sudharshan 
and Bhanu as well as the staff at RMIT- Dr.Lisa Dias, Dr. Emma Goethals, Zahra Homan, 
Ruth, Kate, Howard, Karl Lang, Diane Mileo and Ryan for their help and assistance with the 
VII 
 
laboratory support. I would also like to thank Frank Antolasic for high resolution mass 
spectral analysis and crystal structure analysis, Julie Nierie and sunly for NMR analysis. 
 
I would like to add my special thanks to Dr. Selvakannan Periasamy for all his support in 
Australia  
 
I would like to thank Professor Denise Cuthbert, Professor Andrew Smith and Dr Simon Peel  
for their support in writing thesis. 
 
It gives me immense pleasure to express my heartfelt thanks to my close friends N. Shekar, 
B. Yogeshwar, A. Kishore, K. Suresh, M. Reddy Kumar and B. Hari Krishna for their 
support in my ups and downs, encouragement during the entire period of my research. 
 
I would like thank Mr C.G. Murali Mohan for his financial support during the period of post 
graduation.  
 
I owe more than myself to my beloved father K. Balaswamy, mother. K. Chandrakala dreamt 
that I reach golden heights and sky is the only limit to my success. My appreciation goes to 
my sister K. Radhika, her husband K. Srinivasulu, my brother K. Raghavender and his wife 
K. Laxmi Vanitha and K. Abhiram for their love that relieved, refreshed and rejuvenated to 
continue to take up the task.  
 
I would like to thank everybody who was important to the successful realization of this thesis 
and apologize for my inability to mention their names individually. 
 
Finally, I am thankful for giving me an opportunity to work towards my doctoral degree in 
CSIR-Indian Institute of Chemical Technology, Hyderabad and financial assistance from 
RMIT University in the form of Fellowship is gratefully appreciated. 
 
 
                                                                                        KANDIKONDA SURESH KUMAR 
 
 
VIII 
 
Abstract 
Organic azides and amine derivatives are of great importance in organic synthesis and play a 
vital role in diverse organic transformations, including the synthesis of various bioactive 
molecules, drugs and natural products. In Chapter 1 the properties of organic azides, earlier 
approaches for the synthesis of organic azides and amines from their corresponding alcohols. 
This chapter also discusses applications of organic azides in different fields, such as synthesis 
and biological importance of triazoles and non-natural amino acids.  
The alcohol functional group can serves as a potential electrophiles with respect to green 
chemistry principles. It is not a good leaving group, however activation/protonation of 
alcoholic oxygen makes it a better leaving group. In Chapter 2 the Zirconium tetrachloride 
(ZrCl4) catalysed conversion of carbinols into the corresponding azides (direct azidation) 
with azidotrimethyl silane (TMSN3) in acetonitrile at room temperature in a single step is 
discussed. This chapter also includes synthesis of novel triazole analogues from diverse azide 
scaffolds and their antimicrobial studies.  
Triazole drugs are widely used for the treatment of life‐threatening invasive fungal infections 
in cancer patients. In Chapter 3 the synthesis of new compounds that contain the 
1,2,3‐triazole moiety tethered to substituted vanillin or isovanillin is presented. In our 
synthesis, vanillin and isovanillin were first converted into cyclopentyl/cyclohexyl ethers and 
subsequently treated with methyl Grignard to give the corresponding carbinols. These 
carbinols, after reaction with TMSN3 and ZrCl4 gave the corresponding azides. Treatment of 
these azides with diverse acetylenes under Click chemistry conditions produced the final 
triazoles. The products were screened for their potential anticancer activity on 60 human-
cancer cell lines at a 10 μM dose. With the exception of two triazoles, most others had weak 
or no activity. The two active compounds exhibited strong inhibitory effects against different 
cell lines, with the highest inhibition against breast cancer panel. To elucidate the underlying 
molecular mechanisms involved, the clonogenic potential and anchorage‐independent growth 
of estrogen-receptor positive (MCF7 and T47D) and estrogen-receptor negative 
(MDA‐MB‐231 and MDA‐MB‐468) breast cancer cells respectively and the induction of 
apoptotic pathways were investigated. The results of these biological investigations were also 
presented.  
IX 
 
Organic allyl azides are a specific class of azides that are intermediates in various organic 
reactions. They are easily converted into corresponding allylamines that have many 
applications in the field of medicinal chemistry and for the synthesis of natural products. 
Allyl alcohols are the readily available starting materials for conversion into corresponding 
azides. In Chapter 4 the synthesis of various allyl azides from the corresponding aryl vinyl 
carbinols through a novel rearrangement of the vinyl double bond using a ZrCl4- catalysed 
conversion of diverse aryl vinyl carbinols with TMSN3 in CH3CN at room temperature is 
presented. Furthermore, a rare class of non-natural γ4-amino acids with a carbohydrate side 
chain has been synthesised using this strategy. Non-natural amino acids are unique and they 
offer advantages over the natural amino acids in the site of specific bioconjugation reactions. 
Earlier research on tryptamines has indicated it they have good activity against a Transient 
Receptor Potential Vanilloid (TRPV) channel, which led to the design of selective amine 
derivatives with modifications of the tryptamine side chain. To date, 28 mammalian TRP 
channels have been characterised. The majority of the TRP channels are non-selective cation 
channels expressed on the cell membrane, and many of them exhibit high permeability for 
Ca2+. They moderate sensory functions such as vision, taste transduction, temperature 
sensation and pheromone signalling as well as homeostatic functions such as divalent cation 
flux, hormone release and osmoregulation. In Chapter 5 TRPV channel classification, its role 
in skin, brain and hair in the human body, the drugs so far developed for TRPV3 activity and 
the synthesis of selected amine derivatives as potential TRPV3 antagonists and their 
functional assay is presented. Conclusion and future work are briefly summarised in     
Chapter 6. 
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1.1 Importance of azides and amines in organic synthesis 
 
Azide and amine functionalities play very important roles in organic synthesis. The amine 
group has been extensively utilised in the form of acid-to-amine coupling reactions, reductive 
aminations and natural product synthesis. Likewise, organic azides1 are high-potential 
functional groups to perform various useful reactions in organic synthesis. Peter Grieß2 
discovered these molecules in mid-18th century. Organic azides have many applications3 in 
various fields, including biology, chemistry, material science and medicine. Transformation 
of azides into amines is the easiest process, as amines have a broad range of applications in 
the synthesis of medicinally active compounds.  
 
Aryl azides and alkylazides4 have gained attention after the discovery of phenyl azide (in 
1864) and hydrogen azide (1890), which was expanded during 1950 to 1960. Generally, 
organic azides,5 which are important compounds for the synthesis of triazoles and tetrazoles, 
find many applications in the field of medicinal chemistry. Particular interest is on a 5-amino 
analogue of thymidines,6 which are active in the replication of the herpes simplex virus in cell 
cultures.7 Despite their hazardous explosive nature, organic azides have many applications in 
various organic transformations8,9 such as the conversion of 1,3 dipolar cycloadditions to 
triazoles and as precursors for nitrenes and amines.  
 
1.2 Early approacbybutyhes toward the transformation of the C-O to the C-N bond. 
 
Alcohols are readily available starting materials that can be easily converted into the 
corresponding azides and amines. Some previous approaches that involve the conversion of 
carbinols to corresponding azides are listed as follows.  
 
1.2.1 Synthesis of azides through the Mitsunobu reaction 
  
One of the first methods used for the conversions of alcohols to azides was the Mitsunobu 
reaction,10 which involves the conversion of alcohols to the corresponding azides in the 
presence of Ph3P, DEAD and HN3 with inversion of stereochemistry. Lee et al.
11 applied the 
Mitsunobu reaction conditions for the preparation of azide 2 from the corresponding carbinol 
1 (Scheme 1.1).  
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Scheme 1.1  
 
 
 
 
 
Thompson et al 12 proposed a practical procedure for an alternative to Mitsunobu conditions 
for the synthesis of azide 4 from carbinol 3 in the presence of Ph3P, DEAD and 
Diphenylphosphryl azide (DPPA) with 97%ee along with traces of elimination product 4a 
(Scheme 1.2).  
 
Scheme 1.2  
 
 
 
  
 
1.2.2 Synthesis of azides using NaN3-BF3.Et20  
 
Kumar et al13 proposed a convenient method for the conversion of diverse carbinols to 
azides with NaN3 and BF3.Et2O in 1,4 dioxane at 80-90 °C (Scheme 1.3).  
 
Scheme 1.3 
 
 
 
 
However, saturated aliphatic alcohols were unreactive even after prolonged heating in 
dioxane. These reaction conditions selectively convert secondary allylic or benzylic alcohols 
to give corresponding azides without affecting other types of OH groups in the molecule.  
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1.2.3 Synthesis of azides from alcohol derivatives 
 
1.2.3.1 Diphenylphosphonites for azide synthesis 
 
Kurada and coworkers14 reported that secondary and tertiary alkyl diphenylphosphonites (A) 
(Scheme 1.4) can be prepared from the corresponding alcohols, which on further treatment 
with methoxy benzoquinone (MBQ) and TMSN3 in chloroform at −45 °C produces the 
corresponding azides in good yields.  
 
Scheme 1.4  
 
 
 
 
1.2.3.2 Mesylate derivatives for azide synthesis 
 
Manohar et al.15 reported the use of mesylate as an activating group of alcohols for the 
preparation of azides with NaN3 in dimethyl formamide (DMF) in 85% to 90% yields. 
(Scheme 1.5).  
 
Scheme 1.5 
 
 
 
 
 
 
1.2.4 Preparation of azidesfrom 1-(p-toluenesulfonyl)imidazole (TsIm) 
 
Rad and coworkers16 investigated the transformations of various alcohols into azides using 1-
(p-toluenesulfonyl)imidazole (TsIm) in the presence of NaN3, triethylamine (Et3N) and 
catalytic amounts of tetra-butylammonium iodide in DMF (Scheme 1.6).  
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Scheme 1.6 
 
 
 
 
 
 
1.2.5 Using palladium-catalysed reactions for  synthesis of azides 
 
Sreedhar et al.17 (Scheme 1.7) reported a simple method for the conversion of homoallyl 
alcohols to allyl azides using 3 mol% of PdCl2 and 1.2 equiv. of TMSN3 in CH2Cl2.  
 
Scheme 1.7  
 
 
 
 
 
1.2.6 Oxidative transformation of alcohols to azides 
Prabhu et al.18 investigated the preparation of azides from cinnamyl alcohol 7 using 
Cu(ClO4)2.6H2O in the presence of various oxidants. Use of 2,3-Dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) as oxidant furnished quantitative yield of corresponding nitrile 8, 
whereas chloranil as the oxidant afforded a mixture of nitrile 8 (32%), azide 9 (14%) and 
aldehyde 10 (32%) (Scheme 1.8).  
 
Scheme 1.8 
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1.3 Various synthetic transformations of the C-O bond to the C-N bond 
 
1.3.1 Transformations of the C-O bond to the C-N bond involving π-allyl complexes 
 
Substitution reactions of activated allylic alcohol derivatives using transition metal catalysts19 
with nitrogen atom nucleophiles are one of the most controlled and reliable methods of 
preparing allylamines. Mashima and coworkers20 reported the synthesis of allylamines using 
1 mol% of a Pt-DPEphos complex (Scheme 1.9). This reaction proceeds through π-allyl 
intermediate complex and forms the product. 
Scheme 1.9 
 
 
 
 
 
 
 
 
1.3.2 Lewis acid-catalysed transformation of the C-O bond to the C-N bond 
 
1.3.2.1 Gold-catalysed transformation of the C-O bond to the C-N bond  
 
Widenhoefer et al.21 developed a method of C-N bond formation using a gold catalyst, in 
which allyl alcohol 12 (96% ee) was converted to urea 13 (91% ee) and urea 14 (>95%) using 
methylimidazolidin-2-one 11 and its associated nucleophiles (Scheme 1.10).  
 
Scheme 1.10  
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These reactions occur via secondary π-activation reaction pathways or via Lewis acid 
catalysis that involves carbocationic intermediates with a high regio and syn stereo-
selectivity. 
 
1.3.2.2 Calcium-catalysed transformation of the C-O bond to the C-N bond 
 
Niggemann and co-workers22 reported the conversion of -activated alcohols to amides by 
using calcium salts as Lewis acid catalyst and various amides as a nitrogen source. Thus, the 
reaction of allylic alcohol 15 with phenyl carbamate 16 in the presence of 5 mol% of 
Ca(NTf2)2 as a catalyst and 5 mol% Bu4NPF6 as an additive gave the amide 17 in 89% yield 
(Scheme 1.11).  
 
Scheme 1.11 
 
 
 
 
1.3.3 Transformations of the C-O bond to the C-N bond involving nucleophilic 
substitution 
 
1.3.3.1 Iridium-catalysed transformation 
 
Carreira and coworkers23 reported the application of sulfamic acid (H2NSO3H) as the 
nitrogen source for the conversion of allyl alcohols to corresponding allyl amines in the 
presence of an iridium catalyst and the novel phosphoramidite-olefin ligand24 (Scheme 1.12).   
 
 Scheme 1.12 
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In this reaction, the allyl alcohol forms an iridium allyl species and then undergoes 
nucleophilic substitution to form the corresponding allyl amine in high yields. 
 
1.3.3.2 Silver-catalysed transformation 
 
Rueping et al.25 investigated the use of various metal salts for the azidation of allylic alcohol 
18 and indicated that AgOTf afforded the desired allylic azide 19 in high yields (88%) with 
chemoselectivity (Scheme 1.13). The use of AgNTf2 afforded the corresponding azide as the 
major product through nucleophilic substitution along with traces of silyl ether 19a 
 
Scheme 1.13  
 
 
 
 
 
 
 
1.3.3.3 Bismuth-catalysed transformations 
 
Shibasaki et al26 proposed that bismuth salts could be Lewis acid catalysts for the conversion 
of allylic alcohols to the corresponding allylic amines from propargylic, allylic and benzylic 
alcohols with nucleophiles such as carbamates, sulfonamides and carboxamides (Scheme 
1.14 and Figure 1.1). The reaction of allyl alcohol 20 with tosylamide in the presence of 
bismuth salt (Bi(OTf)3) and additive KPF6 undergoes nucleophilic substitution and affords 
the allyl amine 21 in 94% yield. 
 
Scheme 1.14 
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1.4 Reactions of organic azides  
 
Azides are dipolar in nature and capable of reacting with electrophiles and nucleophiles. The 
reactivity of the azides varies according to the reactivity of the other components involved in 
the reaction. All possible resonance structures of azides were shown in Fig 1.1. For example, 
N1 of the azide structure reacts with electrophile and N3 of the azide reacts with 
nucleiophille in structure IV 
 
 
 
 
 
Figure 1.1: Reactivity of azides. 
 
Azides are considered to be the most important starting material for the formation of 
triazoles. In the Huisgen reaction,27 the cycloaddition of dipoles with dipolarophiles results in 
the formation of triazoles, in which the azides act as a dipole (Figure 1.1), and acetylene acts 
as dipolarophile in the formation of triazoles. The cycloaddition takes place at different rates 
based on the nature of dipolarophile.  
 
1.4.1 Synthesis of 1, 2, 3-triazoles using organic azides 
 
The Click reaction is the reaction of azides with alkynes in the formation of triazoles, from 
the independent investigations of Meldal and Sharpless,28 that leads to the rapid advancement 
in triazole chemistry. These reactions have found wide applications in the synthesis and 
medicinal chemistry. These reactions are amongst a number of efficient and reliable 
processes now known as “click chemistry”. (They are discussed in detail in Section 1.6.) 
 
1.4.2 Synthesis of 1,2,3,4-tetrazole using organic azides 
 
Tetrazoles29 are considered to be the most important building blocks and target structures in 
organic chemistry because of their resistance to acids and bases. Tetrazoles can be 
synthesized directly by a [3+2] dipolar cycloaddition between an organic azide and a nitrile. 
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They have important applications in pharmaceuticals because of their lipophilic nature 
compared with corresponding carboxylic acids and their metabolic stability (Figure 1.2). 
Some tetrazoles such as losartan 2230a exhibit antihypertensive properties; biphenyl tetrazoles 
2330b stimulate the release of the growth hormone. Furthermore, tetrazoles 24 and 25 inhibit 
metalloproteases, and 26 acts as a chloride-channel effector. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Tetrazoles in pharmaceuticals. 
 
1.4.3 Reactions of organoazides with other dipolarophiles 
 
The organic azides can react with allyl cations31 to form dihydro-triazine compounds, 
whereas azides in intermolecular Schmidt reactions with carbocations can form fused 
azabicyclic structures and bridged compounds (Scheme 1.15). 
 
Scheme 1.15 
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1.5 1,2,3-Triazoles  
 
 1.5.1 1,4-disubstituted 1,2,3-triazoles: The Click reaction 
 
The click reaction is said to be the preparation of 1,4-disubstituted 1,2,3-triazoles32a-c by the 
coupling of terminal alkynes and organic azides using a copper (I) salt as a catalyst. This 
reaction is easy to perform and convenient for separating pure products. 
 
Scheme 1.16  
 
An excess amount of sodium ascorbate was added to avoid the formation of cross- coupling 
products in the reaction (Scheme 1.16). In another method, a copper wire replaced the metal 
catalyst and the Cu(I) catalyst was generated in the reaction through the disproportionation 
reaction of the Cu (II)/Cu (0) couple. This method is suitable for the synthesis of specific 1,4-
substituted triazoles, whereas ruthenium(II) complexes32d in azide-alkyne cycloaddition 
produces selective 1,5 disubstituted triazoles.  
 
 1.5.2 Pharmacophore characteristics of 1,2,3-Triazoles 
 
The demand for the synthesis of 1,2,3-triazoles from azides and acetylenes using copper(I)-
catalysed reactions has increased. Since, triazoles can bond with different receptors in 
biological systems through non-covalent, dipole and hydrogen-bonding interactions and can 
perform various biological activities in pharmaceutical field for the discovery of drugs.33  
 
1.5.2.1 1,2,3-triazole activity in various biological fields 
 
Even though there are active drugs in the market, many of them have drawbacks such as 
toxicity and weak potency. This situation demands the researchers to find the new class of 
drugs.34 Molecules with triazole as a substructure was considered as one of these classes. 
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TSAO35a is a drug that treat against HIV that controls the replication of HIV genetetic 
material by inhibiting the reversetranscriptase enzyme. Tazobactam is a drug that controls the 
β-lactamase enzyme that contributes to resistance against the β-lactam antibiotic. Likewise, 
cefatrizine35b and carboxyamidotriazole (CAI)35c are some examples to illustrate  that these 
triazoles are biologically active (Figures 1.3 and 1.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.3:  1,2,3-triazoles as pharmaceutical drugs. 
 
 
 
 
 
 
 
 
                    
      
    
 
 
Figure 1.4: Various medicinal applications of 1,2,3-triazole compounds 
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1.5.2.2 Triazoles as antifungal agents 
 
The usage of antifungal agents has increased rapidly in the last decade. However, the present 
available drugs on the market are lagging behind due to some drawbacks such as toxicity and 
unsuitable for long-term usage. Microorganisms develop resistance against available drugs 
and makes drugs functioning inactive on various diseases. This situation greatly concerns 
researchers to find the new classes of antimicrobial agents and led to the synthesis of novel 
triazole compounds that are active against fungal infections. Fluconazole/bile acid36 
connected with 1,4-disubstituted 1,2,3-triazoles 33 and 34 are novel compounds, which 
demonstrated excellent antifungal activity against Candida species with  minimum inhibition 
concentration (MIC) values in the range of 3.12 to 6.25 mg/mL (Figure 1. 5). 
 
 
 
 
 
 
Figure 1.5: Fluconazole-based novel triazoles 
 
1.5.2.3 Triazoles as anti-tuberculosis agents  
 
Tuberculosis (TB) is a widely spread infectious disease caused by mycobacterium tuberculosis strains. 
Somu and coworkers37 reported the preparation of nucleoside 35, which has exhibited good 
results against TB by inhibiting the mycobacterium (Figure1.6). Costa and coworkers38 
reported two different triazole derivatives 36a and 36b with antimycobacterial profiles.  
 
 
 
 
 
Figure 1.6: Triazole compounds with antimycobacterial activity 
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1.5.2.4 Triazoles as HIV protease inhibitors 
 
Saito et al.39 reported that the carbocyclic and phosphonocarbocyclic analogues of ribavirin 
37 act as anti-Hepatitis C Virus (HCV) inhibitors. These compounds were evaluated against 
the HCV and screened against different viruses to find their range of antibacterial activity 
with other viruses.  
 
 
 
 
 
 
Figure 1.7: HIV Protease Inhibitors 
 
Mohapatra and coworkers investigated the design and synthesis of novel four-membered 
cyclic scaffolds that include the union of a proline-1,2,3-triazole ring and [1,4]-
benzodiazepin-8 (4H) one-ring system.40-42 The series of compounds 38 (Figure 1.7) has 
been found to exhibit good activity for protease inhibition.  
 
1.5.2.5 Triazoles as anticancer compounds 
 
Cancer is a disease that can be considered as a group of diseases associated with abnormal 
cell growth in certain parts of the human body that gradually spreads to other parts. The 
tubilne structure43a has great importance in inhibiting the cancer and its related diseases. This 
structure disturbs the biological processes that are responsible for the growth of cancer cell 
lines. Generally, compounds with a tublin appearance look complex in physical structure and 
difficult to synthesise. However, Manach et al.43b prepared the taxol substitute 39 by click 
chemistry, which can display cytotoxic properties.  
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Figure 1.8: Anticancer bioactive compounds. 
 
4-aryl-5cyano-2H-1,2,3-triazoles 40 (Figure 1.8), which bear a variety of groups on the 4-
phenyl ring, were prepared by Cheng et al.43c These compounds were found active against 
MDA-MB-453 breast-cancer cell lines by inhibiting HER2 tyrosine kinase phosphorylation. 
 
1.5.2.6 Triazoles as antibacterial agents 
 
Phillips et al.44 synthesised a series of 5-substituted oxazolidinone with varying substitution 
at the 5-position of the oxazolidinone ring and investigated their antimicrobial properties. A 
novel compound PH-027 exhibited comparable activity to that of the existing drugs, 
Linezolid and Vancomycin, towards antibiotic-susceptible resistant strains of gram-positive 
bacteria (Figure 1.9). In the present study, some novel triazoles have been synthesised, and 
their antibacterial and anticancer properties investigated. 
 
 
 
 
 
                                
 
 
Figure 1.9: Antibacterial triazole compounds. 
 
1.6 Synthesis of sugar amino acids from organic azides 
 
 
The carbohydrate moiety contains an amine, and acid groups are considered to be sugar 
amino acids. Sugar azides are the best starting materials to prepare such amino acids by 
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reduction45 of azides. Gruner et al.46 stated that preparation of sugar amino acids can be 
achieved using sugar azides.  Since, sugar amino acids are not commercially available, which 
gains the importance of sugar organic azides.  
 
1.6.1 Alpha amino acids 
 
Scheme 1.17  
 
 
 
Early reports47 on stereoselective ylide-based approaches suggest that N-Boc R-amino amide 
45 (Scheme 1.17) was prepared by the substitution of the hydroxy functionality in 43 with an 
azido functional group 44 and subsequent reduction with PPh3. 
 
1.6.2 Beta and gamma amino acids 
 
The synthesis of these sugar amino acids that was less expensive than the previous synthesis 
was reported.48  
 
Scheme 1.18 
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The synthesis of the β-SAA 46 and γ-SAA 47 was achieved by Gruner et al.49 (Scheme 1.18) 
through the conversion of carbinol 48 to azide 49, which on further deprotection with acetic 
acid yielded diol 50. Oxidative cleavage of 50 gave acid 51. Reduction of compound 51 with 
Pd/carbon in the presence of H2 atmosphere furnished the corresponding amine 46, which on 
further protection with the Fmoc group gave β amino acid 46a. Likewise, compound 50 on 
reduction gave the corresponding amine, which on further protection with Fmoc gave 52. 
Oxidation of 52 achieved γ-amino acid 47. Fleet and coworkers50 investigated the preparation 
of sugar azides that can be utilised as key intermediates for the synthesis of β- and γ-SAAs 
(Figure 1.10), in which the azide 53 was used for the synthesis of β-SAA, and sugar azides 54 
and 55 for γ-SAA. In the present study, some sugar azides have been synthesised, and 
attempts have been made to convert them into the corresponding non-natural amino acids.  
 
 
 
 
 
 
Figure 1.10: Sugar azide intermediates for the synthesis of β- and γ-SAAs. 
 
1.7 Objectives of the present study 
 
The development of novel reaction conditions for the direct formation of the C-N bond from 
the C-O bond is a crucial transformation in the field of organic chemistry. The amine 
functional group has a broad range of applications in the field of organic chemistry and 
medicinal chemistry. The research proposal was to initiate work to transform the C-OH bond 
into the C-N bond and to extend the study to synthesise potentially potent molecules such as 
triazoles, amino acids and amine derivatives. The overall work of the present study is divided 
into six chapters as follows. 
 
Chapter I: This chapter gives a general introduction to various reports for the transformation 
of the C-O bond to the C-N bond, the role of organic azides in organic chemistry, triazole 
derivatives and the importance of non-natural amino acids. 
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Chapter II: This chapter describes the brief history of antibiotics, ZrCl4-catalysed 
transformation of known carbinols to azides using TMSN3 as an azide source, the click 
chemistry of azides and antimicrobial properties of synthesised azides and triazoles. 
 
Chapter III: This chapter summarises the synthesis of novel compounds that contain 
the1,2,3‐triazole moiety tethered to substituted vanillin or isovanillin and their cytotoxicity 
studies. 
 
Chapter IV: The focus of this chapter is to synthesise various allyl azides from the 
corresponding aryl vinyl carbinols through a novel rearrangement of the double bond and to 
synthesise a rare class of non-natural amino acids. 
 
Chapter V: The objective of this chapter is to synthesise selected amine derivatives for the 
development of novel TRPV3 agonists to overcome pain. 
 
Chapters VI: This chapter briefly summarises the present study and related future work.  
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The present study describes the use of ZrCl4,
1a
 which was utilised for diverse synthetic 
transformations as a Lewis acid for the conversion of the C-O bond into the C-N bond. A 
variety of carbinols were prepared by a simple Grignard reaction and converted into the 
corresponding azides with TMSN3 in the presence of 10 mol% of ZrCl4
1b 
 
2.1 Introduction  
 
The alcohol functionality, an attractive source of electrophiles in view of green chemistry 
principles,2a is not a good leaving group; hence, derivatisation often becomes important for its 
facile displacement.2b Several methods have been reported3,4 for the direct nucleophilic 
substitution of alcohols, but they generally suffer from drawbacks such as elevated 
temperatures, long reaction times and stoichiometric use of reagents. The development of 
newer methods for the direct conversion of the C-OH bond into a C-NR1R2 bond gains 
significance since the amino group is very common in many natural products and 
pharmaceutically important compounds.5 The azide group is a direct source of amines, in 
addition to its stability and reactivity in click chemistry6 and bioconjugation.7 The most 
common method for its synthesis is the Mitsunobu reaction8 of alcohols with HN3 or its 
analogues.9 Other C-N bond forming reactions include a two-step conversion of an alcohol to 
an azide through a mesylate,10a the palladium-catalysed hydroazidation of homoallyl 
alcohols10b and the gold-catalysed direct amination of benzhydryl alcohols.10c In this project, 
carbinols are converted into the corresponding azides and further transformed into 1,4-
disubstituted 1,2,3-triazole analogues, and both the classes of compounds have been 
investigated for their antimicrobial activity.  
 
2.2 Antibiotics history - a brief account 
 
There are several antibiotics that are currently available in the market, and each therapeutic 
agent has its own history of discovery. Acquaah-Harrison11 stated that the discovery of 
antibiotics became most popular in the twentieth century with the increase in awareness about 
antibacterial activity and infections towards identified diseases.12 Consequently, the lifespan 
of human beings has increased greatly, which is reflected in the rise of sales13 for oral 
antibiotics in 2005 for the United States. Before the advent of modern medicine14 such as 
antibiotics, there was historical evidence that the Chinese people were using naturally 
available materials such as tree barks and herbs as medicine.15 Even though, naturally 
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available medicine provides relief from various diseases, people do not know the exact 
mechanism of activity of the natural products. Later, with the discovery of various 
developments in antibiotics,16 bacterial resistance towards various therapeutic agents was 
analysed. The majority of the antibiotics were classified into two categories: natural and 
synthetic products. Generally, natural antibiotics were biosynthesised from microorganisms 
through the fermentation process.17a,b Natural antibiotics18 have been classified into β-
lactams, aminoglycosides, polyketides and macrolides. These are in widespread use in 
medicine in the world compared to synthetic antibiotics. Synthetic antibiotics were prepared 
through the industrial fermentation,17c the process involves the growth of a particular 
microorganism in a culture medium such as nutrient broths or agar plates. Suitable conditions 
were applied for yield maximisation by maintaining pH, oxygen percentage, temperature and 
nutrient levels. After completion of the process, antibiotics were extracted using organic 
solvents. The synthetic antibiotics were developed through serendipity and also through 
rationally designed approaches. Since the 1930s, there are now three families of synthetic 
antibiotics19: sulfonamides, quinolones and oxazolidinones.  
 
Similarly, triazoles have a high degree of reliability, complete specificity and 
biocompatibility.20 These scaffolds are found in a number of biologically active compounds 
that exhibit various antibacterial activities.21 The construction of a triazole ring from the 
copper(I)-catalysed6 azide and terminal acetylene reaction is a powerful tool for the 
generation of privileged medicinal scaffolds. So, it was planned to design and synthesis of 
azides and convert them in to novel 1,4-disubstituted 1,2,3-triazoles and then to investigate 
their antimicrobial properties. 
 
2.3 Results and Discussions 
 
This chapter describes a study in continuation of interest on the catalytic applications of ZrCl4 
as a Lewis acid for various organic transformations.  Herein, the ZrCl4 catalysed conversions 
has been disclosed, which  involves the synthesis of azides 6-10 from corresponding known 
carbinols 1-5 with ZrCl4 as Lewis acid catalyst and TMSN3 as nucleophile at room 
temperature. Azides 6-10 were further converted to diverse triazoles 6a-d -10a-d, 
respectively, and these were further studies for the antimicrobial properties.’’ 
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Accordingly, carbinol 1 was subjected to 6 with TMSN3 in the presence of ZrCl4 (10 mol%) 
in different solvents to determine the optimal solvent (Scheme 2.1). The reaction of carbinol 
1 in CH3CN gave the desired azide 6 in 90% yield, as indicated in Table 1. By contrast, the 
same reaction in anhydrous CH2Cl2 gave azide 6 in 38% yield. Meanwhile, the reaction of 1 
in toluene or 1,4-dioxane afforded the azide 6 in low yields along with significant amounts of 
the corresponding TMS ether 1A. However, a reaction in nitro methane afforded similar 
yields of azide to that of CH3CN, with no evidence of the formation of 1A. Based on these 
results, CH3CN was used for all subsequent reactions. As the next step, carbinol 1 was treated 
with different mol% of ZrCl4, as indicated in Table 2.1. The amount of the ZrCl4 catalyst was 
also varied (5, 10, and 15 mol%) to determine the optimal concentration. The highest yield of 
the azide product from the reaction between 1 and TMSN3 in CH3CN was obtained using 10 
mol% of ZrCl4 (Table 2.1).  
 
Scheme 2.1 
 
 
 
Furthermore, a comparative study on the conversion of carbinol 1 to azide 6 was conducted 
using NaN3 in the presence of ZrCl4 (10 mol%) in different solvents. The results clearly 
indicate that TMSN3 is superior to NaN3 for the conversion of carbinols to azides (Table 
2.1b). 
Table 2.1: Comparative study of reagents in various solvents. 
The ratio of ZrCl4 a = 5 mol%, b = 10 mol%, and c = 15 mol% 
Solvent No. 
 
Solvent           Yields (%) 
TMSN3/ZrCl4 NaN3/ZrCl4 
6 1A 6 1 
1 CH2Cl2 38 - 26 74 
2 Toluene 24 68 22 78 
3 1,4-dioxane 15 74 19 81 
4 CH3CN
a 73 - 12 88 
5 CH3CN
b 90 - 20 80 
6 CH3CN
c 61 - 14 86 
7 CH3NO2 79 - 19 81 
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Having established the optimal reaction conditions, independent treatments of carbinols 1-5 
with ZrCl4 (10 mol %) in CH3CN at room temperature for 0.5 h afforded respective azides   
6-10 (Scheme 2.2.1 to 2.2.5).  
 
Scheme 2.2.1 
 
 
 
 
The carbinol 1 was sequentially treated with azidotrimethylsilane and ZrCl4 in acetonitrile 
and stirred at 0 °C to room temperature for 30 min furnished 6 in 90% yield. The 1H NMR 
spectrum of azide 6 indicated aryl protons resonating at  7.35 and 7.32 as multiplets that 
integrate to two and three protons each, respectively, and the other aryl protons resonating at 
 7.21, 6.88 as a doublet and a doublet of a triplet that integrated to two protons each 
respectively. Benzylic CH proton resonating at  5.67 as a singlet and methoxy protons 
resonating at  3.97 as a singlet indicates the formation of 6. In the IR spectrum of 6, the 
strong absorbance peak at 2091 cm-1 confirms the presence of azide functionality. The mass 
spectrum of azide 6 has found to be 197 as (M+-N3). 
 
Scheme 2.2.2 
 
 
 
  
The carbinol 2 was sequentially treated with azidotrimethylsilane and ZrCl4 in acetonitrile 
and stirred at 0 °C to room temperature for 30 min afforded 7 in 89% yield. In the 1H NMR 
spectrum of 7, revealed aryl protons resonating at  7.21 as a doublet,  6.86 as a multiplet,  
6.81 as a multiplet that integrated to two, three and two protons each respectively. Alcohol 
proton resonating at  5.61 as a broad singlet, benzylic CH proton resonating at  5.58 as a 
singlet and methoxy protons resonating at  3.88 and  3.80 as singlets that integrated to three 
protons each indicates the formation of 7. In the IR spectrum of 7 strong absorbance peak at 
2091 cm-1 confirms the presence of azide functionality. In mass spectrum of azide 7 has 
found to be 243 as (M+-N3)  
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Scheme 2.2.3 
 
 
 
 
 
The carbinol 3 was sequentially treated with azidotrimethylsilane and ZrCl4 in acetonitrile 
and stirred at 0 °C to room temperature for 30 min gave 8 in 90% yield. In the 1H NMR 
spectrum of 8, indicated aryl protons resonating at  7.86 as a multiplet,  7.65 as a doublet,  
7.51 as a multiplet,  7.44 as a multiplet,  7.25 as a multiplet and  6.86 as a multiplet that 
integrated to three, one, one, two, two and two protons each respectively. Benzylic CH proton 
resonating at  6.34 as a singlet and methoxy protons resonating at   3.77 as a singlet 
indicates the formation of 8.  In the IR spectrum of 8 strong absorbance peak at 2093 cm-1 
confirms the presence of azide functionality. In mass spectrum of azide 8 has found to be 262 
as (M+-N2 +H)  
 
Scheme 2.2.4 
 
 
 
 
The carbinol 4 was sequentially treated with azidotrimethylsilane and ZrCl4 in acetonitrile 
and stirred at 0 °C to room temperature for 30 min gave 9 in 87% yield. In the 1H NMR 
spectrum of 9, revealed aryl protons resonating at  7.25 as a doublet,  6.90 as a doublet that 
integrated to two protons each respectively. Benzylic CH proton resonating at  4.56 as a 
singlet, methoxy protons resonating at  3.81 as a singlet and methyl protons resonating at  
1.5 as a doublet that integrated to three protons indicates the formation of 9. In the IR 
spectrum of 9 strong absorbance peak at 2096 cm-1 confirms the presence of azide 
functionality. In mass spectrum of azide 9 has found to be 192 as (M+-N2 +H)  
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Scheme 2.2.5 
 
 
 
 
The carbinol 5 was sequentially treated with azidotrimethylsilane and ZrCl4 in acetonitrile 
and stirred at 0 °C to room temperature for 30 min afforded 10 in 82% yield. In the 1H NMR 
spectrum of 10, indicated aryl protons resonating at  7.23 as a doublet,  6.91 as a doublet 
that integrated to two protons each respectively. Benzylic CH proton resonating at  4.42 as a 
triplet, methoxy protons resonating at  3.81 as a singlet. Rest of the proton signals appeared 
at the expected chemical shifts. In the IR spectrum of 10 strong absorbance peak at 2091 cm-1 
confirms the presence of azide functionality. In mass spectrum of azide 10 has found to be 
135 as (M-N3)  
 
2.4 Antimicrobial studies 
 
2.4.1 Antimicrobial activity of azides 
 
Azides are energy-rich molecules with many applications24 and are known for their biocidal 
properties. Azides 6-10 were evaluated for their antibacterial activity using the agar-well 
plate method against four bacterial cultures, viz. Escherichia coli, Klebsiella pneumonia, 
Bacillus subtilis and Micrococcus luteus, and compared with the antibacterial activity of 
streptomycin sulphate (Himedia) after incubation at 37 °C for 24 h. The antibacterial activity 
was evaluated by measuring the inhibition zone formed around the wells at a concentration of 
100 µg/mL. Wells containing sterile water and a solvent (DMSO) were used as controls. The 
data revealed that azides 7 and 8 were active against all the test cultures studied (Table 2.2), 
while the remaining azides (6, 9 and 10) indicated no activity. Analysis of the inhibition zone 
data for azides 7 and 8 revealed a 50-55% antibiotic activity, indicating they are less potent 
than the streptomycin sulphate reference. Having found two of the five azides exhibited 
antibacterial activity, it was proposed to convert the corresponding 1,4-disubstituted 1,2,3-
triazoles to further evaluate their antibacterial activity. 
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Table 2.2: Antimicrobial activity of azides 
 
1,2,3-Triazoles can be prepared by the Huisgen 1,3-dipolar cycloaddition reaction,25 and 
these triazoles exhibits a wide range of biological applications that make them very attractive 
targets. Click chemistry reaction conditions were adopted to azides and acetylenes to obtain 
the 1,4-regioisomers26 of triazoles using Cu (I) as a catalyst. Each of the five azides 6-10 was 
independently treated with four acetylenes, viz 11a-d, to afford the 1,4-disubstituted triazoles 
6a-d to 10a-d, respectively. All the triazoles were characterised by spectral and analytical 
methods. 
 
Scheme 2.3.1 
 
 
 
 
 
Azide 6 on reaction with phenyl acetylene 11a in the presence of CuSO4.5H2O and sodium 
ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 6a in 95% 
yield (Scheme 2.3.1). The 1H NMR spectrum of 6a indicated aryl protons resonating at  
7.81, 7.33, 7.12 and 6.91 as multiplets that integrated to two, six, four and two protons each, 
respectively. Triazole protons resonating at  7.6 as a singlet, benzyl protons resonating at 
Entry Aryl azides Zone of growth inhibition (mm) 
E. coli 
 
M. luteus 
 
K. 
pneumonia 
B. subtilise 
 
1 6 
0.00  0.00 0.00 0.00 
2 7 14.33 ± 0.58 16.33 ± 0.58 15.67 ± 0.58 15.33 ± 0.58 
3 8 15.33 ± 0.58 17.67 ± 1.15 14.67 ± 0.58 13.67 ± 0.58 
4 9 
0.00 0.00  0.00 0.00 
5 10 
0.00  0.00 0.00  0.00  
 Control 
(DMSO) 
0.00 0.00 0.00 0.00 
 Streptomycin 
sulphate 
31.67 ± 0.58 31.33 ± 0.58 30.33 ± 0.58 33.67 ± 0.58 
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singlet at 7.10, and methoxy protons resonating at  3.32 as a singlet indicated the formation 
of 6. HRMS further confirmed the product 6a, and (M+ + H) was found to be at m/z 
342.160222.  
 
Scheme 2.3.2 
 
 
 
 
 
 
The azide 7 on reaction with phenyl acetylene 11a in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 7a in 
97% yield (Scheme 2.3.2). In the 1H NMR spectrum of 7a, revealed the aryl protons 
resonating at  7.81, 7.08 and 6.69 as doublets that integrated to two, two and one proton 
each respectively, triazole proton resonating at  7.60 as singlet and other aryl protons 
resonating at  7.33 as multiplet that integrated to four protons, benzylic proton resonating at 
 7.03 as singlet, while  6.9, 6.62 as doublet of doublets that integrated to one proton each 
respectively. Hydroxy proton resonating at  5.75 as a broad singlet and methoxy protons 
resonating at  3.82 as a singlet that integrated to six protons indicates the formation of 7a. 
HRMS further confirmed the product 7a, (M+ + H) found to be at m/z 410.14551.  
 
Scheme 2.3.3 
 
 
 
 
 
The azide 8 on reaction with phenyl acetylene 11a in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 8a in 
94% yield (Scheme 2.3.3). In the 1H NMR spectrum of 8a, showed the aryl protons 
resonating at  7.88, 7.43 and 6.93 as multiplets that integrated to three, six and two protons 
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respectively. Triazole proton resonating at 7.87 as a singlet and other aryl protons resonating 
at  7.79, 7.11 as doublets that integrated to two protons each respectively and one proton 
resonating at  7.29 as a triplet. Benzylic proton resonating at  6.91 as singlet, while 
methoxy protons resonating at  3.82 as a singlet indicates the formation of 8a. HRMS 
further confirmed the product 8a, (2M+ + H) found to be at m/z 783.34424. 
 
Scheme 2.3.4 
 
 
 
 
 
The azide 9 on reaction with phenyl acetylene 11a in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 9a in 
93% yield (Scheme 2.3.4). In the 1H NMR spectrum of 9a, showed the aryl protons 
resonating at  7.79, 7.87, 7.26 and 6.90 as multiplets that integrated to two, one, four and 
two proton respectively. Triazole proton resonating at 7.28 as a singlet and benzylic proton 
resonating at  5.84 as a quartet, while methoxy protons resonating at  3.79 as a singlet and 
methyl protons resonating at  1.99 as a doublet indicates the formation of 9a. HRMS further 
confirmed the product 9a (M+ + H) found to be at m/z 280.14442 
 
Scheme 2.3.5 
 
 
 
 
 
 
The azide 10 on reaction with phenyl acetylene 11a in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 10a in 
91% yield (Scheme 2.3.5). In the 1H NMR spectrum of 10a, revealed the aryl protons 
resonating at  7.80, 6.89 as doublets and triazole proton resonating at  7.66 as a singlet and 
other aryl protons resonating at  7.32 as a multiplet that integrated to five protons. Benzylic 
Chapter II 
 
32 
 
proton resonating at  7.60 as a triplet, methoxy protons resonating at  3.80 as a singlet. The 
presence of alkyl side chain protons at the respective chemical shift values indicates the 
formation of 10a, HRMS further confirmed the product 10a, (M+ + Na) found to be at m/z 
344.17205. In NOE 2D NMR spectrum of 10a, observed a peak at the intersection of triazole 
proton chemical shift resonating at  7.66 and benzylic proton chemical shift resonating at  
7.60 and confirms the formation of 1,4-substituted triazole and it was assumed that rest of the 
triazoles formed as 1,4-substitued triazoles using the same synthetic conditions, even though 
not verified. 
 
Scheme 2.3.6 
 
 
 
 
 
 
The azide 6 on reaction with 1-octyne 11b in the presence of CuSO4.5H2O and sodium-
ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 6b in 92% 
yield (Scheme 2.3.6).  In the 1H NMR spectrum of 6b, showed the aryl protons resonating at 
 7.36, 7.07 as multiplets that integrated to two and five protons respectively. Triazole proton 
resonating at  7.38 as a singlet, benzylic proton resonating at  7.14 as a singlet and other 
aryl protons resonating at  6.88 as a doublet that integrated to two protons. Methoxy protons 
resonating at  3.81 as a singlet. The presence of alkyl side chain protons at the respective 
chemical shift values confirmed the formation of 6b. HRMS further confirmed the product 
6b, (M+ + H) found to be at m/z 350.22284 
 
Scheme 2.3.7 
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The azide 7 on reaction with 1-octyne 11b in the presence of CuSO4.5H2O and sodium-
ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 7b in 97% 
yield (Scheme 2.3.7).  In the 1H NMR spectrum of 7b, revealed the triazole proton observed 
at  7.12, aryl protons resonating at  7.02, 6.56 as doublets that integrated to two and one 
protons respectively, benzylic proton resonating at  6.62 as a singlet and other aryl protons 
resonating at  7.12, 6.94 as singlets that integrated to one proton each, while protons 
observed at  6.87 as a multiplet that integrated to three protons respectively. Methoxy 
protons resonating at  3.81, 3.79 as singlets that integrated to three protons each 
respectively. The presence of alkyl side chain protons at the respective chemical shift values 
confirmed the formation of 7b, HRMS further confirmed the product 7b, (M+ + Na) found to 
be at m/z 418.20992 
 
Scheme 2.3.8 
 
 
 
 
The azide 8 on reaction with 1-octyne 11b in the presence of CuSO4.5H2O and sodium-
ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 8b in 91% 
yield (Scheme 2.3.8).  In the 1H NMR spectrum of 8b, revealed the aryl protons resonating at 
 7.85, 7.44, 7.05, 6.88 and 6.84 as multiplets that integrated to three, three, two, two and one 
respectively. Triazole proton observed at  7.76 as a singlet, benzylic proton resonating at  
7.02 as a singlet. Methoxy protons resonating at  3.80 as a singlet. The presence of alkyl 
sidechain protons at the respective chemical shift values confirmed the formation of 8b, 
HRMS further confirmed the product 8b, (M+ + Na) found to be at m/z 422.21792 
 
Scheme 2.3.9 
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The azide 9 on reaction with 1-octyne 11b in the presence of CuSO4.5H2O and sodium-
ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 9b in 93% 
yield (Scheme 2.3.9).   In the 1H NMR spectrum of 9b, revealed the aryl protons resonating at 
 7.22, 6.86 as doublets that integrated to two protons each respectively. triazole proton 
observed at  7.12 as a singlet, benzylic proton resonating at  5.73 as a quartet. Methoxy 
protons resonating at  3.79 as a singlet. The presence of alkyl side chain protons at the 
respective chemical shift values confirmed the formation of 9b, HRMS further confirmed the 
product 9b, (M+ + H) found to be at m/z 280.20688 
 
Scheme 2.3.10 
 
 
 
 
 
 
The azide 10 on reaction with 1-octyne 11b in the presence of CuSO4.5H2O and sodium-
ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 10b in 96% 
yield (Scheme 2.3.10). In the 1H NMR spectrum of 10b, revealed the aryl protons resonating 
at  7.27, 6.87 as doublets that integrated to two protons each respectively. triazole proton 
observed at  7.17 as a singlet, benzylic proton resonating at  5.62 as a triplet. Methoxy 
protons resonating at  3.79 as a singlet. The presence of alkyl side chain protons at the 
respective chemical shift values confirmed the formation of 10b, HRMS further confirmed 
the product 10b, (M+ + H) found to be at m/z 330.25409.  
 
Scheme 2.3.11 
 
 
 
 
 
The azide 6 on reaction with propargyl alcohol 11c in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 6c in 
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85% yield (Scheme 2.3.11). In the 1H NMR spectrum of 6c, showed triazole proton 
resonating at  7.39 as a singlet, aryl protons resonating at  7.34, 7.06 as multiplets that 
integrated to three and four protons respectively. Benzylic proton resonating at  7.07 as a 
singlet and other aryl protons resonating at  6.88 as doublet that integrated to two protons.  
CH2 protons observed at  4.78 as a singlet. Methoxy protons resonating at  3.80 as a singlet 
indicates the formation of 6c, HRMS further confirmed the product 6c, (M+ + Na) found to be 
at m/z 318.12105 
 
Scheme 2.3.12 
 
 
The azide 7 on reaction with propargyl alcohol 11c in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 7c in 
87% yield (Scheme 2.3.12). In the 1H NMR spectrum of 7c, showed triazole proton 
resonating at  7.39 as a singlet, aryl protons resonating at  7.03, 6.88, 6.57 as doublets that 
integrated to two, three and one protons respectively. Benzylic CH proton resonating at 6.65 
as a singlet and other aryl protons resonating at  6.96 as a singlet that integrated to one 
proton. OH proton observed at  5.76 as a broad singlet. CH2 protons observed at  4.77 as a 
singlet. Methoxy protons resonating at  3.80, 3.70 as singlets that integrated to three protons 
each respectively indicates the formation of 7c, HRMS further confirmed the product 7c , 
(M+ + Na) found to be at m/z 364.12451 
 
Scheme 2.3.13 
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The azide 8 on reaction with propargyl alcohol 11c in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 8c in 
87% yield (Scheme 2.3.13). In the 1H NMR spectrum of 8c, showed aryl protons resonating 
at  7.86, 7.45 and 6.87 as multiplets that integrated to four, three and two protons 
respectively. Triazole proton resonating at  7.30 as a singlet and other aryl protons 
resonating at  7.06 as a doublet that integrated to two protons. Benzylic CH proton 
resonating at 6.90 as a singlet,  OH proton observed at  5.76 as a broad singlet. CH2 protons 
resonating at  4.77 as a singlet. Methoxy protons resonating at  3.80, 3.70 as singlets that 
integrated to three protons each respectively indicates the formation of 8c. HRMS further 
confirmed the product 8c, (2M+ + H) found to be at m/z 691.30292 
 
Scheme 2.3.14 
 
 
 
 
 
 
The azide 9 on reaction with propargyl alcohol 11c in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 9c in 
89% yield (Scheme 2.3.14). In the 1H NMR spectrum of 9c, showed triazole proton 
resonating at  7.38 as a singlet aryl protons resonating at  7.23, 6.89 as doublets that 
integrated to two protons respectively. Benzylic CH proton resonating at 5.77 as a quartet, 
CH2 protons resonating at  4.75 as a singlet. Methoxy protons resonating at  3.80 as 
singlets that integrated to three protons each respectively indicates the formation of 9c, 
HRMS further confirmed the product 9c, (M+ + H) found to be at m/z 234.12392 
 
Scheme 2.3.15 
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The azide 10 on reaction with propagyl alcohol 11c in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 10c in 
86% yield (Scheme 2.3.15). In the 1H NMR spectrum of 10c, showed triazole proton 
resonating at  7.47 as a singlet, aryl protons resonating at  7.29, 6.88 as doublets that 
integrated to two protons respectively. Benzylic CH proton resonating at 5.65 as a triplet, 
CH2 protons resonating at  4.74 as a singlet. Methoxy protons resonating at  3.79 as singlet. 
The presence of alkyl side chain protons at the respective chemical shift values confirmed the 
formation of 10c. HRMS further confirmed the product 10c, (M+ + H) found to be at m/z 
276.17090 
 
Scheme 2.3.16 
 
The azide 6 on reaction with Boc propargylamine 11d in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h furnished the triazole 6d in 
92% yield (Scheme 2.3.16). In the 1H NMR spectrum of 6d, revealed the aryl protons 
resonating at  7.45, 7.07 as multiplets that integrated to four, three protons respectively. 
Triazole proton resonating at  7.39 as a singlet, benzylic proton resonating at  7.12 as a 
singlet and other aryl protons resonating at  6.88 as doublet that integrated to two protons. 
NH proton observed at  5.08 as a broad singlet, CH2 protons resonating at  4.37 as a 
doublet. Methoxy protons resonating at  3.81 as a singlet, while boc protons resonating at  
1.41 as a singlet indicates the formation of 6d. HRMS further confirmed the product 6d, (M+ 
+ Na) found to be at m/z 417.18931 
 
Scheme 2.3.17 
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The azide 7 on reaction with Boc propargylamine 11d in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 7d in 
91% yield (Scheme 2.3.17). In the 1H NMR spectrum of 7d, revealed triazole proton 
resonating at  7.37 as a singlet, aryl protons resonating at  7.02, 6.93 as doublets that 
integrated to two, one proton each, benzylic proton resonating at  6.95 as a singlet and other 
aryl protons resonating at  6.88 as a multiplet that integrated to three, resonating peak at  
6.63 as a doublet that integrated to one proton, resonating peak at  6.57 as a doublet of 
doublet that integrated to one proton respectively. While NH proton observed at  5.76 as a 
broad singlet, OH proton observed at  5.11 as a broad singlet. CH2 protons resonating at  
4.37 as a doublet. Methoxy protons resonating at  3.81 as a singlet, while boc protons 
resonating at  1.41 as a singlet indicates the formation of 7d. HRMS further confirmed the 
product 7d, (M+ + Na) found to be at m/z 463.19299 
 
Scheme 2.3.18 
 
 
 
 
 
The azide 8 on reaction with Boc propargylamine 11d in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 8d in 
89% yield (Scheme 2.3.18). In the 1H NMR spectrum of 8d, revealed aryl protons resonating 
at  7.88, 7.46, 7.38, 7.04, 6.89 and 6.84 as multiplets that integrated to two, two, one, two, 
two and one protons each and other aryl protons resonating at  7.81 as doublet that 
integrated to one proton, triazole proton resonating at  7.77 as a singlet, benzylic proton 
resonating at  7.28 as a singlet. NH proton observed at  5.07 as a broad singlet. CH2 
protons resonating at  4.35 as a doublet. Methoxy protons resonating at  3.80 as a singlet, 
while boc protons resonating at  1.39 as a singlet indicates the formation of 8d, HRMS 
further confirmed the product 8d, (M+ + Na) found to be at m/z 467.20253 
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Scheme 2.3.19 
 
 
 
 
 
 
The azide 9 on reaction with Boc propargylamine 11d in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 9d in 
91% yield (Scheme 2.3.19). In the 1H NMR spectrum of 9d, revealed triazole proton 
resonating at  7.37 as a singlet, aryl protons resonating at  7.21, 6.88  as doublets that 
integrated to two protons each and benzylic protons resonating at  5.74 as a quartet. NH 
proton observed at  5.13 as a broad singlet. CH2 protons resonating at  4.34 as a doublet. 
Methoxy protons resonating at  3.80 as a singlet, while boc protons resonating at  1.41 as a 
singlet indicates the formation of 9d. HRMS further confirmed the product 9d, (M+ + Na) 
found to be at m/z 333.19204 
 
Scheme 2.3.20 
 
 
 
 
 
 
The azide 10 on reaction with Boc propargylamine 11d in the presence of CuSO4.5H2O and 
sodium-ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded the triazole 10d 
in 93% yield (Scheme 2.3.20). In the 1H NMR spectrum of 10d, revealed triazole proton 
resonating at  7.43 as singlet, aryl protons resonating at  7.27, 6.87 as doublets that 
integrated to two protons each and benzylic proton resonating at  5.63 as a triptet. NH 
proton observed at  5.06 as a broad singlet. Methoxy protons resonating at  3.79 as a 
singlet, while boc protons resonating at  1.41 as a singlet. The presence of alkyl side chain 
protons at the respective chemical shift values confirmed the formation of 10d, HRMS 
further confirmed the product 10d, (M+ + Na) found to be at m/z 397.21920 
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Some triazoles exhibit significant antimicrobial activity,27a especially when they are linked to 
N-methyl piperazine.27b Therefore, the synthesised triazoles 6a-d to 10a-d were evaluated for 
their antibacterial behaviour (Table 2.3) against Gram-negative (E. coli and K. pneumoniae) 
and Gram-positive (B. subtilis and M. luteus) microbial strains by adopting the same 
screening methodology used for the azides. All the synthesised triazoles exhibited significant 
antibacterial activity against the tested cultures. 
 
2.4.2 Antimicrobial activity of triazoles 6a-d to 11a-d 
 
Maximum activity was observed for triazole 9b against B. subtilis (25 mm) and M. luteus (24 
mm), whereas minimum activity was indicated for triazole 8d. The activity results were 
measured based on the diameter zone of inhibition. Structure-activity relationship (SAR) 
studies revealed that the parent azide moieties 6, 9 and 10 (phenyl, methyl and isobutyl) 
possessed no activity, whereas good antibacterial activity was observed when they were 
converted into triazoles (6a-d, 9a-d and 10a-d, respectively). Further observations revealed 
that among the triazoles, compounds with NHBoc and n-hexyl side chains (6b, 6d, 9b, 9d, 
10b and 10d) exhibited good antibacterial activity compared to the compounds with phenyl 
and -CH2OH side chains. SAR studies on 7a-d and 8a-d prepared from active azide moieties 
7 and 8 inferred an increase in the antibacterial activity of 7c and 7d, while the triazoles from 
8 displayed diminished activity. 
 
2.4.3 Minimum Inhibition Concentration by the Tube Dilution Method 
 
Of the triazole compounds prepared, 10 were selected for minimum inhibitory concentration 
(MIC) studies (Table 2.4). From these studies, it was evident that triazole 9b inhibited the 
growth of B. subtilis and K. pneumonia at an MIC of 15.625 μg/mL. All the new triazoles 
displayed moderate MIC values (31.25 and 62.5 µg/mL). Furthermore, it was also observed 
that the synthesised triazoles had MIC values that were less than those for the standard 
(streptomycin) against P. putida.  
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Table 2.3: Antimicrobial activity of triazole derivatives 
 
 
 
 
 
 
 
Entry Triazoles 
Zone of growth inhibition (mm) 
E. coli M. luteus K. pneumonia B. subtilis 
1 6a 11.67 ± 0.58 11.67 ± 0.58 11.67 ± 0.58 14.67 ± 0.58 
2 6b 12.33 ± 0.58 14.67 ± 0.58 15.67 ± 0.58 15.33 ± 0.58 
3 6c 12.33 ± 1.15 15.67 ± 0.58 13.00 ± 1.00 11.00 ± 0.00 
4 6d 17.67 ± 0.58 18.33 ± 0.58 15.67 ± 0.58 14.67 ± 0.58 
5 7a 20.33 ± 0.58 11.33 ± 0.58 15.00 ± 0.00 15.67 ± 0.58 
6 7b 16.67 ± 0.58 0.00 ± 0.00 15.33 ± 1.15 14.00 ± 0.00 
7 7c 20.33 ± 0.58 20.67 ± 0.58 21.00 ± 1.00 20.33 ± 0.58 
8 7d 20.00 ± 0.00 14.33 ± 0.58 21.33 ± 0.58 21.33 ± 0.58 
9 8a 0.00 ± 0.00 0.00 ± 0.00 17.00 ± 1.00 16.33 ± 0.58 
10 8b 11.33 ± 0.58 13.67 ± 0.58 11.67 ± 0.58 0.00 ± 0.00 
11 8c 16.33±0.58 15.33±0.58 17.33±0.58 14.67±1.15 
12 8d 0.00 ± 0.00 10.33 ± 0.58 0.00 ± 0.00 0.00 ± 0.00 
13 9a 14.33 ± 0.58 23.00 ± 1.00 15.67 ± 0.58 15.00 ± 0.00 
14 9b 14.67 ± 0.58 23.33 ± 0.58 21.00 ± 0.00 24.67 ± 0.58 
15 9c 12.00 ± 0.00 15.33 ± 0.58 11.67 ± 0.58 11.67 ± 0.58 
16 9d 11.67 ± 0.58 19.33 ± 0.58 12.67 ± 0.58 16.67 ± 0.58 
17 10a 11.33 ± 0.58 15.00 ± 1.00 11.67 ± 1.15 16.00 ± 1.00 
18 10b 11.67 ± 0.58 17.33 ± 0.58 14.67 ± 0.58 16.33 ± 0.58 
19 10c 12.67 ± 1.15 11.00 ± 0.00 12.67 ± 1.15 13.33 ± 0.58 
20 10d 12.33 ± 1.15 18.33 ± 0.58 15.00 ± 1.00 17.67 ± 0.58 
 Control 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
 Standard 
31.67 ± 0.58 31.33 ± 0.58 30.33 ± 0.58 33.67 ± 0.58 
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Table 2.4: Results from MIC studies 
 
Entry Compound 
MIC (µg/mL) 
E. coli B. subtilis K. pneumoniae M. luteus P. putida 
1 6b 31.25 31.25 31.25 31.25 31.25 
2 6d 31.25 31.25 31.25 62.5 62.5 
3 7a 31.25 62.5 31.25 31.25 >125 
4     7c 15.62 62.5 62.5 31.25 62.5 
5 7d 31.25 62.5 62.5 62.5 62.5 
6 8c 62.5 31.25 31.25 31.25 62.5 
7 9a 31.25 62.5 62.5 31.25 62.5 
8 9b >125 15.62 15.62 >125 >125 
9 9d 62.5 62.5 62.5 62.5 62.5 
10 10d 31.25 62.5 62.5 62.5 125 
 
Streptomycin 6.25 6.25 6.25 6.25 150 
 
2.5 Mechanism 
 
It was assumed that all conversions of the C-O bond to the C-N bond underwent nucleophilic 
substitution reactions with the Lewis acid mechanism (Scheme 2.4).  
 
Scheme 2.4 
 
 
 
 
 
 
 
 
Chapter II 
 
43 
 
Treatment of carbinol 1 with TMSN3 in MeCN at 0 
oC gives the TMS-protected product 1A, 
which on reaction with a 10 mol% of ZrCl4 involves binding to the OTMS group in 1A. 
Lewis acid nature of ZrCl4 makes to withdraw electron density from OTMS group, which in 
turn facilitates the C-O bond cleavage. That leads to the generation of carbocation 1B 
followed by a nucleophilic attack by N3 anion for the formation of the corresponding azide 2 
as a product and TMS(OH) as a by-product.  
 
2.6 Conclusion 
 
An efficient method for the conversion of the C-O bond (carbinols) to the C-N bond (azides), 
catalysed by ZrCl4, has been developed. The method reported is not only simple to operate, 
but it also affords azide products in high yields after short reaction times. These azides were 
converted into 1,4-disubstituted 1,2,3-triazoles using click chemistry. The azides and derived 
triazoles were evaluated for their antimicrobial activity against Gram-positive and Gram-
negative bacteria. The study revealed that triazole 9b with methyl and hexyl as side chains 
had maximum activity against B. subtilis (25 mm) and M. luteus (24 mm), and other novel 
triazoles had moderate antibacterial activity. The 1,2,3-triazole that had an alkyl side chain 
and amine functionality displayed good antimicrobial activity compared with triazoles with 
aryl side chains and alcohol functionality. Further SAR studies to derive new compounds 
with greater activity are in progress. 
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1-(Azido(phenyl)methyl)-4-methoxybenzene (6): A stirred solution of alcohol 1 (2.0 g, 
9.35 mmol) in acetonitrile (10 mL) at 0 °C was treated sequentially with azidotrimethylsilane 
(3.0 mL, 23.38 mmol) and ZrCl4 (0.22 g, 0.93 mmol) for 30 min. The reaction mixture was 
diluted with water (10 mL) and extracted with EtOAc (2 x 10 mL). The combined organic 
layers were washed with brine (10 mL) and dried (Na2SO4). The solvent was evaporated, and 
the residue was purified by column chromatography (60-120 mesh Silica gel, 3% EtOAc in 
pet. ether) to afford 6 (2.02 g, 90%) as a yellow liquid. IR (CHCl3): 3030, 2091, 1609, 1510, 
1243, 1174, 1031 cm-1; 1H NMR (300 MHz, CDCl3):  7.37-733 (m, 2H, ArH), 7.32 (m, 3H, 
ArH), 7.21 (d, 2H, J = 8.7 Hz, ArH), 6.88 (dt, 2H, J = 2.1, 8.8 Hz, ArH), 5.67 (s, 1H, ArCH), 
3.97 (s, 3H, OMe); 13C NMR (75 MHz, CDCl3):  159.2, 139.7, 131.6, 128.6, 128.5, 127.8, 
127.1, 113.9, 67.9, 55.1. 
 
 
5-(Azido(4-methoxyphenyl)methyl)-2-methoxyphenol (7): A solution of alcohol 2 (2.0 g, 
7.69 mmol) in acetonitrile (5 mL) at 0 °C was sequentially treated with azidotrimethylsilane 
(2.5 mL, 19.23 mmol) and ZrCl4 (0.18 g, 0.77 mmol) and stirred for 30 min. The work-up 
that has been described for 6 and purification of the residue by column chromatography (60-
120 mesh Silica gel, 5% EtOAc in Pet.ether) afforded 7 (1.95 g, 89%) as a yellow liquid. IR 
(CHCl3): 3508, 2935, 2838, 2091, 1609, 1505, 1238, 1172, 1024, 833, 757 cm
-1; 1H NMR 
(300 MHz, CDCl3):  7.21 (d, 2H, J = 8.4 Hz, ArH), 6.89-6.84 (m, 3H, ArH), 6.81 (m, 2H, 
ArH), 5.61 (br s, 1H, OH), 5.58 (s, 1H, ArCH), 3.88 (s, 3H, OMe), 3.80 (s, 3H, OMe); 13C 
NMR (75 MHz, CDCl3):  159.1, 146.2, 145.6, 133.1, 131.8, 128.5, 118.9, 113.9, 113.6, 
110.4, 67.6, 55.9, 55.2. 
 
1-(Azido(4-methoxyphenyl)methyl)naphthalene (8): A stirred solution of alcohol 3 (2.0 g, 
7.58 mmol) in acetonitrile (10 mL) at 0 °C was sequentially treated with azidotrimethylsilane 
(2.50 mL, 18.95 mmol) and of ZrCl4 (0.18 g, 0.76 mmol) and stirred for 30 min. Workup as  
described for 6 and purification of the residue by column chromatography (60-120 mesh 
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Silica gel, 5% EtOAc in Pet.ether)  8 (2.0 g, 90%) as a yellow liquid; IR (CHCl3): 3052, 
2955, 2836, 2093, 1608, 1510, 1303, 1247, 1174, 1031,781cm-1; 1H NMR (300 MHz, 
CDCl3):  7.90-7.82 (m, 3H, ArH), 7.65 (d, 1H, J = 7.2 Hz, ArH), 7.53-7.49 (m, 1H, ArH), 
7.48-7.40 (m, 2H, ArH), 7.27-7.23 (m, 2H, ArH), 6.88-6.83 (m, 2H, ArH), 6.34 (s, 1H, 
ArCH) 3.77 (s, 3H, OMe); 13C NMR (75 MHz, CDCl3):  159.3, 134.6, 133.9, 131.1, 130.4, 
128.8, 126.3, 125.7, 125.5, 125.1, 123.6, 114.0, 65.6, 55.1. 
 
 
 
1-(1-Azidoethyl)-4-methoxybenzene (9): A stirred solution of  alcohol 9 (2.0 g, 13.16 
mmol) in acetonitrile (10 mL) at 0 °C was sequentially treated with azidotrimethylsilane 
(4.30 mL, 32.90  mmol) and ZrCl4 (0.30 g, 1.31 mmol) and stirred for 30 min. Workup as  
described for 6 and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 5% EtOAc in Pet.ether) afforded 9 (2.02 g, 87%) as a yellow liquid; IR (CHCl3): 
2931, 2837, 2096, 1512, 1244, 1177, 1033, 831 cm-1; 1H NMR (300 MHz, CDCl3):  7.25 (d, 
2H, J = 8.7 Hz, ArH), 6.90 (d, 2H, J = 8.7 Hz, ArH), 4.56 (q, 1H, J = 6.8 Hz, ArCH), 3.81 (s, 
3H, OMe), 1.50 (d, 3H, J = 6.4 Hz, CH3); 
13C NMR (75 MHz, CDCl3):  159.2, 132.6, 127.5, 
113.9, 60.5, 55.0, 21.2.  
 
 
1-(1-Azido-3-methylbutyl)-4-methoxybenzene (10): A stirred solution of  alcohol 5 (2.0 g, 
10.31 mmol) in acetonitrile (10 mL) at 0 °C was sequentially treated with 
azidotrimethylsilane (3.3 mL, 25.78 mmol) and ZrCl4 (0.24 g, 1.03 mmol) and stirred for 30 
min. Workup as  described for 6 and purification of the residue by column chromatography 
(60-120 mesh Silica gel, 5% EtOAc in Pet.ether) afforded 10 (1.8 g, 82%) as a yellow liquid; 
IR (CHCl3): 2956, 2931, 2869, 2837, 2091, 1611, 1512, 1244, 1175, 1033, 830 cm
-1; 1H 
NMR (500 MHz, CDCl3):  7.23 (d, 2H, J = 8.5 Hz, ArH), 6.91 (d, 2H, J = 8.5 Hz, ArH), 
4.42 (t, 1H, J = 7.4 Hz, ArCH), 3.81 (s, 3H, OMe), 1.77-1.70 (m, 1H, CH), 1.67-1.51 (m, 2H, 
CH2), 0.92 (d, 6H, J = 7.6 Hz, 2 x CH3); 
13C NMR (75 MHz, CDCl3):  159.3, 131.7, 128.0, 
113.9, 63.8, 54.9, 44.7, 24.8, 22.3, 22.1. 
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1-((4-Methoxyphenyl)(phenyl)methyl)-4-phenyl-1H-1,2,3-triazole (6a): A solution of 
azide 6 (0.20 g, 0.84 mmol) and phenyl acetylene 11a (0.09 mL, 0.84 mmol) in t-BuOH (1 
mL) and water (1 mL) was treated with sodium ascorbate (0.01g, 0.04 mmol) followed by 
CuSO4.5H2O (0.02 g, 0.08 mmol) at room temperature and stirred for 8 h. The Solvent was 
removed by evaporation from the reaction mixture, residue diluted with water (5 mL) and 
extracted with EtOAc (2 x 10 mL). Combined organic layers were washed with brine (5 mL) 
and dried (Na2SO4). Solvent was evaporated and  purified the residue by column 
chromatography (60-120 mesh Silica gel, 15% EtOAc in pet. ether) to afford 6a (0.27 g, 
95%) as a white solid; mp 157-160 oC; IR (CHCl3): 3032, 2928, 1609, 1512, 1456, 1250, 
1178, 1030, 763, 739 cm-1; 1H NMR (500 MHz, CDCl3):  7.81 (d, 2H,  J = 7.2 Hz, ArH), 
7.60 (s, 1H, CH), 7.45-7.21 (m, 6H, ArH), 7.17-7.07 (m, 5H, ArH, ArCH), 6.91 (d, 2H, J = 
8.7 Hz, ArH), 3.82 (s, 3H, OMe); 13C NMR (75 MHz, CDCl3):  129.6, 128.8, 128.7, 128.4, 
128.1, 127.7, 125.6, 119.5, 114.3, 67.6, 55.3; HRMS (ESI+) m/z calcd for C22H20N3O (M
+ + 
H) 342.16009, found 342.16022. 
 
 
4-Hexyl-1-((4-methoxyphenyl)(phenyl)methyl)-1H-1,2,3-triazole (6b): A solution of azide 
6 (0.20 g, 0.84 mmol) and n-octyne 11b (0.12 mL, 0.84 mmol) in t-BuOH (1 mL) and water 
(1 mL) was treated with sodium ascorbate (0.01 g, 0.04 mmol) followed by CuSO4.5H2O 
(0.02 g, 0.08 mmol) at room temperature and stirred for 8 h. Workup as described for 6a and 
purification of the residue by column chromatography (60-120 mesh Silica gel, 20% EtOAc 
in pet. ether) afforded 6b (0.27 g, 92%) as a pale yellow solid; mp 72-76 oC; IR (CHCl3): 
3019, 2926, 2854, 2315, 1514, 1215, 752, 667 cm-1; 1H NMR (300 MHz, CDCl3):  7.42-
7.30 (m, 3H, ArH, CH), 7.14-7.00 (m, 6H, ArH, ArCH), 6.88 (d, 2H, J = 8.7 Hz, ArH), 3.81 
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(s, 3H, OMe),  2.69 (t, 2H, J = 7.6 Hz, CH2), 1.75-1.53 (m, 2H, CH2) 1.42-1.19 (m, 6H, 3 x 
CH2), 0.86 (t, 3H, J = 6.4 Hz, CH3); 
13C NMR (75 MHz, CDCl3):  159.5, 148.1, 138.7, 
130.3, 129.5, 128.7, 128.2, 127.6, 120.4, 114.1, 67.2, 55.2, 31.4, 29.3, 28.8, 25.7, 22.4, 13.9; 
HRMS (ESI+) m/z calcd for C22H28N3O (M
+ + H) 350.22269, found 350.22284. 
 
 
(1-((4-Methoxyphenyl)(phenyl)methyl)-1H-1,2,3-triazol-4-yl)methanol (6c): A solution of 
azide 6 (0.20 g, 0.83 mmol) and propargyl alcohol 11c (0.05 mL, 0.83 mmol) in t-BuOH (1 
mL) and water (1 mL) was treated with sodium-ascorbate (0.01 g, 0.04 mmol) followed by 
CuSO4.5H2O (0.02 g, 0.08 mmol) at room temperature and stirred for 8 h. Workup as 
described for 6a and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 50% EtOAc in pet. ether) afforded 6c (0.21g, 85%) as a viscous oil;  IR (CHCl3): 
2923, 2852, 2319, 1513, 772, 699 cm-1; 1H NMR (500 MHz, CDCl3):  7.39 (s, 1H,  CH), 
7.38-7.30 (m, 3H, ArH), 7.11-7.00 (m, 5H, ArH, ArCH), 6.88 (d, 2H, J = 7.9 Hz, ArH), 4.78 
(s, 2H, CH2), 3.80 (s, 3H, OMe); 
13C NMR (75 MHz, CDCl3):  159.6, 147.4, 138.3, 129.9, 
129.5, 128.7, 128.3, 127.6, 121.8, 114.2, 67.6, 56.0, 55.2; HRMS (ESI+) m/z calcd for 
C17H17N3O2Na (M
+ + Na) 318.12130, found 318.12105.    
 
 
t-Butyl(1-((4-methoxyphenyl)(phenyl)methyl)-1H-1,2,3-triazol-4-yl)methylcarbamate 
(6d): A solution of azide 6 (0.20 g, 0.70 mmol) and 11d (0.13 g, 0.84 mmol)  in t-BuOH (1 
mL) and water (1 mL)  was treated with sodium-ascorbate (0.01 g, 0.04 mmol) followed by 
CuSO4.5H2O (0.02 g, 0.08 mmol)  at room temperature and stirred for 8 h. Workup as 
described for 6a and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 30% EtOAc in pet. ether) afforded 6d (0.30 g, 92%) as a white solid; mp 105-108 
oC; IR (CHCl3): 2922, 2852, 2315, 1515, 1214, 754, 667 cm
-1; 1H NMR (500 MHz, CDCl3): 
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 7.45 (m, 5H, ArH, CH), 7.13-6.99 (m, 4H, ArH, ArCH), 6.88 (d, 2H, J = 8.3 Hz, ArH), 
5.17-5.01 (br s, 1H, NH), 4.37 (d, 2H, J = 5.8 Hz, CH2), 3.81 (s, 3H, OMe), 1.41 (s, 9H, 3 x 
CH3); 
13C NMR (75 MHz, CDCl3): 159.6, 155.7, 145.0, 138.4, 130.0, 129.5, 128.8, 128.3, 
127.6, 121.8, 114.2, 79.6, 67.6, 55.3, 36.1, 28.3; HRMS (ESI+) m/z calcd for C22H26N4O3Na 
(M+ + Na) 417.18971, found 417.18931. 
 
 
 
2-Methoxy-5-((4-methoxyphenyl)(4-phenyl-1H-1,2,3-triazol-1-yl)methyl)phenol (7a): A  
solution of azide 7 (0.20 g, 0.70 mmol) and phenyl acetylene 11a (0.07 g, 0.70 mmol)  in t-
BuOH (1 mL) and water (1 mL) was treated with sodium-ascorbate (0.01 g, 0.03 mmol) 
followed by CuSO4.5H2O (0.02 g, 0.07 mmol) at room temperature and stirred for 8 h. 
Workup as described for 6a and purification of the residue by column chromatography (60-
120 mesh Silica gel, 15% EtOAc in pet. ether) afforded 7a (0.26 g, 97%) as a yellow solid; 
mp 168-172 oC; IR (CHCl3): 3020, 2317, 1214, 742, 667  cm
-1; 1H NMR (500 MHz, CDCl3): 
 7.81 (d, 2H,  J = 7.2 Hz, ArH), 7.60 (s, 1H, CH), 7.53-7.21 (m, 4H, ArH), 7.08 (d, 2H, J = 
8.7 Hz, ArH), 7.03 (s, 1H, ArCH), 6.9 (dd, 2H, J = 8.7, 2.3 Hz, ArH), 6.69 (d, 1H, J = 1.3 Hz, 
ArH), 6.62 (dd, 1H, J = 8.3, 1.3 Hz, ArH), 5.75 (br s, 1H, OH), 3.82 (s, 6H, 2 x OMe); 13C 
NMR (75 MHz, CDCl3):  159.6, 147.3, 146.7, 145.9, 131.5, 130.5, 130.3, 129.2, 128.7, 
128.1, 125.6, 119.8, 119.5, 114.3, 114.2, 110.7, 67.7, 55.9, 55.3; HRMS (ESI+) m/z calcd for 
C23H21N3O3Na (M
+ + Na) 410.14751, found 410.14551. 
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5-((4-Hexyl-1H-1,2,3-triazol-1-yl)(4-methoxyphenyl)methyl)-2-methoxyphenol (7b): A 
solution of  azide 7 (0.20 g, 0.70 mmol) and n-octyne 11b (0.1 mL, 0.70 mmol)  in t-BuOH 
(1 mL) and water (1 mL) was treated with sodim-ascorbate (0.01 g, 0.15 mmol) followed by 
CuSO4.5H2O (0.02 g, 0.07 mmol) at room temperature and stirred for 8 h. Workup as 
described for 6a and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 20% EtOAc in pet. ether) afforded 7b (0.27 g, 97%) as a yellow syrup; IR 
(CHCl3): 2924, 2853, 2316, 1215, 771, 667 cm
-1; 1H NMR (300 MHz, CDCl3):  7.12 (s, 1H, 
CH), 7.02 (d, 2H, J = 8.4 Hz,  ArH), 6.94 (s, 1H, ArH), 6.87 (m, 3H, ArH), 6.62 (s, 1H, 
ArCH), 6.56 (d, 1H, J = 7.9 Hz, ArH), 3.81 (s, 3H, OMe), 3.79 (s, 3H, OMe), 2.69 (t, 2H, J = 
7.4 Hz, CH2), 1.71-1.57 (m, 2H, CH2), 1.44-1.21 (m, 6H, 3 x CH2), 0.86 (t, 3H, J = 5.45 Hz, 
CH3); 
13C NMR (75 MHz, CDCl3):  159.4, 148.1, 146.8, 145.7, 130.6, 130.4, 129.1, 120.9, 
120.4, 114.5, 114.1, 110.6, 67.2, 55.8, 31.4, 29.3, 28.8, 25.7, 22.4, 13.9; HRMS (ESI+) m/z 
calcd for C23H29N3O3Na (M
+ + Na) 418.21011, found 418.20992. 
 
 
5-((4-(Hydroxymethyl)-1H-1,2,3-triazol-1-yl)(4-methoxyphenyl)methyl)-2-
methoxyphenol (7c): A solution of azide 7 (0.20 g, 1.53 mmol) and propargyl alcohol 11c 
(0.04 mL, 0.70 mmol) in t-BuOH (1 mL) and water (1 mL) was treated with sodium-
ascorbate (0.01 g, 0.03 mmol) followed by CuSO4.5H2O (0.02 g, 0.07 mmol) at room 
temprature and stirred for 8 h. Workup as described for 6a and purification of the residue by 
column chromatography (60-120 mesh Silica gel, 50% EtOAc in pet. ether) afforded 7c (0.21 
g, 87%) as a yellow syrup; IR (CHCl3): 3019, 2922, 2852, 2313, 1214, 768, 667 cm
-1; 1H 
NMR (500 MHz, CDCl3):  7.39 (s, 1H, CH), 7.03 (d, J = 7.9 Hz, 2H, ArH), 6.96 (s, 1H, 
ArH), 6.88 (d, 3H, J = 7.9 Hz, ArH), 6.65 (s, 1H, ArCH), 6.57 (d, 1H, J = 7.9 Hz, ArH), 5.90-
5.72 (br s, 1H, OH), 4.77 (s, 2H, CH2) 3.80 (s, 3H, OMe), 3.79 (s, 3H, OMe); 
13C NMR (75 
MHz, CDCl3):  159.5, 147.2,146.8, 145.8, 130.2, 129.9, 129.1, 121.8, 120.9, 114.6, 114.1, 
110.7, 67.5, 55.9, 55.3, 56.2; HRMS (ESI+) m/z calcd for C18H19N3O4Na (M
+ + Na) 
364.12678, found 364.12451. 
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t-Butyl(1-((3-hydroxy-4-methoxyphenyl)(4-methoxyphenyl)methyl)-1H-1,2,3-triazol-4-
yl)methylcarbamate (7d): A solution of azide 7 (0.20 g, 0.70 mmol) and 11d (0.11 g, 0.70 
mmol) in t-BuOH (1 mL) and water (1 mL) was treated with Na-ascorbate (0.01 g, 0.03 
mmol) followed by CuSO4.5H2O (0.02 g, 0.07 mmol) at room temperature and stirred for 8 h. 
Workup as described for 6a and purification of the residue by column chromatography (60-
120 mesh Silica gel, 30% EtOAc in pet. ether) afforded 7d (0.28 g, 91%) as a yellow syrup; 
IR (CHCl3): 2924, 2853, 2316, 1215, 771, 667 cm
-1; 1H NMR (500 MHz, CDCl3):  7.37 (s, 
1H, CH), 7.02 (d, 2H, J = 8.5 Hz, ArH), 6.95 (s, 1H, ArCH),  6.91-6.84 (m, 3H, ArH), 6.63 
(d, 1H, J = 1.7 Hz, ArH), 6.60-6.53 (dd, 1H, J = 8.1, 1.7 Hz, ArH), 5.76 (br s, 1H, NH ), 
5.17-5.04 (br s, 1H, OH), 4.37 (d, J = 5.8 Hz, 2H, CH2), 3.81 (s, 3H, OMe), 3.79 (s, 3H, 
OMe), 1.41 (s, 9H, 3 x CH3); 
13C NMR (75 MHz, CDCl3):  159.6, 155.7, 146.6, 145.9, 
138.4, 131.5, 130.2,  129.2, 121.8, 119.7, 114.2 (2C), 110.6, 77.2, 67.3, 60.4, 55.9, 55.3, 55.3, 
28.3; HRMS (ESI+) m/z calcd for C23H28N4O5Na (M
+ + Na) 463.19519, found 463.19299. 
 
 
1-((4-Methoxy phenyl) (naphthalen-1-yl) methyl)-4-phenyl-1H-1,2,3-triazole (8a): A 
solution of azide 8 (0.20 g, 0.69 mmol) and phenyl acetylene 11a (0.07 mL, 0.69 mmol) in t-
BuOH (1 mL) and water (1 mL) was treated with sodium-ascorbate (0.01 g, 0.03 mmol) 
followed by CuSO4.5H2O (0.02 g, 0.07 mmol)  at room temperature and stirred for 8 h. 
Workup as described for 6a and purification of the residue by column chromatography (60-
120 mesh Silica gel, 15% EtOAc in pet. ether) afforded 8a (0.25 g, 94%) as a white solid;  
mp 172-174 oC; IR (CHCl3): 2957, 1609, 1511, 1251, 1177, 1030, 757, 693 cm
-1; 1H NMR 
(500 MHz, CDCl3):  7.92-7.82 (m, 4H, ArH, CH), 7.79 (d, 2H, J = 7.8 Hz, ArH), 7.53-7.33 
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(m, 6H, ArH), 7.29 (t, 1H, J = 7.2 Hz, ArH), 7.11 (d, 2H, J = 8.3 Hz, ArH), 6.95-6.87 (m, 3H, 
ArH, ArCH), 3.81 (s, 3H, OMe); 13C NMR (75 MHz, CDCl3):  159.7, 147.3, 134.1, 133.8, 
130.6, 130.5, 129.7, 129.5, 129.4, 128.9, 128.7, 128.1, 127.1, 126.1, 125.7, 125.6, 125.1, 
123.0, 120.1, 114.4, 64.7, 55.3; HRMS (ESI+) m/z calcd for C52H43N6O2 (2M
+ + H) 
783.34420, found 783.34424. 
 
 
4-Hexyl-1-((4-methoxyphenyl)(naphthalen-1-yl)methyl)-1H-1,2,3-triazole (8b): A 
solution of azide 8 (0.20 g, 0.69 mmol) and n-octyne 11b (0.1 mL, 0.69 mmol) in t-BuOH (1 
mL) and water (1 mL) was treated with sodium-ascorbate (0.01 g, 0.03 mmol) followed by 
CuSO4.5H2O (0.02 g, 0.07 mmol) at room temperature and stirred for 8 h. Workup as 
described for 6a and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 20% EtOAc in pet. ether) afforded 8b (0.25 g, 91%) as a yellow syrup; IR 
(CHCl3): 2926, 2854, 1610, 1511, 1250, 1177, 1034, 784, 757 cm
-1; 1H NMR (500 MHz, 
CDCl3):  7.90-7.80 (m, 3H, ArH), 7.76 (s, 1H, CH), 7.51-7.37 (m, 3H, ArH), 7.07-7.03 (m, 
2H, ArH), 7.02 (s, 1H, ArCH), 6.90-6.86 (m, 2H, ArH), 6.85-6.82 (m, 1H, ArH),  3.80 (s, 3H, 
OMe), 2.67 (t, 2H, J = 7.6 Hz, CH2), 1.65-1.58 (m, 2H, CH2) 1.33-1.22 (m, 6H, 3 x CH2), 
0.85 (t, 3H, J = 5.5 Hz, CH3
 ); 13C NMR (125 MHz, CDCl3):  159.5, 148.0, 134.4, 133.8 
130.7, 130.1, 129.3, 128.8, 126.9, 126.0, 125.6, 125.1, 123.1, 121.2, 114.3, 77.2, 64.4, 55.2, 
31.4, 29.3, 28.8, 25.7, 22.5, 13.9; HRMS (ESI+) m/z calcd for C26H29N3ONa (M
+ + Na) 
422.22028, found 422.21792. 
 
 
 
(1-((4-Methoxyphenyl)(naphthalen-1-yl)methyl)-1H-1,2,3-triazol-4-yl)methanol (8c): A 
solution of azide 8 (0.20 g, 0.69 mmol) and propargyl alcohol 11c (0.04 mL, 0.69 mmol)  in 
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t-BuOH (1 mL) and water (1 mL) was treated with sodium-ascorbate (0.01 g, 0.03 mmol) 
followed by CuSO4.5H2O (0.02 g, 0.07 mmol) at room temperature and stirred for 8 h. 
Workup as described for 6a and purification of the residue by column chromatography (60-
120 mesh Silica gel, 50% EtOAc in pet. ether) afforded  8c (0.21 g, 87%) as a yellow solid; 
mp 90-94 oC; IR (CHCl3): 3306, 2926, 1610, 1512, 1251, 1177, 1031, 785, 754 cm
-1 ; 1H 
NMR (500 MHz, CDCl3):  7.98-7.75 (m, 4H, ArH), 7.56-7.35 (m, 3H, ArH), 7.30 (s, 1H, 
CH), 7.06 (d, 2H, J = 8.7 Hz, ArH), 6.93-6.81 (m, 3H, 2 ArH,  ArCH), 4.76 (s, 2H, CH2) 3.80 
(s, 3H, OMe), 2.33 (br s, 1H, OH); 13C NMR (75 MHz, CDCl3):  159.6, 147.1, 133.8, 133.7, 
130.4, 129.4, 129.3, 128.8, 126.9, 126.1 125.6, 125.1, 12.8  114.4, 77.2, 64.8, 55.9, 55.2, 
29.6; HRMS (ESI+) m/z calcd for C42H39N6O4 (2M
+ + H) 691.30273, found 691.30292. 
 
t-Butyl(1-((4-methoxy phenyl)(naphthalen-1-yl)methyl)-1H-1,2,3-triazol-4-yl) methyl 
carbamate (8d): A solution of azide 8 (0.20 g, 0.69 mmol) and 11d (0.11 g, 0.69 mmol)   in 
t-BuOH (1 mL) and water (1 mL) was treated with sodium-ascorbate (0.01 g, 0.03 mmol) 
followed by CuSO4.5H2O (0.02 g, 0.07 mmol) at room temperature and stirred for 8 h. 
Workup as described for 6a and purification of the residue by column chromatography (60-
120 mesh Silica gel, 30% EtOAc in pet. ether)  afforded 8d (0.27 g, 89%) as a light yellow 
solid; mp 66-70 oC; IR (CHCl3): 3351, 2928, 1700, 1168, 1229, 1170, 1031, 753 cm
-1; 1H 
NMR (500 MHz, CDCl3):  7.91-7.84 (m, 2H, ArH), 7.81 (d, 1H, J = 8.9 Hz, ArH), 7.77 (s, 
1H, CH) 7.51-7.42 (m, 2H, ArH), 7.41-7.36 (m, 1H, ArH), 7.28 (s, 1H, ArCH), 7.07-7.02 (m, 
2H, ArH), 6.90-6.28 (m, 2H, ArH), 6.85-6.82 (m, 1H, ArH), 5.13-5.00 (br s, 1H, NH), 4.35 
(d, 2H, J = 5.6 Hz, CH2), 3.80 (s, 3H, OMe), 1.39 (s, 9H, 3 x CH3); 
13C NMR (75 MHz, 
CDCl3):  159.7, 155.7, 134.0, 133.8, 130.6, 129.8, 129.5, 129.3, 128.9, 127.0, 126.1, 125.7, 
125.1, 122.9, 122.5, 114.4, 79.6, 77.2, 64.7, 55.3, 36.3, 28.3; HRMS (ESI+) m/z calcd for 
C26H28N4O3Na (M
+ + Na) 467.20536, found 467.20253. 
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1-(1-(4-Methoxyphenyl)ethyl)-4-phenyl-1H-1,2,3-triazole (9a): A solution of azide 9 (0.20 
g, 1.12 mmol) and phenyl acetylene 11a (0.12 mL, 1.12 mmol)  in t-BuOH (1 mL) and water 
(1mL)  was treated with sodium-ascorbate (0.01 g, 0.06 mmol) followed by CuSO4.5H2O 
(0.03 g, 0.11 mmol)  was added  and stirred for 8 h. Workup as described for 6a and 
purification of the residue by column chromatography (60-120 mesh Silica gel, 15% EtOAc 
in pet. ether) afforded 9a (0.29 g, 93%) as a white solid; mp 122-126 oC; IR (CHCl3): 3019, 
1515, 1214, 742, 697, 626  cm-1; 1H NMR (300 MHz, CDCl3):  7.80-7.77 (m, 2H, ArH), 
7.58-7.57 (m, 1H, ArH), 7.42-7.26 (m, 5H, CH, ArH), 6.92-6.87 (m, 2H, ArH), 5.87-5.80 (q, 
1H, J = 6.8 Hz, ArCH), 3.79 (s, 3H, OMe), 1.99 (d, 3H, J = 6.8 Hz, CH3); 
13C NMR (75  
MHz, CDCl3):  159.5, 147.4, 131.7, 130.6, 128.6, 127.8, 127.7, 125.5, 118.2, 114.2, 59.6, 
55.2, 21.2; HRMS (ESI+) m/z calcd for C17H18N3O (M
+ + H) 280.14444, found 280.14442. 
 
 
4-Hexyl-1-(1-(4-methoxyphenyl)ethyl)-1H-1,2,3-triazole (9b): A solution of azide 9 (0.20 
g, 1.13 mmol) and n-octyne 11b (0.16 mL, 1.13 mmol) in t-BuOH (1 mL) and water (1 mL)  
was treated with sodium-ascorbate (0.01 g, 0.06 mmol) followed by CuSO4.5H2O (0.03 g, 
0.11 mmol) at room temperature and stirred for 8 h. Workup as described for 6a and 
purification of the residue by column chromatography (60-120 mesh Silica gel, 20% EtOAc 
in pet. ether)  afforded 9b (0.30 g, 93%) as a pale yellow solid; mp 43-47 oC; IR (CHCl3): 
2928, 2856, 1612, 1514, 1249, 1034, 833, 749 cm-1; 1H NMR (300 MHz, CDCl3):  7.22 (d, 
2H, J = 8.7 Hz, ArH), 7.12 (s, 1H, CH), 6.86 (d, 2H, J = 8.7 Hz, ArH), 5.73 (q, 1H,  J = 7.2 
Hz, ArCH), 3.79 (s, 3H, OMe), 2.66 (t, 2H, J = 7.6 Hz, CH2), 1.92 (d, 3H, J = 6.8 Hz,  CH3), 
1.64-1.57 (m, 2H, CH2), 1.34-1.28 (m, 6H, 3 x CH2)  0.86 (m, 3H, CH3) ; 
13C NMR (75  
MHz, CDCl3):  159.3, 148.1, 132.1, 127.6, 118.9, 114.0, 59.2. 55.1, 31.3, 29.2, 28.7, 25.6, 
22.3, 21.2, 13.8; HRMS (ESI+) m/z calcd for C17H26N3O (M
+ + H) 280.20704, found 
280.20688. 
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(1-(1-(4-Methoxyphenyl)ethyl)-1H-1,2,3-triazol-4-yl)methanol (9c): A solution of azide 9 
(0.20 g, 1.13 mmol) and propargyl alcohol 11c (0.06 mL, 1.13 mmol) in t-BuOH (1 mL) and 
water (1 mL) was treated with sodium-ascorbate (0.01 g, 0.11 mmol) followed by 
CuSO4.5H2O (0.03 g, 0.11 mol) at room temperature and stirred for 8 h. Workup as described 
for 6a and purification of the residue by column chromatography (60-120 mesh Silica gel, 
50% EtOAc in pet. ether) afforded 9c (0.23 g, 89%) as a yellow syrup; IR (CHCl3): 2921, 
2851, 2310, 1514, 1259, 1218, 1140, 772  cm-1; 1H NMR (500 MHz, CDCl3):  7.38 (s, 1H, 
CH), 7.23 (d, 2H, J = 8.43 Hz, ArH), 6.89 (d, 2H, J = 8.43 Hz, ArH) 5.77 (q, 1H, J = 6.9 Hz, 
ArCH), 4.75 (s, 2H, CH2), 3.80 (s, 3H, OMe), 1.95 (d, 3H,  J = 6.9 Hz , CH3), 1.82-1.66 (bs, 
1H, OH); 13C NMR (75 MHz, CDCl3):  159.5, 147.5, 131.5, 127.8, 120.4, 114.2, 59.7, 55.8, 
55.2, 21.1; HRMS (ESI+) m/z calcd for C12H16N3O2 (M
+ + H) 234.12370, found 234.12392. 
 
 
 
t-Butyl (1-(1-(4-methoxyphenyl)ethyl)-1H-1,2,3-triazol-4-yl)methylcarbamate (9d): A 
solution of azide 9 (0.20 g, 1.13 mmol) and 11d (0.17 g, 1.13 mmol) in t-BuOH (1 mL) and 
water (1 mL) was treated with sodium-ascorbate (0.01 g, 0.06 mmol) followed by 
CuSO4.5H2O (0.03 g, 0.11 mmol) at room temperature and stirred for 8 h. Workup as 
described for 6a and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 30% EtOAc in pet. ether) afforded 9d (0.34 g, 91%) as a white solid; mp 124-128 
oC;  IR (CHCl3): 3019, 2926, 2855, 1214, 746, 667 cm
-1; 1H NMR (500 MHz, CDCl3):  7.37 
(s, 1H, CH), 7.21 (d, 2H, J = 8.3 Hz, ArH), 6.88 (d, 2H, J = 8.3 Hz, ArH), 5.74 (q, 1H, J = 
6.8 Hz, ArCH), 5.20-5.07 (br s, 1H, NH), 4.34 (d, 2H,  J = 5.6 Hz, CH2), 3.80 (s, 3H, OMe), 
1.93 (d, 3H, J = 6.8 Hz, CH3)  1.41 (s, 9H, 3 x CH3); 
13C NMR (75 MHz, CDCl3):  159.6, 
115.7, 145.2, 131.7, 127.8, 120.3, 114.2, 79.6, 59.7, 55.3, 36.1, 28.3, 21.2; HRMS (ESI+) m/z 
calcd for C17H25N4O3 (M
+ + H) 333.19212, found 333.19204. 
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1-(1-(4-Methoxyphenyl)-3-methylbutyl)-4-phenyl-1H-1,2,3-triazole (10a): A solution of 
azide 10 (0.20 g, 0.91 mmol) and phenyl acetylene 11a (0.17 g, 0.91 mmol)  in t-BuOH (1 
mL) and water (1 mL) was treated with sodium-ascorbate (0.08 g, 0.04 mmol) followed by 
CuSO4.5H2O (0.02 g, 0.09 mmol) at room temperature and stirred for 8 h. Workup as 
described for 6a and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 15% EtOAc in pet. ether) afforded 10a (0.27 g, 91%) as a white solid; mp 111-114 
oC; IR (CHCl3): 3722, 3641, 2924, 2314, 1215, 770, 667 cm
-1; 1H NMR (300 MHz, CDCl3): 
 7.80 (d, 2H,  J = 7.2 Hz, ArH), 7.66 (s, 1H, CH), 7.43-7.21 (m, 5H, ArH), 6.89 (d, 2H, J = 
8.7 Hz, ArH), 5.71 (t, 1H, J = 7.6 Hz, ArCH), 3.80 (s, 3H, OMe), 2.44-2.31 (ddd, 1H, J = 6.4, 
8.7, 13.9 Hz, CH), 2.25-2.05 (m, 1H, CH), 1.47 (m, 1H, CH), 0.99 (d, 3H, J = 6.8 Hz, CH3), 
0.97 (d, 3H, J = 6.8 Hz, CH3); 
13C NMR (75 MHz, CDCl3):  159.6, 147.5, 131.0, 130.6, 
128.7, 128.3, 127.9, 125.5, 118.1, 114.2, 62.7, 55.2, 43.9, 24.8, 22.3, 22.2; HRMS (ESI+) m/z 
calcd for C20H23N3ONa (M
+ + Na) 344.17333, found 344.17205. 
 
4-Hexyl-1-(1-(4-methoxyphenyl)-3-methylbutyl)-1H-1,2,3-triazole (10b): A solution of 
azide 10 (0.20 g, 0.91 mmol) and n-octyne 11b (0.13 mL, 0.91 mmol) in t-BuOH (1 mL) and 
water (1 mL) was treated with sodium-ascorbate (0.08 g, 0.04 mmol) followed by 
CuSO4.5H2O (0.02 g, 0.09 mmol) at room temperature and stirred for 8 h. Workup as 
described for 6a and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 20% EtOAc in pet. ether) afforded 10b (0.29 g, 96%) as a pale yellow solid; mp 
58-62 oC; IR (CHCl3): 2924, 2854, 2314, 1219, 772 cm
-1; 1H NMR (300 MHz, CDCl3):  
7.27 (d, 2H,  J = 8.7 Hz, ArH), 7.17 (s, 1H, CH), 6.87 (d, 2H, J = 8.7 Hz, ArH), 5.62 (t, 1H, J 
= 7.9 Hz, ArCH), 3.79 (s, 3H, OMe),  2.65 (t, 2H, J = 7.9 Hz,  CH2), 2.35-2.21 (ddd, 1H, J = 
6.8, 8.3, 13.9 Hz, CH), 2.12-2.00 (m, 1H, CH), 1.68-1.53 (m, 1H, CH), 1.48-1.13 (m, 8H, 4 x 
CH2), 1.0-0.77 (m, 9H, 3 x CH3); 
13C NMR (75 MHz, CDCl3):  159.4, 148.3, 131.3, 128.2, 
118.9, 114.1, 62.3, 55.2, 43.9, 31.4, 29.3, 28.5, 25.7, 24.7, 22.4, 22.2, 13.9; HRMS (ESI+) 
m/z calcd for C20H32N3O (M
+ + H) 330.25399, found 330.25409. 
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(1-(1-(4-Methoxyphenyl)-3-methylbutyl)-1H-1,2,3-triazol-4-yl)methanol (10c): A 
solution of azide 10 (0.20 g, 0.91 mmol) and propargyl alcohol 11c (0.05 mL, 0.91 mmol) in 
t-BuOH (1 mL) and water (1 mL) was treated with sodium-ascorbate (0.01 g, 0.04 mmol) 
followed by CuSO4.5H2O (0.02 g, 0.09 mmol) at room temperature  and stirred for 8 h. 
Workup as described for 6a and purification of the residue by column chromatography (60-
120 mesh Silica gel, 20% EtOAc in pet. ether) afforded 10c (0.21 g, 86%) as a yellow syrup; 
IR (CHCl3): 2921, 2851, 2310, 1514, 1259, 1218, 1140, 772 cm
-1; 1H NMR (300 MHz, 
CDCl3):  7.47 (s, 1H, CH), 7.29 (d, 2H, J = 8.7 Hz, ArH), 6.88 (d, 2H, J = 8.7 Hz, ArH), 
5.65 (t, 1H, J = 7.9 Hz, ArCH), 4.74 (s, 2H, CH2), 3.79 (s, 3H, OMe), 2.30 (ddd, 1H,  J = 6.8, 
8.5, 13.9 Hz, CH), 2.18-2.03 (m, 1H, CH), 1.41 (m, 1H, CH), 0.96 (d, 3H, J = 6.6 Hz, CH3), 
0.94 (d, 3H, J = 6.6 Hz, CH3); 
13C NMR (75 MHz, CDCl3):  159.6, 149.9, 130.7, 128.3, 
120.3, 114.3, 62.8, 56.2, 55.3, 43.8, 24.7, 22.2; HRMS (ESI+) m/z calcd for C15H22N3O (M
+ 
+ H) 276.17065, found 276.17090. 
 
 
t-Butyl (1-(1-(4-methoxy phenyl)-3-methyl butyl)-1H-1,2,3-triazol-4-yl) methyl 
carbamate (10d): A solution of azide 10 (0.20 g, 0.91 mmol) and 11d (0.14 g, 0.91 mmol) in 
t-BuOH (1 mL) and water (1 mL) was treated with sodium-ascorbate (0.01 g, 0.04 mmol) 
followed by CuSO4.5H2O (0.02 g, 0.09 mmol) at room temperature and stirred for 8 h. 
Workup as described for 6a and purification of the residue by column chromatography (60-
120 mesh Silica gel, 30% EtOAc in pet. ether) afforded 10d (0.32 g, 93%) as a pale yellow 
solid; mp 104-107 oC; IR (CHCl3): 3020, 2318, 1214, 745, 667 cm
-1; 1H NMR (300 MHz, 
CDCl3):  7.43 (s, 1H, CH), 7.27 (d, 2H, J = 8.5 Hz, ArH), 6.87 (d, 2H,  J = 8.5 Hz, ArH), 
5.63 (t, 1H, J = 7.9 Hz, ArCH), 5.10-5.01 (br s, 1H, NH), 4.34 (d, 2H, J = 5.9 Hz, CH2), 3.79 
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(s, 3H, OMe), 2.29 (m, 1H, CH), 2.07 (m, 1H, CH), 1.66 (m, 1H, CH), 1.41 (s, 9H, 3 x CH3), 
0.96 (d, 3H, J = 6.5 Hz, CH3), 0.94 (d, 3H, J = 6.6 Hz, CH3); 
13C NMR (75 MHz, CDCl3):  
159.5, 155.7, 145.1, 130.9, 128.2, 120.3, 114.2, 79.5, 62.7, 55.2, 43.9, 36.1, 28.2, 24.7, 22.2; 
HRMS (ESI+) m/z calcd for C20H30N4O3Na  (M
+ + Na) 397.22101, found 397.21920. 
_________________________________________________________________ 
 
2.8.1 Experimental procedure for MIC studies 
 
All the test strains (E. coli, B. subtilis, K. pneumonia, M. luteus and P. putida), each 1 mL 
volume (OD equal to match the turbidity of a MacFarland 0.5 standard tube) were inoculated 
in nutrient broth (1 mL) with final compound concentrations of 250 µg/mL to 0 µg/mL and 
standard drug (Streptomycin) concentration from 400 µg/mL to 6.25 µg/mL. All the tubes 
were incubated at 37 oC for 12-16 h. The turbidity of each tube was measured with respect to 
a control tube. MIC values are defined as the lowest concentration of compound at which 
growth is completely inhibited for at least for 8 h. 
________________________________________________________________________ 
 
 
2.9 References 
 
1.   (a) Zhang, Z.-H.; Li, T.-S. Curr. Org. Chem. 2009, 13, 1-30; (b) Sharma, G. V. M.; Kumar, K.  
      S.; Kumar, B. S.; Reddy, S. V.; Prakasham, R. S.; Hugel, H.  Synth. Commun. 2014, 44,      
      3156-3164. 
2.  (a) Anastas, P. T.; Warner, J. C. Green Chemistry: Theory and Practice; Oxford  
      University Press: New York, 1998; (b) Iovel, I.; Mertins, K.; Kischel, J.; Zapf, A.;     
      Beller, M. Angew. Chem., Int. Ed. 2005, 44, 3913-3917.  
3.   (a)  Coote, S. J.; Davies, S. G.; Middlemiss, D.; Naylor, A. Tetrahedron Lett. 1989, 30,  
      3581-3588. (b) Khalaf, A. A.; Roberts, R. M. J. Org. Chem. 1973, 38, 1388-1395 ; (c)     
      Khalaf, A. A.; Roberts, R. M. J. Org. Chem. 1972, 37, 4227-4235. (d) Khalaf, A. A.;      
      Roberts, R. M. J. Org. Chem. 1969, 34, 3571-3574; (e) Khalaf, A. A.; Roberts, R. M. J.  
      Org. Chem. 1971, 36, 1040-1044; (f) Sundberg, R. J.; Laurino, J. P. J. Org. Chem. 1984,  
      49, 249-254; (g) Davis, B. R.; Johnson, S. J.; Woodgate, P. D. Aust. J. Chem. 1987, 40,  
      1283-1299. 
Chapter II 
 
58 
 
4.  (a) Liu, J.; Muth, E.; Flore, U.; Henkel, G.; Merz, K.; Sauvageau, E.; Schwake, E.;  
      Dyker, G. Adv. Synth. Catal. 2006, 348, 456-462; (b) Hongbo, Q.; Noriyuki, Y.;  
      Shigeki, M.; Masakatsu, S. Angew. Chem, Int. Ed. 2007, 46, 409-413; (c) Noji, M.;     
      Konno, Y.; Ishii, K. J. Org. Chem. 2007, 72, 5161-5167; (d) Yasuda, M.; Somyo, T.;  
      Baba, A. Angew. Chem., Int. Ed. 2006, 45, 793-796; (e) Sanz, R.; Martinez, A.; Miguel,  
      D.; Gutierrez, J. M. A.; Rodriguez, F. Adv. Synth. Catal. 2006, 348, 1841-1845. 
5.   (a) Brase, S.; Gil, C.; Knepper, K.; Zimmermann, V. Angew. Chem., Int. Ed. 2005, 44,  
       5188-5240; (b) Scriven, E. F. V.; Turnbull, K. Chem. Rev. 1988, 88, 297-368; (c) Boyer,  
       J. H.; Canter, F. C. Chem. Rev. 1954, 54, 1-57; (d) Smith, P. A. S. Org. React. 1946, 3,  
       337-449; (e) Sheradsky, T. The Chemistry of the Azido Group (ed) S M Patai, New    
       York: Interscience, 1971, 331. 
6.    (a) Lutz, J.-F. Angew. Chem., Int. Ed. 2007, 46, 1018-1025; (b) Kolb, H. C.; Finn, M. G.;  
       Sharpless, K. B.  Angew. Chem., Int. Ed. 2001, 40, 2004-2021; (c) Kolb, H. C.;           
       Sharpless,  K. B. Drug Discovery Today 2003, 8, 1128-1137.    
7.   (a) Kohn, M.; Breinbauer, R. Angew. Chem., Int. Ed. 2004, 43, 3106-3116; (b) Lee, L. V.;  
       Mitchell, M. L.; Huang, S.-J.; Fokin, V. V.; Sharpless, K. B.; Wong, C.-H. J. Am. Chem.  
       Soc. 2003, 125, 9588-9589.  
8.   (a) Mitsunobu, O.; Wada, M.; Sano, T. J. Am. Chem. Soc. 1972, 94, 679-680; (b) Hughes,  
       D. L. Org. React. 1992, 42, 358-359; (c) Loibner, H.; Zbiral, E. Helv. Chim. Acta 1977,  
       60, 417-425; (d) Mitsunobu, O. Synthesis 1981, 1-28; (e) Hughes, D. L. Org. Prep.  
       Proceed. Int. 1996, 28, 127-164; (f) Saito, A.; Saito, K.; Tanaka, A.; Oritani, T.           
      Tetrahedron Lett. 1997, 38, 3955-3958; (g) Fabiano, E.; Golding, B. T.; Sadeghi, M. M.  
      Synthesis 1987, 190-192; (h) Bessodes, M.; Abushanab, E.; Antonakis, K. Tetrahedron  
       Lett. 1984, 25, 5899-5902; (i) Mitsunobu, O. Bull. Chem. Soc. Jpn. 1967, 40, 4235-4238; 
      (j) Lee, S. H.; Yoon, J.; Chung, S. H.; Lee, Y. S. Tetrahedron 2001, 57, 2139-2145. 
9.   (a) Lal, B.; Pramanik, B. N.; Manhas, M. S.; Bose, A. K. Tetrahedron Lett. 1977, 18,  
      1977-1980; (b) Mizuno, M.; Shioiri, T. Chem. Commun. 1997, 22, 2165-2166; (c) Viaud,  
       M. C.; Rollin, P. Synthesis 1990, 130-132; (d) Yu, C.; Liu, B.; Hu, L. Org. Lett. 2000, 2,  
       1959-1961; (e) Rad, M. N. S.; Behrouz, S.; Khalafi, N. A. Tetrahedron Lett. 2007, 48,  
       3445-3449; (f) Hendrickson, J. B.; Hussoin, M. S. J. Org. Chem. 1987, 52, 4137-4139;     
       (g) Hendrickson, J. B.; Hussoin, Md. S. J. Org. Chem. 1989, 54, 1144-1149; (h)        
       Hendrickson, J. B.; Hussoin, Md. S. Synlett 1990, 7, 423-427; (i) Elson, K. E.; Jenkins,  
       I. D.; Loughlin, A. L. Org. Biomol. Chem. 2003, 1, 2958-2965. (j)  Lee, J.; Kang, M.;  
       Shin, M.; Kim, J.-M.; Kang, S.-U.; Lim, J.-O.; Choi, H.-K.; Suh, Y.-G.; Park, H.-G.; Oh,  
Chapter II 
 
59 
 
       U.; Kim, H.-D.; Park, Y.-H., Ha, H.-J.; Kin, Y.-H.; Toth, A.; Wang, Y.; Tran, R.;  
       Pearce, L. V.; Lundberg, D. J.; Blumberg, P. M. J. Med. Chem. 2003, 46, 3116-3126. (k)     
       Bez, G.; Baruah, N. Chem. Lett. 2006, 35, 542-543. 
10.  (a) Manohar, P.; Baskaran, S.; Murali, A. Eur. J. Org. Chem. 2011, 27, 5297-5302; (b)  
       Sreedhar, B.; Surendra, P.; Ravi, V. Tetrahedron Lett. 2010, 51, 4037-4041; (c) Prim,   
       D.; Terrasson, V.; Campagne, J. M. Adv. Synth. Catal. 2006, 348, 2063-2067. 
11. Acquaah-Harrison, G. Antibacterial Agents: 1, 4-Disubstituted 1, 2, 3-Triazole Analogues  
       of the Oxazolidinone (Doctoral dissertation, Ohio University, 2010). 
12.   Nicolauou, K. C.; Chen, J. S.; Edmonds, D. J.; Estrada, A. A. Angew. Chem., Int. Ed.  
        2009, 48, 660-719. 
13.   Christoffersen,R.E. Nat. Biotechnol. 2006, 24, 1512-1514. 
14.   Keshavjee, S.; Farmer, P. E. N. Engl. J. Med. 2012, 367, 931-936. 
15.  Zhu, Y. P.; Woerdenbag, H. J. Pharm. World Sci. 1995, 17, 103-112. 
16.   Silver, L. L.; Bostian, K. A. Antimicrobial agents and chemotherapy, 1993, 37, 377 
        -383. 
17. (a) Hobbs, D. C.; English, A. R. J. Med. Pharm. 1961, 4, 207-210; (b) Batohelor, T.;  
        Doyle, F.; Nayler, J. H. C.; Rolinson, G. Nature. 1959, 183, 257- 258; (c) Elander, R. P.   
         Appl.Microbiol. Biotechnol. 2003, 61, 385-392. 
18. (a)Fleming, A. Brit. J. Exp. Pathol. 1929, 10, 226-236; (b) For a general review of  
      streptomycin effects see Davis, B. D., and D. S. Feingold, The Bacteria,ed. I. C. Gunsalus  
      and R. Stanier (New York: Academic Press, 1962), vol. 4, p.343; (c) Duggar, B. M. Ann.   
      N. Y. Acad. Sci. 1948, 51, 177-181; (d) Wiley, P. F.; Gale, R.; Pettinga, C. W.; Gerzon, K.  
      J. Am. Chem. Soc. 1957,  79, 6074-6077; (e) Janssens, J.; Peeters, T. L.; Vantrappen, G.;  
      Tack, J.; Urbain, J. L.; De Roo, M.; Bouillon, R.  N. Engl. J. Med. 1990, 322, 1028-1031. 
19. (a) Fischbach, M. A.; Walsh, C. T. Science. 2009, 325, 1089-1093; (b) Lesher, G. Y.;  
      Froelich, E. J.; Gruett, M. D.; Bailey, J. H.; Brundage, R. P. J. Med. Chem. 1962, 5, 1063- 
      1065; (c) Chien, J. W.; Kucia, M. L.;  Salata, R. A. Clin. Infect. Dis. 2000, 30, 146-151. 
20. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angew. Chem., Int. Ed. 2001, 40, 2004-2021. 
21. Thirumurugan, P.;  Matosiuk, D.; Jozwiak,  K. Chem.Rev. 2013, 113, 4905- 4979. 
22. (a) Sharma, G. V. M.; Reddy, Ch. G.; Krishna, P. R. J. Org. Chem, 2003, 68, 4574- 
      4575; (b) Sharma, G. V. M.; Janardhan. J.; Lakshmi. P. S.; Krishna, P. R. Tetrahedron  
      Lett. 2004, 45, 6963-6965; (c) Sharma, G. V. M.; Srinivas, B.; Krishna, P. R. Lett.   
      Org. Chem. 2005, 2, 297-307; (d) Sharma, G. V. M.; Janardhan, J.; Lakshmi, P. S.;  
      Krishna, P. R. Tetrahedron Lett. 2005, 46, 6119-6121; (e) For review on applications     
Chapter II 
 
60 
 
      of ZrCl4 : Smitha, G.; Chandrasekhar, S.; Reddy, Ch. S. Synthesis 2008, 6, 829-855; (f)  
      For review on applications of Zirconium(IV) Compounds in Organic Synthesis:      
      Zhang, Z.-H.; Li, T.-S. Curr. Org. Chem. 2009, 13, 1-30. 
23. (a) Majumdar, K. K.;  Cheng, C. H. Org. Lett. 2000, 2, 2295-2298; (b) Hermite, N. L.;  
      iraud, A.; Provot, O.; Peyrat, J.; Alami, M.; Brion, J. Tetrahedron Lett. 2006 , 62,  
      11994-12002; (c) Singh, P.; Dinda, S. K.; Shaqfta; Panda, G.; RSC Advances 2013, 3,     
      12100-12103; (d) Sharma, G. V. M.; Reddy, K. L.; Laxmi, P. S.; Ravi, R.; Kunwar, A.  
      C. J. Org. Chem. 2006, 71, 3967-3969.  
24. (a) Borden, W. T.; Gritsan, N. P,; Hadad, C. M.; Karney. W. L.; Kemnitz, C. R.;  Platz, 
      M. S. Acc. Chem. Res. 2000, 33, 765-771. (b) Gritsan, N. P.; Platz. M. S. Adv. Phys. 
       Org. Chem. 2001, 36, 255-304.                                                                                                                                       
25. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem., Int. Ed. 
      2002, 41, 2596-2599.                                                                                                                                
26. Lu, Y.; Gervay, H. J. Carbohydr. Res. 2007, 342, 1636-1650.                                                 
27. (a) Isloo, A. M.; Kalluraya, B.; Shetty, P. Eur. J. Med. Chem. 2009, 44, 3784-3787. (b)  
      Khedar, P.; Pericherla, K.; Singh, R. P.; Jha, P. N.; Kumar, A. Med. Chem. Res. 2015, 24,  
      3117-3126. 
Chapter III 
 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________ 
 
Chapter III 
Synthesis of triazole-vanillin molecular 
hybrids and their cytotoxicity studies 
 
________________________________________________________________ 
 
 
 
 
 
 
Chapter III 
 
62 
 
This chapter deals with the synthesis of new compounds that contain the1,2,3‐triazole moiety 
tethered to substituted vanillin or isovanillin and their cytotoxicity studies. 
 
3.1 Introduction 
 
Cancer
1 
is the second most dangerous disease in the world after heart failure. Recent studies 
indicated that triazole derivatives
2
 of the phosphodiesterase 4 (PDE4) inhibitor to be potent 
against cancer cell lines. The PDE4
3
 is a member of the super-family of enzymes that can 
break down cyclic adenosine monophosphate and significantly works against tumour cells. 
An investigation on the effect of the PDE4 inhibitor that induces intracellular accumulation 
of cyclic adenosine monophosphate on malignant B-cells chronic lymphocytic leukemia
4a
 has 
indicated that, it can inhibit the growth of tumour cells in the body and cause selective 
apoptosis
4b
 on malignant cells without any side effects. A study of the pathophysiological 
role of PDE4 with possible therapeutic prospects on various lung-cancer
5
 cell lines has 
indicated that PDE4 can be targeted for effective lung-cancer therapy. 
 
 Most of the PDE4 drugs have PDE4 catechol-based chemical structures. In light of the above 
reports, rolipram (Figure 3.1),
6 
which has exhibited selective PDE4B (sub-type of 
phosphodiesterase 4) activity, was chosen as the basic structure
7
 for designing and 
synthesising compounds. Rolipram has several medicinal properties,
8
 which include anti-
inflammatory, antitumour and immunosuppressive, besides being considered to be a 
treatment for disseminated sclerosis and psychosis-related problems.
 
 
 
 
 
 
 
Figure 3.1: Rolipram 
Triazoles are regarded as an attractive class of heterocyclic compounds
9
 because of their 
diverse biological properties.
10
 A study on the 1,2,3‐triazole as a core structure has found it to 
hinder the tyrosine kinase
11
 and to have several remarkable applications in cancer therapy. 
The physical characteristics of triazoles include rigidity, a capability to make the hydrogen 
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bond, modest dipole behaviour and stability under in vivo conditions. These properties make 
triazoles ideal drug targets for anticancer agents. The interesting results of the 
aforementioned findings made us to design and synthesise novel compounds based on 
rolipram. It was proposed that the heterocyclic moiety of the rolipranm was replaced by a 
triazole ring with diverse substituents and to investigate their anticancer properties.   
 
3.2 Results and discussions 
 
Accordingly, vanillin and isovanillin were converted into cyclopentyl/cyclohexyl ethers
12
 and 
subsequently treated with MeMgI to give the corresponding carbinols. Treatment of the 
carbinols with TMSN3
13
 and ZrCl4 Lewis acid catalyst gave the azides. Treatment of azides 
with acetylenes under click conditions afforded triazole derivatives, whose anticancer 
properties were further evaluated.  
 
3.2.1 Synthesis of novel triazole derivatives 
 
Scheme 3.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commercially available cyclic ketones 2 and 2a were subjected to reduction with NaBH4 in 
Methanol (MeOH) at room temperature to give corresponding alcohols 3 (67%) and 3a 
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(69%), which on treatment with methanesulphoonyl chloride and Et3N in CH2Cl2 afforded 
the corresponding mesylates 4 and 4a, respectively. Treatment of 4 and 4a independently 
with vanillin and isovanillin in the presence of K2CO3 in toluene under reflux furnished 
corresponding cyclic ethers 5 (87%)/5a (90%) and 6 (62%)/6a (64%), respectively (Scheme 
3.1). 
 
Treatment of the cyclic ether that had aldehyde functionality 7
14 
with the Grignard reagent 
that was prepared from methyl iodide and Mg turnings in diethyl ether at 0 °C afforded 
carbinol 9 in 87% yield. The 
1
H NMR spectrum of 9 indicated aryl protons resonating at  
6.93 as a multiplet that integrated to three protons, CH protons resonating in the chemical 
shift region at  4.8 as a multiplet that integrated to two protons and methoxy protons 
resonating at  3.83 as a singlet. The presence of cyclic alkyl-group protons at the respective 
chemical shift values indicates the formation of 9. The mass spectrum of carbinol 9 has a 
mass fragmentation peak at 219 as (M
+
-OH). 
 
Scheme 3.2.1 
 
 
 
Furthermore, carbinol  9 on  reaction with TMSN3 in the presence of ZrCl4 (10 mol%) Lewis 
acid in CH3CN at room temperature to give the azide 11 in 78% yield (Scheme 3.2.1). The 
1
H 
NMR spectrum of 11 indicated aryl protons resonating at  6.84 as a multiplet that integrated 
to three protons, OCH proton resonating in the chemical shift region at  4.76 as a multiplet 
that integrates to one proton, benzylic proton resonating at 4.54 as a quartet, and methoxy 
protons resonating at  3.86 as a singlet. The presence of cyclic alkyl-group protons at the 
respective chemical shift values indicates the formation of 11. In the IR spectrum of 11, a 
strong absorbance peak at 2100 cm
-1
 confirms the presence of azide functionality. The mass 
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spectrum of azide 11 has a mass fragmentation peak at 219 as (M
+
-N3). Treatment of 
aldehyde 8
14 
with the Grignard reagent prepared from methyl iodide and Mg turnings in ether 
at 0 °C afforded carbinol 10 in 89% yield. The 
1
H NMR spectrum of 10 indicated aryl 
protons resonating at  6.93 as a multiplet that integrated to three protons, CH protons 
resonating in the chemical shift region at  4.80 as multiplets that integrated to two protons 
and methoxy protons resonating at  3.83 as a singlet. The presence of cyclic alkyl-group 
protons at the respective chemical shift values indicates the formation of 10. The mass 
spectrum of carbinol 10  has a mass fragmentation peak at 219 as (M
+
-OH) 
 
Scheme 3.2.2 
 
 
 
 
 
 
 
  
Further, carbinol 10 on reaction with TMSN3 in the presence of ZrCl4 (10 mol%) Lewis acid 
in CH3CN at room temperature to give the azide 12 in 78% yield (Scheme 3.2.2). The 
1
H 
NMR spectrum of 12, indicated   aryl protons resonating at  6.84 as a multiplet integrated to 
three protons, OCH proton resonating in the chemical shift region at  4.8 as a multiplet that 
integrated to one proton and benzylic proton resonating at  4.53 as a quartet, methoxy 
protons resonating at  3.84 as a singlet. The rest of cyclic alkyl-group protons at the 
respective chemical shift values indicates the formation of  12.  In the IR spectrum of 12 
strong absorbance peak at 2097 cm
-1
 confirms the presence of azide functionality. The mass 
spectrum of azide 12 has a  mass fragmentation peak at 219 as (M
+
-N3).  
 
Treatment of aldehydes 7a
14 
with Grignard reagent prepared from methyl iodide and Mg 
turnings in ether at 0 °C  afforded the carbinol 9a in 87% yield. The 
1
H NMR spectrum of 9a, 
indicated the aryl protons resonating at  6.86 as a multiplet that  integrated to three protons, 
benzylic protons resonating at  4.85 as a quartet integrated to one proton and OCH proton 
resonating at  4.16 as a multiplet and methoxy protons resonating at  3.87 as a singlet. The 
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presence of cyclic alkyl group protons at the respective chemical shift values indicates the 
formation of  9. In mass spectrum of  carbinol 9a has found mass fragmentation peak at 233 
as (M
+
-OH)  
 
Scheme 3.2.3 
 
 
 
 
 
 
 
 
 
 
Further, the carbinol 9a, on reaction with TMSN3 in the presence of ZrCl4 (10 mol%) Lewis 
acid in CH3CN at room temperature to give the azide 11a in 73% yield (Scheme 3.2.3). In the 
1
H NMR spectrum of 11a, showed the aryl protons resonating at  6.84 as a multiplet that 
integrated to three protons and  benzylic proton resonating at  4.56 as a quartet, OCH proton 
resonating in the chemical shift region at  4.18 as a multiplet that integrated to one proton, 
methoxy protons resonating at  3.87 as a singlet and the presence of cyclic alkyl group 
protons at the respective chemical shift values indicates the formation of  11a. In the IR 
spectrum of 11a strong absorbance peak at 2099 cm
-1
 confirms the presence of azide 
functionality. In mass spectrum of azide 11a has found to be 233 as (M
+
-N3). 
 
Treatment of aldehydes 8a
14 
with Grignard reagent prepared from methyl iodide and Mg 
turnings in ether at 0 °C  afforded the carbinol 10a in 88% yield. In the 
1
H NMR spectrum of 
10a, showed the aryl protons resonating at  6.9 as a multiplet that integrated to three 
protons, benzylic proton resonating in the chemical shift region at  4.82 as a quartet and 
OCH proton resonating at  4.21 as a multiplet that integrated to one proton and methoxy 
protons resonating at   3.84 as a singlet. The presence of cyclic alkyl group protons at the 
respective chemical shift values indicates the formation of  10a. In mass spectrum of carbinol 
10a  has found mass fragmentation peak at 233 as (M
+
-OH) 
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Scheme 3.2.4 
 
 
 
 
 
 
 
 
Further, the carbinol 10a, on reaction with TMSN3 in the presence of ZrCl4 (10 mol%) Lewis 
acid in CH3CN at room temperature to give the azide 12a in 78% yield (Scheme 3.2.4). In the 
1
H NMR spectrum of 12a, showed the aryl protons resonating at  6.89 as a multiplet that 
integrated to three protons and  benzylic proton resonating at  4.54 as a quartet, OCH proton 
resonating in the chemical shift region at  4.18 as a multiplet, methoxy protons resonating at 
 3.86 as a singlet and the presence of cyclic alkyl group protons at the respective chemical 
shift values indicates the formation of 12a. In the IR spectrum of 12a strong absorbance peak 
at 2099 cm
-1
 confirms the presence of azide functionality. In mass spectrum of azide 12a has 
found mass fragmentation peak at 233 as (M
+
-N3). 
 
After successfully converting the C-OH bond into the C-N3 bond, azides were converted into 
a triazole by a one-step reaction. A total of eight triazoles were prepared using two different 
acetylenes: phenylacetylene was chosen for the aromatic side chain, and n-octyne for the 
alkyl side chain  
 
Scheme 3.3.1 
 
 
 
 
 
 
Azide 11 on reaction with phenylacetylene in the presence of CuSO4.5H2O and sodium 
ascorbate in aq. t-BuOH (1:1) at room temperature for 8 h afforded triazole 13a in 91% yield 
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(Scheme 3.3.1). The 
1
H NMR spectrum of 13a indicated aryl protons resonating at  7.78 as a 
doublet, triazole protons resonating at  7.60 as a singlet and other aryl protons resonating at 
 7.34 and  6.86 as multiplets that integrated to three protons each, respectively, benzyl 
proton resonating as a quartet at  5.78 and methoxy protons resonating at  3.80 as a singlet, 
and the rest of the protons resonating at respective chemical shift values that indicated the 
formation of 13a. High Resolution Mass Spectrum (HRMS) further confirmed the product 
13a, (M
+ 
+ H) found to be at m/z 364.20250.  
 
Scheme 3.3.2 
 
 
 
 
 
 
 
 
 
The azide 11a on reaction with phenylacetylene in the presence of CuSO4.5H2O and sodium-
ascorbate in aq.t-BuOH (1:1) at room temperature for 8 h afforded the triazole 15a in 97% 
yield (Scheme 3.3.2). In the 
1
H NMR spectrum of 15a, showed the aryl protons resonating at 
 7.78 as a doublet, triazole proton resonating at  7.60 as a singlet and other aryl protons 
resonating at  7.39, 7.30 as multiplets that integrated to two and one protons each 
respectively, while aryl proton resonating at  6.89 as a multiplet that integrated to two 
protons, benzyl proton resonating as a quartet at  5.78, methoxy protons resonating at  3.81 
as a singlet and rest of the protons resonating at respective chemical shift values indicates the 
formation of 15a. HRMS further confirmed the product 15a, (M
+ 
+ Na) found to be at m/z 
400.20010  
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Scheme 3.3.3 
 
 
 
 
 
 
 
The azide 12 on reaction with phenylacetylene in the presence of CuSO4.5H2O and sodium-
ascorbate in aq.t-BuOH (1:1) at room temperature for 8 h afforded the triazole 14a in 92% 
yield (Scheme 3.3.3). In the 
1
H NMR spectrum of 14a, showed the aryl protons resonating at 
 7.77 as a doublet, triazole proton resonating at  7.60 as a singlet and other aryl protons 
resonating at  7.34, 6.86 as multiplets that integrated to three protons each respectively, 
benzyl proton resonating  at  5.78 as a quartet and methoxy protons resonating at  3.85 as a 
singlet and rest of the protons resonating at respective chemical shift values indicates the 
formation of 14a. HRMS further confirmed the product 14a, (M
+ 
+ H) found to be at m/z 
364.20216  
 
Scheme 3.3.4 
 
 
 
 
 
 
 
 
The azide 12a on reaction with phenylacetylene in the presence of CuSO4.5H2O and sodium-
ascorbate in aq.t-BuOH (1:1) at room temperature for 8 h afforded the triazole 16a in 97% 
yield (Scheme 3.3.4). In the 
1
H NMR spectrum of 16a, showed the aryl protons resonating at 
 7.77 as a doublet, triazole proton resonating at  7.58 as a singlet and other aryl protons 
resonating at  7.34, 6.88 as multiplets that integrated to three protons each respectively, 
benzyl proton resonating as a quartet at  5.80, methoxy protons resonating at  3.85 as a 
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singlet and rest of the protons resonating at respective chemical shift values indicates the 
formation of 16a. HRMS further confirmed the product  16a, (M
+ 
+ Na) found to be at m/z 
400.19925.  
 
Scheme 3.3.5 
 
 
 
 
 
 
 
 
 
The azide 11 on reaction with 1-octyne in the presence of CuSO4.5H2O and sodium-ascorbate 
in aq.t-BuOH (1:1) at room temperature for 8 h afforded the triazole 13b in 93% yield 
(Scheme 3.3.5). In the 
1
H NMR spectrum of 13b, showed the triazole proton resonating at  
7.13 as a singlet aryl protons resonating at  6.84, 6.73 as singlets that integrated to two and 
one protons each respectively, benzyl proton resonating at  5.71 as a quartet, methoxy 
protons resonating at  3.83 as a singlet and rest of the protons resonating at respective 
chemical shift values indicates the formation of 13b. HRMS further confirmed the product 
13b, (M
+ 
+ Na) found to be at m/z 372.26514  
 
Scheme 3.3.6 
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The azide 11a on reaction with 1-octyne in the presence of CuSO4.5H2O and sodium-
ascorbate in aq.t-BuOH (1:1) at room temperature for 8 h afforded the triazole 15b in 90% 
yield (Scheme 3.3.6). In the 
1
H NMR spectrum of 15b, showed the triazole proton resonating 
at  7.12 as a singlet, aryl protons resonating at  6.79 as a multiplet that integrated three 
protons, benzyl proton resonating  at  5.70 as a quartet and methoxy protons resonating at   
3.79 as a singlet and rest of the protons resonating at respective chemical shift values 
indicates the formation of 15b. HRMS further confirmed the product 15b, (M
+ 
+ Na) found to 
be at m/z 386.28052  
 
Scheme 3.3.7 
 
 
 
 
 
 
 
The azide 12 on reaction with 1-octyne in the presence of CuSO4.5H2O and sodium-ascorbate 
in aq.t-BuOH (1:1) at room temperature for 8 h afforded the triazole 14b in 92% yield 
(Scheme 3.3.7). In the 
1
H NMR spectrum of 14b, showed the triazole proton resonating at  
7.12 as singlet, aryl protons resonating at  6.83, 6.74 as singlets that integrated to two and 
one protons respectively, benzyl proton resonating at  5.70 as a quartet and methoxy protons 
resonating at  3.79 as a singlet and rest of the protons resonating at respective chemical shift 
values indicates the formation of 14b. HRMS further confirmed the product 14b, (M
+ 
+ Na) 
found to be at m/z 394.24673. 
 
Scheme 3.3.8 
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The azide 12a on reaction with 1-octyne in the presence of CuSO4.5H2O and sodium-
ascorbate in aq.t-BuOH (1:1) at room temperature for 8 h afforded the triazole 16b in 89% 
yield (Scheme 3.3.8). In the 
1
H NMR spectrum of 16b, showed the triazole proton resonating 
at  7.11 as a singlet, aryl protons resonating at  6.85,  6.87 as a singlet that integrated to 
two and one protons respectively. Benzyl proton resonating at  5.69 as a quartet and 
methoxy protons resonating at  3.84 as a singlet and rest of the protons resonating at 
respective chemical shift values indicates the formation of 16b. HRMS further confirmed the 
product 16b, (M
+ 
+ Na) found to be at m/z 386.28020  
 
3.3 Biology 
 
3.3.1 Anticancer activity 
 
In the present study, a series of eight triazoles, ie. 13a, b; 14a, b; 15a, b; and 16a; b (Figure 
3.2), were synthesised. To the best of our knowledge, the anticancer potential of the 
synthesised scaffolds has not been previously reported. According to the National Cancer 
Institute (NCI) protocol, all the eight compounds were screened against a cancer cell-line 
panel of NCI 60. The protocol used for the investigation of NCI 60 cell lines has been 
reported,
15-17
 but a brief account is as follows: 
 
     
Figure 3.2: Rolipram triazole derivatives 
 
The cell lines from the NCI 60 panel were organised into sub-panels that represented 
leukemia, melanoma and cancers of the lung, colon, kidney, ovary, breast, prostate and central 
nervous system. All the cells were grown in a suitable growth medium supplemented with 
foetal bovine serum for 24 h. The test compounds were dissolved in Dimethyl Sulfoxide 
Chapter III 
 
73 
 
(DMSO) and incubated with the cells at a final concentration of 10 μM for 24 h. The assay 
was terminated by the addition of cold trichloroacetic acid, and the cells were fixed and 
stained with sulforhodamine B. The bound stain was solubilised, and the UV-Visible colour 
absorbance was read on an automated plate reader. The measured absorbance was directly 
proportional to the cell growth.  
 
In the present study, eight triazoles (13a, b; 14a, b; 15a, b; and 16a, b) were assessed for their 
growth-inhibition activity (anticancer potential) against 60 different human cancer cell lines 
that covered wide histologies. Triazoles 13a (NSC 768684) and 15a (NSC 768688) exhibited 
the best cytotoxicity against a large number of cell lines in the NCI60 cell-line panel that 
represents common tumours.   
 
 
 
 
Figure 3.3: Heat map displaying cytotoxic potential for the series of triazoles prepared. 
 
The screening process started with the evaluation of all the compounds against the 60 human 
tumour cell lines at a single dose of 10.0 µM. The output from the single dose screen is 
reported as a mean graph. The percentage of growth inhibition was compared to a DMSO-
treated standard, and a comparative summary of the growth inhibition is shown as a heat map 
in Figure 3.3. The screening results indicated that triazole compounds from the present study 
have low to moderate activity against most of the cell lines in the NCI60 panel. Notably, the 
analysis indicated that triazoles 13a and 15a were active in causing significant growth 
inhibition of 10 distinct cell lines, which are represented in Table 3.1. This suggested that the 
combination of ‘cyclo alkoxy’ group at fourth position of aromatic ring and ‘phenyl’ group as 
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side chain to the triazole ring resulted in an increased inhibitory effect compared to the other 
molecules designed in our set.  
3.3.2 Studies of mechanism of action for anticancer activity 
 
The results from the initial screening revealed that 13a and 15a were the most active against the 
breast-cancer cell line MDA-MB-468, with growth inhibition amounts of 94.9 and 91.1%, 
respectively. Therefore, to determine their anticancer potential and the molecular mechanism 
involved in the anti cancr activity, various studies were performed, including clonogenic 
potential, anchorage‐independent growth of estrogen-receptor-positive (MCF7 and T47D) and 
estrogen-receptor-negative (MDA‐MB‐231 and MDA‐MB‐468) breast-cancer cells. 
Furthermore, we investigated the induction of apoptotic pathways. Details of various 
experiments are described below. 
 
Table 3.1: Growth-inhibition percentages of cell lines in NCI 60. 
 
Cell Line % Inhibition (13a)  % Inhibition (15a) 
K-562 66.0 74.1 
RPMI-8226 63.9 65.0 
NCI-H23 54.6 52.3 
HCT-116 47.7 57.5 
SF-295 53.0 59.8 
SK-MEL-5 74.0 70.0 
NCI/ADR-RES 55.0 50.7 
CAKI-1 50.4 51.3 
MCF7 51.8 50.2 
MDA-MB-468 94.9 91.1 
 
3.3.2.1 Screening of clonogenic potential in breast-cancer cells for triazoles 13a and 15a  
 
The clonogenic assay was performed on MCF7, T47D, MDA-MB-231 and MDA-MB-468 
cells with different concentrations of triazoles 13a and 15a ranging from 1.0 µM to 100 µM. 
(Figures 3.4 and 3.5). Treatment of triazoles 13a and 15a with breast cancer cell lines 
resulted in dose-dependent and statistically significant inhibition of clonogenicity. Treatment 
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with 5 µM of triazoles 13a and 15a resulted in ~50-60% inhibition of clonogenicity, and at 
higher concentrations (100 µM), a greater inhibitory effect was observed (Figure 3.4 and 3.5).  
 
Figure 3.4: Screening of clonogenic potential for compound 13a 
 
Figure 3.5:  Screening of clonogenic potential for compound 15a 
 
MCF7, MDA-MB-231, MDA-MB-468 and T47D breast-cancer cells were treated with 
triazoles 13a and 15a of various concentrations and subjected to an anchorage-dependent 
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colony-formation assay. The results indicated that both triazoles 13a and 15a inhibit the 
clonogenic potential of breast-cancer cells based on the concentration of a compound used in 
the assay. 
 
Cleavage of poly(ADP-ribose)polymerase (PARP) facilitates cellular disassembly and serves 
as a marker of cells that undergo apoptosis.
18
 MCF7, T47D, MDA-MB-231 and MDA-MB-
468 cells were treated with 13a of different concentrations (5, 10 and 25 µM), and the PARP 
levels were determined. Upon treatment with triazole 13a, MCF7 cells indicated an induction 
of cleaved PARP within 6 h after treatment, which remained elevated after 24 h, whereas 
T47D cells exhibited a stronger effect 24 h after treatment.  
 
Figure 3.6: Cleavage of PARP in breast-cancer cells with compound 13a. 
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The same effects were observed in MDA-MB-231 and MDA-MB-468 upon treatment with 
triazole 13a. A to D is the representation of activity images for the different cell lines in 
Figure 3.6. (A) MCF7, (B) T47D, (C) MDA-MB-468 and (D) MDA-MB-231 breast-cancer 
cells were treated with triazole 13a of various concentrations for 6 h and 24 h, and equal 
amount of protein lysates were subjected to SDS-PAGE analysis, which was followed by 
immunoblot analysis using specific antibodies against cleaved PARP and total PARP.  
 
To determine the anticancer potential of triazole 15a, breast-cancer cells (MCF7, MDA-MB-
468 and MD-MB-231) were treated with triazole 15a of increasing concentration (5, 10 and 
25 µM) for 6 h and 24 h. From the results obtained, MCF7 cells did not exhibit a significant 
alteration in cleaved-PARP levels after 6 h of treatment at any of the tested concentrations. 
The higher concentration of triazole 15a (10 and 25 µM) induced PARP cleavage in MCF7 
cells after 24 h. In MDA-MB-468 cells, triazole 15a significantly induced elevated levels of 
cleaved PARP, whereas in MDA-MB-231 cells, only a moderate increase in cleaved PARP 
was observed after 6 h and 24 h of treatment (Figure 3.7). Overall, treatment with triazoles 
13a and 15a indicated an induction in cleaved PARP (Figure 3.6 and 3.7), thus indicating 
apoptotic induction. 
 
Figure 3.7: Cleavage of PARP in breast-cancer cells with triazole 15a 
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A-C are the images for activity results on different cell lines (Figure 3.7). (A) MCF7, (B) 
MDA-MB-468 and (C) MDA-MB-231 breast-cancer cells were treated with various 
concentrations of triazole 15a for 6 h and 24 h (Figure 3.6), and an equal amount of protein 
lysates was subjected to SDS-PAGE analysis, which was followed by immunoblot analysis 
using specific antibodies against cleaved PARP and total PARP. The results indicated that 
triazoles 13a and 15a increase cleavage of PARP in a concentration-dependent manner, thus 
indicating their potential to induce apoptosis. 
 
3.3.2.2 Screening of 13a and 15a against an X-linked inhibitor of apoptosis protein 
(XIAP) in breast-cancer cells  
 
Furthermore, we investigated the involvement of XIAP
19, 20
 in 13a- and 15a-mediated 
apoptotic induction.  
 
Figure 3.8: Screening of triazoles 13a and 15a against XIAP in breast-cancer cells.  
 
An investigation of the treatment of T47D, MDA-MB-468 and MDA-MB-231 breast-cancer 
cells with 13a and 15a of increasing concentration (5, 10 and 25 µM) for 24 h resulted in a 
significant reduction of XIAP expression in all cells (Figure 3.8). A and B are the images for 
the representation of screening of triazoles 13a and 15a, respectively. (A) T47D, MDA-MB-
468, and MDA-MB-231 breast-cancer cells were treated with 13a of various concentrations 
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for 24 h (Figure 8A), and an equal amount of protein lysates were subjected to SDS-PAGE 
analysis, which was followed by immunoblot analysis using specific antibodies against 
XIAP. Actin was used as a control, and various concentrations of triazole 15a were also 
screened against (B) MDA-MB-468 and MDA-MB-231 breast-cancer cells with similar 
conditions. The results indicated that the treatment of triazoles 13a and 15a with breast 
cancer cells decreases the expression of XIAP (an anti-apoptotic protein) in a concentration-
dependent manner, thus indicating its potential to induce apoptosis. 
 
3.3.2.3 Screening of the epidermal growth factor receptor and the human epidermal 
growth factor receptor 2 in breast-cancer cells with triazoles 13a and 15a.  
 
Activation of the epidermal growth factor receptor (EGFR) and human epidermal growth 
factor receptor 2 (Her2) in response to various extracellular stimuli has been known to play 
important roles in breast carcinogenesis.
21-23
  
 
 Figure 3.9: Screening of the epidermal growth factor receptor (EGFR) and human epidermal 
growth factor receptor 2 (Her2) in breast cancer cells with triazoles 13a and 15a.  
 
BT474 cells were treated with 5, 10 and 25 µM of triazoles 13a and 15a for 24 h. The results 
indicated that effective inhibition of EGFR phosphorylation in BT474 cells on treatment with 
10 and 25 µM of triazoles 13a and 15a, whereas a 5 µM concentration indicated no change in 
phosphorylation levels (Figures 3.9A and 3.9B). Treatment of 10 µM and 25 µM triazole 13a 
with cells reduced phosphorylation of Her2 (Figure 3.9A). Treatment with triazole 15a 
resulted in effective inhibition of Her2 phosphorylation at 5, 10 and 25 µM (Figure 3.9B). 
(A) BT474 breast-cancer cells were treated with various concentrations of triazole 13a 
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(Figure 3.9A) for 24 h, and an equal amount of protein lysates were subjected to SDS-PAGE 
analysis, which was followed by immunoblot analysis using specific antibodies against 
phospho-EGFR (Tyr992) (p-EGFR), total EGFR, phospho-Her2 (p-Her2), and Her2. Actin 
was used as a control. The similar screening method was applied to triazole 15a against (B) 
BT474 breast cancer cells that were treated with 15a of various concentrations triazole 
(Figure 3.9B). The results indicated that the treatment of triazoles 13a and 15a decreased the 
phosphorylation of EGFR and Her2 in a concentration-dependent manner, thus indicating its 
potential to inhibit two important upstream kinase pathways in breast-cancer cells. 
 
3.4 Conclusion 
 
In summary, new triazole-vanillin-coupled molecular hybrids were prepared, and they were 
screened for their anticancer activity against 60 human cancer cell lines that represent diverse 
histologies. Two triazoles, 13a and 15a, exhibited high inhibitory activity against a host of 
cell lines. Mechanistic studies on breast-cancer cell lines (MCF7, MDA-MB-231 and T47D) 
indicated that both of the triazoles 13a  and 15a inhibit breast-cancer cells’ clonogenic 
potential in a concentration-dependant manner. Furthermore, the triazoles were found to 
activate the cleavage of PARP and inhibit the XIAP in breast-cancer cells and the 
phosphorylation of the EGFR network.  
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1-(4-(Cyclopentyloxy)-3-methoxyphenyl) ethanol (9): To a well-stirred suspension of Mg 
turnings (65 mg, 27.2 mmol) in ether (10 mL), methyl iodide (1.6 mL, 27.2 mmol) was added 
at room temperature. A solution of aldehyde 7 (2 g, 9.09 mmol.) in ether (10 mL) was added 
to the resultant mixture at 0 °C and allowed to stir for 1 h at room temperature. The reaction 
mixture was quenched with saturated aqueous NH4Cl (50 mL) and extracted into EtOAc (2 × 
50 mL). The combined organic layers were washed with water (50 mL), brine (50 mL) and 
dried (Na2SO4). The solvent was evaporated under reduced pressure, and the residue was 
purified by column chromatography (60-120 mesh Silica gel, 15% EtOAc in pet. ether) to 
afford carbinol 9 (1.86 g, 87%) as a light-yellow oil. IR (CHCl3): 2962, 2924, 2869, 2310, 
1694, 1505, 1418, 1218, and 772 cm
-1
; 
1
H NMR (300 MHz, CDCl3):  6.93 (m, 3H, ArH), 
4.80 (m, 2H, CH), 3.83 (s, 3H, OMe), 2.02-1.77 (m, 6H, 3 × CH2), 1.67-1.57 (m, 2H, CH2), 
1.46 (d, 3H, J = 6.4 Hz, CH3); 
13
C NMR (75 MHz, CDCl3):  149.9, 146.9, 138.3, 117.5, 
114.6, 109.3, 80.4, 70.2, 55.9, 32.7, 24.9, and 23.9. 
 
 
 
 
 
 
4-(1-Azidoethyl)-4-(cyclopentyloxy)-3-methoxybenzene (11): To a solution of 9 (1 g, 4.2 
mmol) in acetonitrile (5 mL) at 0 °C, azido trimethylsilane (1.4 mL, 10.59 mmol) was added, 
which was followed by ZrCl4 (98 mg, 0.42 mmol) was added in portion wise. After it stirring 
for 2 h, the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 × 
30 mL). The combined organic layers were washed with brine (10 mL) and dried (Na2SO4). 
The solvent was evaporated and the residue was purified by column chromatography (60-120 
mesh Silica gel, 10% EtOAc in pet. ether) to afford 11 (0.86 g, 78%) as a light-yellow oil. IR 
(CHCl3): 2922, 2852, 2310, 2100, 1512, 1419, 1222, 986, and 772 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3):  6.84 (m, 3H, ArH), 4.76 (m, 1H, OCH), 4.54 (q, 1H, J = 6.8 Hz, ArCH), 3.86 (s, 
3H, OMe), 1.93-1.62 (m, 8H, 4 × CH2), 1.50 (d, 3H, J = 6.8 Hz, CH3); 
13
C NMR (75 MHz, 
CDCl3):  149.9, 147.5, 132.9, 118.6, 114.3, 110.0, 80.2, 60.9, 55.9, 32.7, 24.0, and 21.4. 
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1-(1-(4-(Cyclopentyloxy)-3-methoxyphenyl)ethyl)-4-phenyl-1H-1,2,3-triazole (13a): A 
solution of azide 11 (0.20 g, 0.766 mmol) and phenylacetylene (0.1 mL, 0.93 mmol) in t-
BuOH (1 mL) and water (1 mL) was treated with sodium ascorbate (30 mg, 0.15 mmol) 
followed by CuSO4.5H2O (19 mg, 0.076 mmol) at room temperature and stirred for 8 h. The 
solvent was removed by evaporation from the reaction mixture, and the residue was diluted 
with water (5 mL) and extracted with EtOAc (2 × 10 mL). The combined organic layers were 
washed with brine (5 mL) and dried (Na2SO4). The solvent was evaporated. and the residue 
was purified by column chromatography (60-120 mesh Silica gel, 15% EtOAc in pet. ether) 
to afford 13a (0.25 g, 91%) as a white solid. mp 96-100 
o
C; IR (CHCl3): 2920, 2851, 1693, 
1513, 1462, 1219, and 772 cm
-1
; 
1
H NMR (300 MHz, CDCl3):  7.78 (d, 2H, J = 7.5 Hz, 
ArH), 7.60 (s, 1H, ArH), 7.41-7.27 (m, 3H, ArH, CH), 6.90-6.82 (m, 3H, ArH,), 5.78 (q, 1H, 
J = 6.8 Hz, ArCH), 4.76 (m, 1H, CH), 3.80 (s, 3H, OMe), 1.98 (d, 3H, J = 7.1 Hz, CH3), 
1.95-1.60 (m, 8H, 4 × CH2); 
13
C NMR (75 MHz, CDCl3):  150.2, 147.9, 147.5, 131.8, 130.6, 
128.6, 127.9, 125.5, 118.5,118.2, 114.5, 110.7, 80.39, 59.9, 56.1, 32.7, 24.0, and 21.2; HRMS 
(ESI+): m/z calculated for C22H26N3O2 (M
+
 + H) = 364.20195; found 364.20250. 
 
 
 
 
 
 
 
1-(1-(4-(Cyclopentyloxy)-3-methoxyphenyl)ethyl)-4-hexyl-1H-1,2,3-triazole (13b): A 
solution of azide 11 (0.20 g, 0.76 mmol) and n-octyne (0.1 mL, 0.76 mmol) in t-BuOH (1 
mL) and water (1 mL) was treated with sodium ascorbate (30 mg, 0.15 mmol) followed by 
CuSO4.5H2O (19 mg, 0.076  mmol) at room temperature and stirred for 8 h. Workup as 
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described for 13a and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 15% EtOAc in pet. ether) afforded  13b (0.27 g, 93%) as a yellow gummy liquid; 
IR (CHCl3): 2920, 2851, 1693, 1513, 1462, 1219, 772 cm
-1
; 
1
H NMR (300 MHz, CDCl3):  
7.13 (s, 1H, ArH), 6.84 (s, 2H, ArH), 6.73 (s, 1H, CH), 5.71 (q, 1H, J = 7.2 Hz, ArCH), 4.70 
(m, 1H, CH), 3.83 (s, 3H, OMe), 2.67 (t, 2H, J = 7.6 Hz, CH2), 1.98-1.74 (m, 9H, CH3, 3 x 
CH2), 1.74-1.41 (m, 6H, 3 x CH2), 1.70-1.53 (m, 4H,  2 x CH2), 0.86 (m, 3H, CH3); 
13
C NMR 
(75 MHz, CDCl3):  149.9, 148.4, 147.8, 132.4, 119.1, 118.4, 113.3, 111.6, 80.4, 59.6, 55.9, 
32.7, 31.5, 29.4, 28.8, 25.7, 23.9, 22.5, 21.2, 14.0 HRMS (ESI+): m/z calcd. for C22H34N3O2 
(M
+
 + Na) 372.26455, found 372.26514. 
 
 
 
 
 
 
 
 
1-(3-(Cyclopentyloxy)-4-methoxyphenyl) ethanol (10): To a  well stirred suspension of Mg 
turnings (65 mg, 27.2mmol) in ether (10 mL) methyl iodide (1.6 mL, 27.2 mmol) was added  
at room temperature. A solution of aldehyde 8 (2 g, 9.09 mmol.) in ether (10mL) was added 
at to this Grignard solution at 0 °C and allowed to stir for 1 h at room temperature. Workup 
as described for 9 and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 15% EtOAc in pet. ether) afforded  10 (1.9 g, 89%) as a light-yellow oil. IR 
(CHCl3): 3019, 2932, 2856, 2313, 1694, 1511, 1446, 1423, 1215, 745 cm
-1
; 
1
H NMR(300 
MHz, CDCl3):  6.93 (m, 3H, ArH), 4.80 (m, 2H, CH), 3.83 (s, 3H, OMe), 2.02-1.77 (m, 6H, 
3 x CH2), 1.67-1.57 (m, 2H, CH2), 1.46 (d, 3H, J = 6.4 Hz, CH3); 
13
C NMR (75 MHz, 
CDCl3):  149.4, 147.7, 138.4, 117.5, 112.4, 111.8, 80.4, 70.2, 56.1, 32.8, 25.0, 24.0. 
 
 
 
 
 
4-(1-Azidoethyl)-2-(cyclopentyloxy)-1-methoxybenzene (12): To a solution of 10 (1 g, 4.2 
mmol) in acetonitrile (5 mL) at 0 
o
C azidotrimethylsilane (1.4 mL, 10.59 mmol) followed by 
ZrCl4 (98 mg, 0.42 mmol)  portion wise was added and stirred for 2 h. Workup as described 
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for 11 and purification of the residue by column chromatography (60-120 mesh Silica gel, 
5% EtOAc in pet. ether) afforded azide 12 (0.86 g, 78%) as a light yellow oil. IR (CHCl3): 
2957, 2924, 2852, 2097, 1591, 1512, 1231, 1138, 985, 772 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3):  6.84 (s, 3H, ArH),  4.80 (m, 1H, OCH), 4.53 (q, 1H, J = 6.8 Hz, ArCH), 3.84 (s, 
3H, OMe), 1.99-1.51 (m, 8H, 4 x CH2), 1.51 (d, 3H, J = 6.8 Hz, CH3); 
13
C NMR (75 MHz, 
CDCl3):  149.9, 147.8, 133.2, 118.7, 113.3, 111.9, 80.5, 60.9, 56.1, 32.8, 24.0, 21.4.  
 
 
 
 
 
 
 
1-(1-(3-(Cyclopentyloxy)-4-methoxyphenyl)ethyl)-4-phenyl-1H-1,2,3-triazole (14a): A 
solution of azide 12 (0.20 g, 0.76 mmol) and phenylacetylene (0.1 mL, 0.76 mmol) in t-
BuOH (1 mL) and water (1 mL) was treated with sodium ascorbate (30 mg, 0.15 mmol) 
followed by CuSO4.5H2O (19 mg, 0.07 mmol) at room temperature and stirred for 8 h. 
Workup as described for 13a and purification of the residue by column chromatography (60-
120 mesh Silica gel, 15% EtOAc in pet. ether) afforded  14a (0.26 g, 92%) as a white solid; 
mp 90-94 
o
C; IR (CHCl3): 2921, 2851, 2310, 1726, 1514, 1441, 1257, 1220, 771cm
-1
; 
1
H 
NMR (300 MHz, CDCl3):  7.77 (d, 2H, J = 7.2 Hz, ArH), 7.60 (s, 1H, ArH), 7.44-7.26 (m, 
3H, ArH), 6.92-6.82 (m, 3H, ArH, CH) 5.78 (q, 1H, J = 7.2 Hz, ArCH), 4.72 (m, 1H, CH), 
3.85 (s, 3H, OMe), 2.01 (d, 3H, J = 7.2 Hz, CH3), 1.91-1.53 (m, 8H, 4 x CH2); 
13
C NMR (125 
MHz, CDCl3):  150.2, 148.0, 147.5, 132.0, 130.7, 128.7, 127.9, 125.6, 118.6, 118.2, 113.5, 
111.8, 80.5, 59.9, 50.6, 32.7, 23.9, 21.5; HRMS (ESI+) m/z calcd for C22H25N3O2 (M
+
 + H) 
364.20195, found 364.20216. 
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1-(1-(3-(Cyclopentyloxy)-4-methoxyphenyl)ethyl)-4-hexyl-1H-1,2,3-triazole (14b): A 
solution of azide 12 (0.20 g, 0.76 mmol) and n-octyne (0.1 mL, 0.76 mmol) in t-BuOH (1 
mL) and water (1 mL) was treated with sodium ascorbate (30 mg, 0.15 mmol) followed by 
CuSO4.5H2O (19 mg, 0.076  mmol) at room temperature and stirred for 8 h. Workup as 
described for 13a and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 15% EtOAc in pet. ether) afforded  14b (0.26 g, 92%) as a white solid; IR 
(CHCl3): 2921, 2852, 2310, 1514, 1259, 1258, 1217, 1140, 1030, 997, 772 cm
-1
; 
1
H NMR 
(300 MHz, CDCl3):  7.12 (s, 1H,  ArH), 6.83 (s, 2H, ArH), 6.74 (s, 1H, CH), 5.70 (dd, 1H, J 
= 13.9, 7.2 Hz, ArCH), 4.75 (m, 1H, CH), 3.79 (s, 3H, OMe), 2.66 (t, 2H, J = 7.6 Hz, CH2), 
1.99-1.79 (m, 10H, 5 x CH2), 1.70-1.54 (m, 5H, CH2, CH3), 1.37-1.25 (m, 7H, 2 x CH2, CH3); 
13
C NMR (125 MHz, CDCl3):  150.1, 148.3, 147.8, 132.3, 119.1, 118.6, 114.4, 110.7, 80.4, 
59.6, 56.1, 32.8, 31.5, 29.4, 28.9, 25.7, 24.0, 22.5, 21.2, 14.0; HRMS (ESI+): m/z calcd for 
C22H33N3O2Na (M
+
 + Na) 394.24650, found 394.24673.  
 
 
 
 
 
 
1-(4-(Cyclohexyloxy)-3-methoxyphenyl)ethanol (9a): To a  well stirred suspension of Mg 
turnings (62 mg, 25.6 mmol) in ether (10 mL) methyl iodide (1.6 mL, 25.6mmol) was added  
at room temperature. A solution of aldehyde 7a (2 g, 8.5 mmol.) in ether (10mL) was added 
at to this Grignard solution at 0 °C and allowed to stir for 1 h at room temperature. Workup 
as described for 9 and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 15% EtOAc in pet. ether) afforded  9a (1.85 g, 87%) as a light-yellow oil. IR 
(CHCl3): 3030, 2924, 2853, 2310, 1732, 1588, 1504, 1417, 1258, 1220, 772 cm
-1
; 
1
H NMR 
(300 MHz, CDCl3):  6.98-6.81 (m, 3H, ArH), 4.85 (q, 1H, J = 6.6 Hz, ArCH), 4.16 (m, 
1H,CH), 3.87 (s, 3H, OMe), 2.13-1.94 (m, 2H, CH2), 1.89-1.69 (m, 2H, CH2), 1.49 (d, 3H, J 
= 6.4 Hz, CH3), 1.40-1.20 (m, 6H, 3 x CH2); 
13
C NMR (75 MHz, CDCl3):  150.6, 146.5, 
138.9, 117.5, 116.3, 109.6, 77.4, 70.3, 56.0, 32.6, 25.6, 24.9, 24.1. 
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4-(1-Azidoethyl)-1-(cyclohexyloxy)-2-methoxybenzene (11a): To a solution of 9a (1 g, 4.0 
mmol) in acetonitrile (5 mL) at 0 
o
C azidotrimethylsilane (1.3 mL, 10.0 mmol) followed by 
ZrCl4 (93 mg, 0.4 mmol)  portion wise was added and stirred for 2 h. Workup as described for 
11 and purification of the residue by column chromatography (60-120 mesh Silica gel, 5% 
EtOAc in pet. ether) afforded azide 11a (0.8 g, 73%) as a light yellow oil. IR (CHCl3): 2926, 
2853, 2309, 2099, 1511, 1221, 772 cm
-1
; 
1
H NMR (500 MHz, CDCl3):  6.90-6.82 (m, 3H, 
ArH),  4.56 (q, 1H, J = 6.5, ArCH), 4.18 (m, 1H, OCH), 3.87 (s, 3H, OMe), 2.02 (m, 2H, 
CH2), 1.82 (m, 2H, CH2),  1.62-148 (m, 7H, 2 x CH2, CH3), 1.40-1.24 (m, 2H, CH2); 
13
C 
NMR (75 MHz, CDCl3):  150.7, 147.13, 133.7, 118.7, 116.1, 110.5, 77.3, 61.0, 56.1, 31.9,  
25.6,  24.1, 21.4.  
 
 
 
 
 
 
 
 
1-(1-(4-(Cyclohexyloxy)-3-methoxyphenyl)ethyl)-4-phenyl-1H-1,2,3-triazole (15a): A 
solution of azide 11a (0.2 g, 0.73 mmol) and phenylacetylene (0.1 mL, 0.73 mmol) in t-
BuOH (1 mL) and water (1 mL) was treated with sodium ascorbate (30 mg, 0.14 mmol) 
followed by CuSO4.5H2O (19 mg, 0.073  mmol) at room temperature and stirred for 8 h. 
Workup as described for 13a and purification of the residue by column chromatography (60-
120 mesh Silica gel, 15% EtOAc in pet. ether) afforded  15a (0.27 g, 97%) as a white solid; 
mp 118-122 
o
C; IR (CHCl3): 3019, 2926, 2854, 2312, 1550, 1512, 746 cm
-1
; 
1
H NMR (500 
MHz, CDCl3):  7.78 (d, 2H, J = 7.7 Hz, ArH), 7.60 (s, 1H, ArH), 7.39 (t, 2H, J = 7.7 Hz, 
ArH), 7.30 (t, 1H, J = 7.7 Hz, ArH), 6.91-6.86 (m, 2H, ArH ), 6.84 (s, 1H, CH), 5.78 (q, 1H, 
J = 7.1 Hz, ArCH), 4.19 (m, 1H, CH), 3.81 (s, 3H, OMe), 2.00 (d, 3H, J  = 7.1 Hz, Me), 1.81 
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(m, 2H, CH2), 1.59-1.52 (m, 4H, 2 x CH2), 1.38-1.25 (m, 4H, 2 x CH2); 
13
C NMR (75 MHz, 
CDCl3,  298K):  150.7, 147.6, 147.4, 132.3, 130.6, 128.7, 127.9, 125.6, 118.7, 118.2, 115.7, 
110.8, 77.2, 60.0, 56.1, 31.9, 25.5, 24.0, 21.2; HRMS (ESI+): m/z calcd for C23H27N3O2Na 
(M
+
 + Na) 400.19955, found 400.20010. 
 
 
 
 
 
 
 
1-(1-(4-(Cyclohexyloxy)-3-methoxyphenyl)ethyl)-4-hexyl-1H-1,2,3-triazole (15b): A 
solution of azide 11a (0.2 g, 0.72 mmol) and n-octyne (0.1 mL, 0.72 mmol) in t-BuOH (1 mL) 
and water (1 mL) was treated with sodium ascorbate (30 mg, 0.14 mmol) followed by 
CuSO4.5H2O (19 mg, 0.072  mmol) at room temperature and stirred for 8 h. Workup as 
described for 13a and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 15% EtOAc in pet. ether) afforded  15b (0.25 g, 90%) as a yellow liquid. IR 
(CHCl3): 2920, 2852, 2311, 1512, 1461, 1219, 1142, 772 cm
-1
; 
1
H NMR (300 MHz, CDCl3):  
7.12 (s, 1H,  ArH), 6.87-6.71(m, 3H, ArH, CH), 5.70 (q, 1H, J = 6.8, ArCH), 4.17 (m, 1H, 
CH), 3.79 (s, 3H, OMe), 2.67 (t, 2H, J = 7.5 Hz, CH2), 2.03-1.44 (m, 11H, 4 x CH2, CH3), 
1.34-1.29 (m, 10H, 5 x CH2), 0.86 (t, 3H, J  = 6.4 Hz, CH3); 
13
C NMR (75 MHz, CDCl3):  
150.7, 148.4, 147.3, 132.9, 119.1, 118.6, 115.8, 110.9, 77.2, 59.6, 56.0, 31.9, 31.5, 29.4, 28.9, 
25.7, 25.5,  24.0, 22.5, 21.3, 13.9; HRMS (ESI+): m/z calcd for C23H36N3O2 (M
+
 + Na) 
386.28020, found 386.28052. 
 
 
     
 
 
 
1-(3-(Cyclohexyloxy)-4-methoxyphenyl) ethanol (10a): To a  well stirred suspension of Mg 
turnings (62 mg, 25.6 mmol) in ether (10 mL) methyl iodide (1.6 mL, 25.6mmol) was added  
at room temperature. A solution of aldehyde 8a (2 g, 8.5 mmol) in ether (10mL) was added at 
to this Grignard solution at 0 °C and allowed to stir for 1 h at room temperature. Workup as 
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described for 9 and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 15% EtOAc in pet. ether) afforded  10a (1.85 g, 88%) as a light-yellow oil. IR 
(CHCl3): 2960, 2922, 2852, 2310, 1510, 1258, 1221, 1135, 991,772 cm
-1
; 
1
H NMR (300 
MHz, CDCl3):  6.9 (m, 3H, ArH), 4.82 (q, 1H, J = 6.4 Hz, ArCH), 4.21 (m, 1H,CH), 3.84 (s, 
3H, OMe), 2.05-1.59 (m, 6H, 3 x CH2), 1.468 (d, 3H, J = 6.4 Hz, CH3), 1.41-1.25 (m, 4H, 2 x 
CH2); 
13
C NMR (75 MHz, CDCl3):  149.9, 147.3, 138.4, 118.1, 113.7, 111.9, 77.2, 70.1, 
56.0, 31.9, 25.5, 24.9, 24.0.  
 
 
 
 
 
 
4-(1-Azidoethyl)-2-(cyclohexyloxy)-1-methoxybenzene (12a): To a solution of 10a (1 g, 
4.0 mmol) in acetonitrile (5 mL) at 0 
o
C azidotrimethylsilane (1.3 mL, 10.0 mmol) followed 
by ZrCl4 (93 mg, 0.4 mmol)  portion wise was added and stirred for 2 h. Workup as described 
for 11 and purification of the residue by column chromatography (60-120 mesh Silica gel, 
5% EtOAc in pet. ether) afforded azide 12a (0.81 g, 78%) as a light yellow oil; IR (CHCl3): 
2925, 2853, 2099, 1511, 1447, 1258, 1221, 772 cm
-1
; 
1
H NMR (500 MHz, CDCl3):  6.89 
(m, 3H, ArH), 4.54 (q, 1H, J = 6.5 Hz, ArCH), 4.18 (m, 1H, CH), 3.86 (s, 3H, OMe), 2.01 
(m, 2H, CH2), 1.82 (m, 2H, CH2), 1.59 (m, 7H, 2 x CH2, CH3), 1.32-1.26 (m, 2H, CH2); 
13
C 
NMR (75 MHz, CDCl3):  133.1, 119.2, 114.6, 111.9, 77.4, 76.8, 76.3, 60.8, 55.9, 31.9, 25.6, 
24.0, 21.4.  
 
 
 
 
 
 
 
 
1-(1-(3-(Cyclohexyloxy)-4-methoxyphenyl)ethyl)-4-phenyl-1H-1,2,3-triazole (16a): A 
solution of azide 12a (0.20 g, 0.73 mmol) and phenylacetylene (0.1 mL, 0.73 mmol) in t-
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BuOH (1 mL) and water (1 mL) was treated with sodium ascorbate (30 mg, 0.14 mmol) 
followed by CuSO4.5H2O (19 mg, 0.073  mmol) at room temperature and stirred for 8 h. 
Workup as described for 13a and purification of the residue by column chromatography (60-
120 mesh Silica gel, 15% EtOAc in pet. ether) afforded  16a (0.25 g, 91%) as a white solid; 
mp 110-114 
o
C; IR (CHCl3): 2923, 2853, 2310, 1512, 1457, 1259, 1220, 1025, 771 cm
-1
; 
1
H 
NMR (300 MHz, CDCl3):  7.77 (d, 2H, J = 7.2 Hz, ArH), 7.58 (s, 1H, ArH), 7.41-7.27 (m, 
3H, ArH), 6.93-6.83 (m, 3H, ArH, CH), 5.80 (q, 1H, J =   7.2 Hz, ArCH), 4.15 (m, 1H, CH), 
3.85 (s, 3H, OMe), 1.98 (d, 3H, J = 7.1 Hz, CH3), 1.80-1.46 (m, 6H, 3 x CH2), 1.37-1.23 (m, 
4H, 2 x CH2); 
13
C NMR (75 MHz, CDCl3,  298K):  150.8, 147.6, 147.4, 132.1, 130.7, 128.7, 
127.9, 125.6, 119.3,118.2, 115.2, 112.2, 77.2, 59.8, 56.0, 31.8, 25.5, 23.8, 21.2; HRMS 
(ESI+): m/z calcd for C23H27N3O2Na (M
+
 + Na) 400.19955, found 400.19925. 
 
 
 
 
 
 
 
1-(1-(3-(Cyclohexyloxy)-4-methoxyphenyl)ethyl)-4-hexyl-1H-1,2,3-triazole (16b): A 
solution of azide 12a (0.2 g, 0.72 mmol) and n-octyne (0.1 mL, 0.72 mmol) in t-BuOH (1 
mL) and water (1 mL) was treated with sodium-ascorbate (30 mg, 0.14 mmol) followed by 
CuSO4.5H2O (19 mg, 0.072  mmol) at room temperature and stirred for 8 h. Workup as 
described for 13a and purification of the residue by column chromatography (60-120 mesh 
Silica gel, 15% EtOAc in pet. ether) afforded  16b (0.24 g, 89%) as a yellow gummy liquid; 
IR (CHCl3): 3019, 2922, 2852, 2311, 1215, 771 cm
-1
; 
1
H NMR (300 MHz, CDCl3):  7.11 (s, 
1H,  ArH), 6.85 (s, 2H, ArH), 6.78 (s, 1H, CH), 5.69 (dd, 1H, J = 7.2, 13.9 Hz, ArCH), 4.12 
(m, 1H, CH), 3.84 (s, 3H, OMe), 2.66 (t, 2H,  J = 7.6 Hz, CH2), 1.91 (d, 3H, J = 7.2 Hz, 
CH3), 1.78-1.45 (m, 8H, 4 x CH2), 1.37-1.17 (m, 10H,  5 x CH2), 0.86 (t, 3H, J = 6.4 Hz, 
CH3); 
13
C NMR (125 MHz, CDCl3,  298K):  150.7, 148.4, 147.3, 132.5, 119.2, 119.0, 115.2, 
112.1, 77.4, 59.2, 56.0, 31.8, 31.5, 29.4, 28.9, 25.8, 25.5, 23.9, 22.5, 21.3, 14.0; HRMS 
(ESI+): m/z calcd for C23H36N3O2 (M
+
 + H) 386.28055, found 386.28020. 
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3.7 Cell culture and reagents 
 
 Human breast cancer cell lines (MCF7, T47D, MDA-MB-468 and MDA-MB-231) were 
obtained from The American Type Culture Collection (ATCC) and cultured according to 
supplier’s instructions. The MCF7 cell line exhibits an epithelial phenotype and is a well-
accepted representative of estrogen-receptor-positive “luminal” type breast cancer. The T47D 
cell line represents “luminal” type breast cancer and expresses an estrogen receptor and 
progesterone receptor. The MDA-MB-468 cell line represents “basal A” type breast cancer 
and does not express an estrogen receptor or progesterone receptor. The MDA-MB-231 cell 
line is a highly invasive “basal B” type and estrogen-independent fibroblastic human breast 
cancer cell line with stellate morphology. Antibodies for PARP, cleaved-PARP, XIAP, 
phospho-EGFR, EGFR, phospho-Human epidermal growth factor receptor-2 (Her2), and 
Her2 were purchased from Cell Signaling Technology (Danvers, MA) and Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA). Antibodies for actin were procured from Siga.  
 
3.7.1 Clonogenicity assay  
 
Human breast cancer MCF-7 cells were plated in 12-well cell culture plates at a density of 
250 cells per well and were allowed to grow for 24 hours followed by treatment with NSC-
772451. The cells were grown for the next 10 days and the wsc-772451 medium was replaced 
every alternate day. After 10 days incubation, the cells were fixed with formaldehyde and the 
stained with crystal violet (0.1% in 20% methanol). No.of colonies were counted manually. 
Colonies containing >50 cells were counted. Pictures were taken using a digital camera.
 24
 
 
3.7.2 Western blotting 
 
MCF7 and MDA-MB-231 cells were scraped into 250 μL of ice cold modified 
Radioimmunoprecipitation assay (RIPA) buffer to prepare whole cell lysates. An equal 
amount of lysate protein was resolved on sodium dodecyl sulphate polyacrylamide gel, 
transferred to a nitrocellulose membrane, and western blot analysis was performed. 
Immunodetection was performed using systems like Enhanced Chemiluminescence (ECL) 
system, Amersham Pharmacia Biotech Inc., Arlington Heights, IL according to the 
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manufacturer’s instructions. The blots are representative of multiple independent 
experiments. 
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The focus of this chapter is on the synthesis of various allyl azides from the corresponding 
aryl vinyl carbinols through a novel rearrangement of the double bond and the synthesis of a 
rare class of non-natural amino acids. 
 
4.1 Introduction 
 
The utility of allylamines increased considerably in the areas of organic and medicinal 
chemistry, as they have applications in natural products,
1
 amino acids,
2
 biologically active 
compounds
3
 and material science.
4
 Allyl azides are a special class of organic azide
5
 
compounds and can be easily converted into corresponding ally amines through mild 
reduction conditions.
6
 The focus of researchers has grown to synthesising azides in a 
convenient approach and developing click chemistry
7 
for the preparation of potent triazoles. 
The ready availability of allylic alcohols makes them ideal precursors for the preparation of 
allylic azides. However, since hydroxy groups are not good leaving groups, transformation
8 
of alcohols into halides, carboxylates, phosphates, carbonates or sulfonates is necessary to 
facilitate their displacement by nitrogen nucleophiles. Although a few methods
9
 exist in the 
literature, a novel procedure for the synthesis of allyl azides in a single step would be 
advantageous. Our interest was to study the ZrCl4-catalysed transformations of the C-O bond 
to the C-N bond that involve nucleophilic substitution reactions
10
 of phenyl allyl carbinols as 
well as their associated substituents’effects. This approach resulted in the double-bond 
isomerisation of aryl vinyl carbinols to produce allyl azides. The method was then applied to 
synthesise non-natural γ4-amino acids using allyl azides as key intermediates. In summary, a 
facile method for allyl azides synthesis was developed and utilised to synthesise a rare class 
of non-natural γ4- amino acids.  
 
4.2 Results and discussions 
 
Our investigation into transformations of the C-O bond into the C-N bond
11 
was extended to 
aryl vinyl carbinols. Accordingly, the treatment of 4-anisaldehyde 1 (Scheme 4.1) with vinyl 
magnesium bromide in THF at 0 °C for 15 min afforded aryl vinyl carbinol 2 (74%). The 
reaction of carbinol 2 with TMSN3 in the presence of ZrCl4(10 mol%) as a Lewis acid 
catalyst in CH3CN at room temperature for 2 h gave allyl azide 3. In the 
 1
H NMR spectrum 
of azide 3, olefinic protons resonating as a doublet at   6.59 ( J = 15.7 Hz) and a doublet of 
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triplets at  6.10 ( J = 15.7, 7.0 Hz), each of which integrate to one proton. In the IR spectrum 
of 3, the appearance of a strong absorption peak at 2,098 cm
-1
 indicated azide functionality. 
 
Scheme 4.1  
 
 
 
  
4.2.1 Preparation of aryl vinyl carbinols and their conversion to allylic azides 
 
To investigate the generality of the synthesis of ZrCl4-catalysed allylic azide, various 
substituted aryl vinyl carbinols were prepared. Accordingly, the treatment of ketone 4 with 
vinyl magnesium bromide in THF at 0 °C for 15 min afforded carbinol 5 in 68% yield. In the
 
1
H NMR spectrum of 5, olefinic protons were observed at   6.12 as a doublet of a doublet,  
5.26 as a doublet,  5.18 as a doublet, each of which integrated to one proton; methyl protons 
resonating at  1.64 as a singlet; and the rest of the protons appeared at the expected chemical 
shifts that supported the formation of product 5. The IR spectrum of 5 exhibited a strong 
absorption peak at 3,400 cm
-1
, thus confirming the presence of alcohol functionality (Scheme 
4.2.1a).  
 
Scheme 4.2.1a 
 
 
 
 
 
Carbinol 5 in a Lewis acid-catalysed reaction with TMSN3 in the presence of ZrCl4 (10 
mol%) in CH3CN at room temperature for 2 h gave azide 6 as a mixture of  E/Z isomers in a 
ratio of 4:1 or 1:4 in 81% yield. The mixture was inseparable on column chromatography 
using Silica gel (100-200 mesh) chromatogram, and the ratio of azide 6 was calculated based 
on the 
1
H NMR spectrum of 6. The 
1
H NMR spectrum of 6 confirmed the product, in which 
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olefinic protons appeared as a doublet of a triplet at  5.86 and 5.64, CH2 protons resonating 
as a doublet at  3.97 and 3.65, methyl protons resonating at  2.09 as singlet, and the rest of 
the protons appeared at the expected chemical shifts that support the formation of product 6. 
In the IR spectrum of 6, an appearance of a strong absorption peak at 2,094 cm
-1
 indicated 
azide functionality.  
 
Scheme 4.2.1b 
 
 
 
 
 
The oxidation of alcohol 7
12a 
under Swern conditions gave aldehyde 7a, and a Grignard 
reaction of 7a with the reagent prepared from p-bromoanisole and Mg turnings in THF 
afforded the corresponding carbinol 8 in 81% yield. In the 
1
H NMR spectrum of 8, aromatic 
protons resonating at  7.71-7.55,  7.45-7.30,  7.29-7.25 and  6.85-6.74 as multiplets that 
integrate to four, six, two, and two protons, respectively. Benzylic protons resonating as a 
doublet at  5.28, olefinic protons resonating at  5.25 as a singlet that integrated to two 
protons, OCH2 protons resonating at  4.12 as an AB quartet, and methoxy protons 
resonating at  3.80 as a singlet, thus confirming the formation of carbinol 8. 1H NMR 
spectrum exhibited the carbinol 8 along with traces of an aliphatic impurity. In the IR 
spectrum of 8, an appearance of a strong absorption peak at 3,430 cm
-1
 supported the 
presence of alcohol functionality. Further, HRMS (ESI+) m/z of 8 found 445.12107 for (M
+ 
+ 
Na), thus confirming the formation of  carbinol 8 (Scheme 4.2.1b).  
 
Carbinol 8 from a Lewis acid-catalysed reaction with TMSN3 in the presence of ZrCl4 (10 
mol%) in CH3CN at room temperature gave azide 9 as a mixture of E/Z isomers in a ratio of 
1:1 in 76% yield. The mixture was inseparable during column chromatography using a Silica 
gel (100-200 mesh) chromatogram and the ratio of azide 9 was calculated based on the 
1
H 
NMR spectrum. The 
1
H NMR spectrum of 9 confirmed the product, in which OCH2 protons 
resonating at  4.41 and  4.33  as multiplets, NCH2 protons resonating at  4.06 and  4.03 
as multiplets, each of which integrated to one proton, and the rest of the protons appeared at 
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the expected chemical shifts that support the formation of the product. Furthermore, the IR 
spectrum 9 indicated a strong absorption peak at 2,097 cm
-1 
supports the presence of azide 
functionality in compound 9.
  
 
Scheme 4.2.1c
 
 
 
 
Similarly, the treatment of 10 with p-bromoanisyl magnesium bromide [prepared from p-
bromoanisole and Mg turnings in THF] in THF furnished the known carbinol 11
12b
 in 82% 
yield (Scheme 4.2.1c). Carbinol 11 on a Lewis acid-catalysed reaction with TMSN3 in the 
presence of ZrCl4 (10 mol%) in CH3CN at room temperature gave trans-azide 12 in 79% 
yield. In the 
1
H NMR spectrum of 12, olefinic protons resonating at  6.53 as a doublet with a 
coupling constant of 15.8 Hz, another olefinic proton resonating at  5.99 as a doublet of a 
doublet with coupling constants of 15.8 and 7.6 Hz, CH protons resonating at  4.15 as a 
multiplet, and CH3 protons resonating at  1.36 as a doublet, thus indicated the evidence of 
the formation of the azide 12 with the isomerisation of the double bond with trans-
configuration. In the IR spectrum of 12, an appearance of a strong absorption peak at       
2,100 cm
-1
 indicated azide functionality. 
 
 After an efficient rearrangement reaction (two steps in one reaction) was found, it was 
envisioned that this synthetic transformation may be applicable to the synthesis of various γ2, 
γ3, and γ4 non-natural amino acids, whereby the phenyl group could be envisaged to act as a 
surrogate acid functionality and the azide group as a masked amine.  
 
4.3 Previous research on γ-amino acids and their derivatives 
 
Non-natural amino acids have significant importance in performing the diverse biological 
functions
13
 of proteins. This in turn influences the peptide chain to fold into specific 3D 
structures. β- Peptides are the derivatives of the β-amino acids, which represent the smallest 
step away from α-amino acid. The addition of a further carbon unit to the backbone of each 
β-peptide leads to γ-peptides, which provide large conformational space in contrast to β-
peptides.
14
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Hagihara et al.
15
 investigated the application of γ-amino acids with the synthesis and 
characterisation of vinylogous amino acids and their derivatives. They synthesised 
vinylogous polypeptides with the repeating unit of extended vinylogous amino acids
16
, which 
are prepared from the insertion of (E)-ethenyl unit between carbonyl carbon and Cα carbon 
(Figure 4.1).  
 
 
 
Figure 4.1: Vinylogous γ- amino acid 
 
Gennari et al.
17
 developed vinylogous sulfonamido-peptides (Figure 4.2), which have a 
similarity in structure to γ-peptides, in which the acid functionality in the monomer of the γ-
amino acid was replaced by sulfonic acid and the peptide bond was replaced by 
sulfonamide.
18
  
 
 
 
                      
Figure 4.2: Sulphur-containing vinylogous amino acid. 
Research on cyclopropane γ-peptides19 revealed that they exhibit a parallel-sheet structure in 
the solid state. Mighty et al.
20
   conducted their research on X-ray crystallography analysis of 
capped γ-peptides and stated that these peptides take a helical conformation and a 
supramolecular parallel, double-helical structure by intermolecular hydrogen bonding and -
 stacking interactions in the solid state. 
 
 Vasudev et al.
21 
reported helices and ribbons in γ-peptides, which were derived from 
constrained acyclic γ-amino acids. Furthermore, Baldauf and co-workers22 indicated that 
helix formation in vinylogous peptides can be controlled by (E) and (Z) double bonds in γ-
amino acid monomers, The NMR and X-ray studies of γ-tetra- and hexa-peptides,23 prepared 
from the (R, R, R) γ-amino acids with side chains at 2, 3 and 4 positions, exhibited 14 helices 
in the crystal state, whereas Dado and Gellman
24
 analysed the H bonding of nearest 
neighbours in γ-amino acid derivatives through FTIR and NMR studies. Sharma and 
coworkers
25
 synthesised mixed γ-peptide with an alternate coupling of γ4-amino acid and γ-
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aminobutyric acid (GABA) residues indicated the presence of left-handed 9-helix in it. 
Recently, Farrera-Sinfreu et al.
26
 studied the structural behaviour of γ-peptides derived from 
γ-amino-L-proline using CD and NMR and concluded that they indicated secondary 
structures even in aqueous solutions.  
 
The above reports all suggest that the design of non-natural oligomers that form diversified 
secondary structures is an active area of research.
27 The importance of γ-amino acids in the 
synthesis of non-natural oligomers motivated our study to focus on designing and 
synthesising some diverse non-natural γ-amino acids with carbohydrate side chains. Our aim 
was to synthesise various aryl-allyl-carbinol systems using a carbohydrate as a side chain and 
convert them it into non-natural amino acids using the approach of rearranging the 
doublebond.  
 
4.4 The conversion of carbohydrate side-chain aryl vinyl carbinols to allylic azides 
 
4.4.1 The synthesis of γ2-amino acids with carbohydrate side chains.28  
 
Accordingly, the requisite glucosyl aldehyde 13 was prepared by a known sequence of steps 
as follows (Scheme 4.2.2a): 
 
Scheme 4.2.2a 
 
 
 
 
 
 
 
 
 
 
Thereafter, the treatment of aldehyde 13 (Scheme 4.3b) with p-bromoanisyl magnesium 
bromide (in situ generation of p-bromoanisole and Mg turnings in THF) afforded carbinol 
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14
29 
in 80% yield as a separable diastereomeric mixture on  TLC. The ratio of both isomers 
was found 1.5 : 8.5 based on the 
1
H NMR spectrum. Both isomers were collected together 
during Silica gel (100-200 mesh) column chromatogrphy and proceeded to the next step. The 
oxidation of 14 under Swern-reaction conditions gave ketone 15 in a quantitative yield, which 
was taken to the next step without any further purification. The treatment of 15 with vinyl 
magnesium bromide in THF furnished carbinol 16 in 71% of yield. A single isomer was 
formed, and it was isolated using Silica gel (100-200 mesh) column chromatography. The 
1
H 
NMR spectrum of 16 revealed olefinic protons resonating at  6.08 as a doublet of a doublet 
that integrated to one proton, vinyl protons resonating as doublets at  5.27 and 5.08 that 
integrated to one proton each, C1H protons resonating at  5.98 as a doublet, C2H protons 
resonating at  4.44 as a doublet, C4H protons resonating at  4.37 as a doublet, and C3H 
protons resonating at  3.32 as a doublet, whereas the rest of the protons resonating at 
expected chemical shifts that confirmed the formation of carbinol 16. In the IR spectrum of 
16, the appearance of a strong absorption peak at 3,454 cm
-1
 confirmed alcohol functionality. 
HRMS (ESI+) m/z found 359.1467 for (M
+ 
+ Na) indicated the formation of aryl vinyl 
carbinol 16 (Scheme 4.2.2b). The absolute stereochemistry of carbinol 16 was not identified. 
 
Scheme 4.2.2b 
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The treatment of carbinol 16 with ZrCl4 (10 mol%) and TMSN3 in Acetonitrile at room 
temperature for 2 h afforded azide 17 as a mixture of E/Z or Z/E diastereomers in 81% yield 
with a ratio of 97:3. The mixture was inseparable on column chromatography using the Silica 
gel (100-200 mesh), and the ratio of azide 17 was calculated based on the 
1
H NMR spectrum. 
In the
 1
H NMR spectrum of 17, the appearance of resonances at  7.10 and  6.85-6.79 as 
multiplets that correspond to aromatic that integrated to two protons each, the appearance of 
resonance at δ 5.98 as a multiplet that corresponds to olefinic protons and C1H protons. C3H 
protons resonating at δ 4.87 as a singlet, C2H protons resonating at δ 4.49 as a doublet, CH3 
protons resonating at δ 3.76 as a singlet, and CH2 protons resonating at δ 3.76 and 3.62 as 
multiplets that integrated to 0.8 and 1.2 protons, respectively. The acetonide protons that 
resonating at  1.44 and 1.27 as singlets confirmed the formation of carbinol 17. In the IR 
spectrum of 17, the appearence of a strong absorption peak at 2,098 cm
-1
 confirmed the 
presence of azide functionality. HRMS (ESI+) m/z found 384.1565 for (M
+ 
+ Na) supported 
the formation of the product.  
 
Attempts to reduce the double bond and azide group in 17 with various reducing agents such 
as Pd/C, PtO2, Pd(OAc)2 and Raney Ni in the presence of a hydrogen atmosphere failed to 
form the desired amine 18. Attempted experiments for the reduction are discussed in Section 
4.5 
 
4.4.2 Synthesis of the γ3- amino acid with a carbohydrate side chain  
 
Similarly, alcohol 19
30
 was prepared by a reported procedure as follows (Scheme 4.2.3a).  
 
Scheme 4.2.3a 
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Alcohol 19
 
was subjected to oxidation under Swern-reaction conditions for 3 h to give 19a  in 
a quantitative yield, which was proceeded to the next step without any further purification. 
The treatment of 19a with p-bromoanisole and Mg turnings in THF afforded carbinol 20 as a 
mixture of diastereomers with a 3:2 ratio in 72% yield. The mixture was inseparable on 
column chromatography using a Silica gel (100-200 mesh) chromatogram, and the ratio of 
carbinol 20 was calculated based on the 
1
H NMR spectrum. The 
1
H NMR spectrum of 
compound 20 indicated that aromatic protons resonating at  7.29, 6.86 as multiplets that 
integrated to two protons each, and methoxy protons resonating at  3.30 as a singlet that 
confirmed the formation of the product. In the IR spectrum of 20, the appearance of a strong 
absorption peak at 3,445 cm
-1
 gave the evidence for alcohol functionality. HRMS (ESI+) m/z 
found 359.1469 for (M
+ 
+ Na) further supported the confirmation of the product (Scheme 
4.2.3b).  
 
Scheme 4.2.3b 
 
 
 
 
 
 
 
 
 
 
Furthermore, reaction of carbinol 20 with TMSN3 and ZrCl4 (10 mol%) in CH3CN at room 
temperature for 2 h furnished azide 21 as a mixture of diastereomers with a ratio of 7:3 in 
74% yield. The mixture was inseparable on column chromatography using the Silica gel 
(100-200 mesh) chromatogram, and the ratio of azide 21 was calculated based on the 
1
H 
NMR spectrum. In the 
1
H NMR spectrum of 21, aromatic protons resonating as multiplets at 
 7.24-7.14 and  6.9-6.85 and integrated to two protons each; olefinic protons resonating at 
 6.85 and  6.75 as singlets that integrated to 0.7 and 0.3 protons, respectively; C1H protons 
resonating as a doublet at  6.02 and  5.94 that integrated to 0.7 and 0.3 protons, 
respectively; C2H protons resonating as a doublet at  5.18 and  4.82 that integrated to 0.7 
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and 0.3 protons, respectively; and C4H protons resonating as a doublet at  4.65 and  4.57 
that integrated to 0.7 and 0.3 protons, respectively. CH2 protons resonating at  4.12-3.96 as a 
multiplet, C3H proton resonating as a doublet at  3.82 and  3.75 that integrated to 0.7 and 
0.3 protons, respectively. Acetanide protons that resonating at  1.38 as a singlet confirmed 
the product. In the IR spectrum of 21, an appearance of a strong absorption peak at         
2,098 cm
-1
 confirmed the presence of azide functionality. The HRMS further confirmed 
product 21, for which (M
+ 
+ Na) was found at m/z of 384.1539. 
 
Similarly to that of the γ2-amino acid above, the synthesis of the γ3-amino acid was not 
successful owing to the difficulty of the double bond to undergo reduction  
 
4.5 Attempted styrene double-bond reduction experiments  
 
Various methods were employed to reduce the styrene double bond and allyl azide 
functionality for compounds 17 and 21. All attempted double-bond reductions using the 
reactions/reagents and conditions presented in Table 4.1 failed to get desired amines. Their 
failure was attributed to the steric interference by the bulky phenyl groups, which may 
prevent the reduction of the double bond.  
 
Table 4.1: Reagents and conditions for double-bond reduction 
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4.6 Synthesis of γ4-amino acids  
 
The synthesis of γ4-amino acid was aimed at synthesising the reported alcohol 2336 from the 
known sequence of steps as indicated below (Scheme 4.2.4a). 
Scheme 4.2.4a 
 
 
 
 
Alcohol 23 upon oxidation under Swern-reaction conditions for 2 h gave aldehyde 23a 
(Scheme 4.2.4b). The treatment of aldehyde 23a with p-bromoanisole and Mg turnings in 
THF afforded carbinol 24 in 85% yield as a mixture of diastereomers with a ratio of 7:3. The 
mixture was inseparable on column chromatography using the Silica gel (100-200 mesh), and 
the ratio of carbinol 24 was calculated based on the 
1
H NMR spectrum of 24. 
 
In 
1
H NMR 
spectrum, aromatic protons resonating as a multiplet at  7.31 and  6.88 that integrate to two 
protons each. benzylic protons resonating as a multiplet at  4.60, aryl methoxy protons 
resonating as a singlet at  3.08, and the rest of the protons appeared at the expected chemical 
shifts that supported the formation of product 24. In the IR spectrum of 24, the appearance of 
a strong absorption peak at 3,445 cm
-1
 confirmed the presence of azide functionality. 
Furthermore, HRMS that showed (M
+ 
+ Na) peak at m/z 359.1470 confirmed the formation of 
product 24. 
 
Carbinol  24 reacted withTMSN3 in the presence of ZrCl4 (10 mol %) in CH3CN at room 
temperature to afford a mixture of azides 25a/25b with a ratio on 4:1 through concomitant 
isomerisation of the double bond with 81% of yield. These isomers were separable by column 
chromatography (60-120 mesh Silica gel; 5% EtOAc in pet. ether). The optical rotation of 
azide 25a found to be []D = -135.92 (c 0.38, CHCl3). The 
1
H NMR spectrum of azide 25a, 
showed olefinic protons resonating at  6.70 as a doublet and at δ 5.91 as a doublet of a 
doublet that integrated to one proton each. C5H proton resonating at  4.42 as a triplet, 
whereas the rest of the protons resonating at the expected chemical shifts. In the IR spectrum, 
the appearance of a strong absorption peak at 2,102 cm
-1
 confirms the presence of azide 
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functionality. HRMS further confirmed the product (25a), where (M
+ 
+ Na) was found at m/z 
384.1539. The stereochemistry of compound 25a as drawn was assumed based on the starting 
material 24 used in the synthesis of 25a; this is, however, not verified.  
 
Scheme 4.2.4b 
 
 
The optical rotation of azide 25b was found to be []D = +228.43 (c 0.22, CHCl3). In the 
1
H 
NMR spectrum of azide 25b, olefinic protons resonating at  6.67 as a doublet and at δ 6.10 
as a doublet of a doublet, C5H protons resonating at  4.39 as a multiplet, and the rest of the 
protons resonating at the expected chemical shifts. In the IR spectrum of 25b, the appearance 
of a strong absorption peak at 2,098 cm
-1
 confirmed the presence of azide functionality. 
HRMS further confirmed the formation of azide 25b, in which (M
+ 
+ Na) was found at m/z 
384.1539. The stereochemistry of compound 25b as drawn was assumed based on the starting 
material 24 used in the synthesis of 25b; this is, however, not verified (Scheme 4.2.4b). 
 
The separated homologous azides 25a and 25b were subjected to reduction independently 
with Pd/C in methanol under as an H2 atmosphere at room temperature for 6 h to give the 
corresponding amines (Scheme 4.2.4c), which on independent protection with (Boc)2O and 
Et3N in CH2Cl2 gave Boc-protected amines 26a in 81% yield and 26b in 79% yield. The 
optical rotation of compound 26a was found to be []D = −83.42 (c 0.22, CHCl3). In the 
1
H 
NMR spectrum of 26a, CH2 protons resonating at δ 2.69, δ 2.60 and δ 1.89 as multiplets that 
integrated to one, one and two protons, respectively, Boc protons resonating at  1.46 as a 
singlet, and the rest of the protons resonating at the expected chemical shifts. In the IR 
spectrum of 26a, the appearance of a strong absorption peak at 3,345 cm
-1
 confirmed the 
presence of amine functionality. HRMS further confirmed product 26a, where (M
+ 
+ Na) was 
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found at m/z 438.2495. The stereochemistry of compound 26a as drawn was assumed based 
on the subsequent synthesis of carbinol 24; this is, however, not verified.  
 
The optical rotation of 26b was []D = +48.76 (c 0.41, CHCl3). In the 
1
H NMR spectrum of 
26b, CH2 protons resonating at δ 2.79-2.54 and δ 1.97-1.62 as multiplets that integrated to 
two protons each, Boc protons resonating at δ 1.46 as a singlet, and the rest of the protons 
resonating at the expected chemical shifts. In the IR spectrum 26b, an appearance of a strong 
absorption peak at 3,380 cm
-1
 confirmed the presence of amine functionality. HRMS further 
confirmed the product 26b, in which (M
+ 
+ Na) was found m/z peak at 438.2497. The 
stereochemistry of compound 26b as drawn was assumed based on the subsequent synthesis 
of carbinol 24; this is, however, not verified (Scheme 4.2.4c).  
 
Scheme 4.2.4c 
 
 
 
 
 
 
 
 
 
Finally, the oxidative cleavage of phenyl rings 26a and 26b with NaIO4, RuCl3, in acetone : 
water : CCl4 = 1 : 1: 1.5 furnished acids 27a and 27c, respectively. Compounds 27a and 27c 
on independent esterification with CH2N2, [generated in situ at 0 °C with N-
nitrosomethylurea and 20 % KOH solution] gave γ4-amino acid 27b in 78% yield and 27d in 
73% yield, respectively.  
 
The optical rotation of 27b was found to be []D = −92.34 (c 1.0, CHCl3). The 
1
H NMR 
spectrum of 27b indicated ester methoxy protons attached to an acid group that resonating at 
δ 3.68 as a singlet and disappearance of aromatic protons confirmed the product formation. 
The 
13
C NMR exhibited the signal at δ 174.2, which indicated the presence of the ester group 
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in the product. In the IR spectrum, an appearance of a strong absorption peak at 3,400 cm
-1
 
confirmed the presence of amine functionality. HRMS further confirmed the product 27b, 
where (M
+ 
+ Na) found at m/z peak at 390.2131.  
 
The optical rotation of compound 27d was found to be []D = +179.43 (c 0.53, CHCl3). The 
1
H 
NMR spectrum of  27d indicated that ester methoxy protons that resonating at δ 3.67 as a 
singlet and, the disappearance of aromatic protons confirmed the formation of the product, 
and the rest of the protons resonating at expected chemical shifts. The 
13
C NMR exhibited a 
signal at δ 174.2, which indicated the presence of the ester group in the product. In the IR 
spectrum, the appearance of a strong absorption peak at 3,420 cm
-1
 confirmed the presence of 
amine functionality. HRMS further confirmed the presence of product 27d, in which (M
+ 
+ 
Na) found at m/z peak at 390.2135. In addition, []D = −92.34 (c 1.0, CHCl3) for compound 
27b was in good accordance with previously reported values
16
. Thus, above analytical data 
evidently proves the absolute stereocentres in 27b and 27d. 
 
4.7 Allyl azide isomerisation mechanism  
 
To elucidate the mechanism involved in the double-bond isomerisation, the reaction of 
carbinol 10 in the presence of a Lewis acid catalyst was performed, in which carbinol 10 was 
activated through the formation of the corresponding trimethylsilyl ether 10a, which 
undergoes nucleophilic addition (azide addition) to the olefin with concerted elimination of 
the trimethylsilyloxy group and double-bond isomerisation (Scheme 4.3). This hypothesis 
was confirmed by a controlled experiment, in which carbinol 10 was treated with TMSN3 in 
Acetonitrile (MeCN) at 0 °C in the absence of a Lewis acid. Only trimethyl silyl ether 
product 10a was isolated, and no azido product could be detected, even after extended 
reaction times.  
 
Scheme 4.3 
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After the addition of a catalytic amount of ZrCl4 to the reaction mixture, ZrCl4 binds to the 
OTMS group in silyl ether 10a and withdraws electron density, which in turn facilitates C-O 
bond cleavage or directly activates silyl ether 10a towards nucleophile attack by an N3 anion 
that forms a corresponding allylic azide as the only product. Thus, the reaction was presumed 
to undergo a nucleophilic addition (azide addition), olefin isomerisation and OTMS 
displacement to form the allylic azide. 
 
4.8 Conclusion 
 
In conclusion, a simple and efficient method was developed for the synthesis of allylic azides 
from aryl vinyl carbinols using ZrCl4 as a Lewis acid catalyst. This method was applied to 
aryl vinyl carbinols that contain various carbohydrate side chains, thus giving the desired 
products in high yields. This methodology was utilised to synthesise carbohydrate side-chain 
γ4-amino acids and some key intermediates for the preparation of carbohydrate side-chain γ2- 
and γ3-amino acids. Attempted experiments on reduction of sterically hindered double bonds 
were unsuccessful for the synthesis of γ2- and γ3-amino acids. 
  
4.9 Experimental section 
 
 
 
 
 2-(4-Chlorophenyl)but-3-en-2-ol (5): To the  stirred solution of p-chloroacetophenone 4 
(1.0 g, 6.49 mmol) in THF (5 mL) at 0 
o
C, vinylmagnesium bromide (16.23 mL, 16.23 mmol, 
1 M in THF) was added and the resultant mixture was stirred for 15 min. The reaction 
mixture was quenched with saturated aqueous NH4Cl (30 mL) and extracted with EtOAc (2 x 
30 mL). The combined organic layers were washed with water (30 mL), brine (30 mL) and 
dried (Na2SO4). Solvent was evaporated under reduced pressuren purified the residue by 
column chromatography (60-120 mesh Silica gel, 10% EtOAc in pet. ether) to afford 5 (0.80 
g, 74%) as a light yellow oil.
 
IR (CHCl3): 3400, 2981, 2931, 1675, 1491, 1094, 1013, 928, 
742cm
-1
; 
1
H NMR (300 MHz, CDCl3):  7.39 (d, 2H, J = 8.6 Hz, ArH), 7.28 (d, 2H, J = 8.6 
Hz, ArH), 6.12 (dd, 1H, J = 17.4, 10.6 Hz, olefinic), 5.26 (d, 1H, J = 17.4Hz, olefinic), 5.18 
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(d, 1H, J = 10.6 Hz, olefinic), 1.87 (brs, 1H,  OH), 1.64 (s, 3H, Me).
 13
C NMR (75 MHz, 
CDCl3)  δ 145.05, 144.50, 132.84, 128.35, 126.85, 112.89, 74.55, 29.41.  
 
 
 
(E)-1-(4-Azidobut-2-en-2-yl)-4-chlorobenzene (6): To a solution of 5 (0.50 g, 2.74 mmol) 
in acetonitrile (3 mL) at 0 °C was added azido trimethylsilane (0.95 g, 8.24 mmol) followed 
by ZrCl4 (7 mg) in portion wise. After stirring for 2 h, the reaction mixture was diluted with 
water (15 mL) and extracted with EtOAc (2 x 10 mL). The combined organic layers were 
washed with brine (10 mL) and dried (Na2SO4). Solvent was evaporated and  and purified the 
residue by column chromatography (60-120 mesh Silica gel, 10% EtOAc in pet. ether) to 
afford 6 as a (4:1) mixture of isomers (0.31 g, 71%) as a light yellow oil. IR (CHCl3): 2924, 
2094, 1593, 1489, 1252, 1094, 1012, 818 cm
-1
;
 1
H NMR (300 MHz, CDCl3):  7.33-7.09 (m, 
4H, ArH), 5.86 (dt, 0.7H, J = 7.36, 1.32 Hz, olefinic), 5.64 (dt, 0.3H, J = 7.36, 1.32 Hz, 
olefinic), 3.97 (d, 1.6H, J = 7.17 Hz, CH2), 3.65 (d, 0.4H, J = 7.36 Hz, CH2), 2.09 (s, 3H, 
Me). 
13
C NMR (125 MHz, CDCl3) δ 140.91, 140.26, 133.63, 128.61, 127.34, 120.87, 48.64, 
16.38. 
 
 
 
 
2-((tert-Butyldiphenylsilyloxy) methyl)-1-(4-methoxyphenyl) prop-2-en-1-ol (8):  To a 
suspension of Mg turnings (0.218 g, 9.07 mmol) in THF (10 mL), p-bromoanisole (1.14 mL, 
9.07 mmol) was added and stirred for 0.5 h. The mixture was cooled to 0 °C and a solution of 
7a (0.95 g, 29.41 mmol) in THF (5 mL) was added after 0.5 h. Workup as described for 5 and 
purification of the residue by column chromatography (60-120 mesh Silica gel, 10% EtOAc 
in pet. ether) afforded  8 (1.03 g, 82%) as a light yellow oil. IR (CHCl3): 2931, 1609, 1511, 
1428, 1249, 1112, 828, 741, 702 cm
-1
 
1
H NMR (500 MHz, CDCl3):  7.7-7.55 (m, 4H, ArH), 
7.45-7.30 (m, 6H, ArH), 7.29-7.25, (m, 2H, ArH),  6.85-6.74 (m, 2H, ArH), 5.28 (d, J = 3.0 
Hz 1H, ArCH), 5.22 (s, 2H, olefinic), 4.19-4.07 (AB quartet, J = 13.3 Hz,  2H, OCH2), 3.80 
(s, 3H, OMe), 2.70 (d,, J = 3.0 Hz, 1H, OH), 1.04 (s, 9H, 3 x CH3).
 13
C NMR (75 MHz, 
CDCl3) δ 159.19, 149.11, 135.66, 135.64, 134.26, 133.11, 129.89, 129.88, 113.88, 112.33, 
75.61, 65.42, 55.43, 26.91, 19.27.  
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(E)-(2-(Azidomethyl)-3-(4-methoxyphenyl)allyloxy)(t-butyl)diphenylsilane (9): To a 
solution of 8 (0.50 g, 1.15 mmol) in acetonitrile (3 mL) at 0 
o
C azidotrimethylsilane (0.44 
mL, 3.47 mmol) followed by ZrCl4 (0.068)  portion wise was added and stirred for 2 h. 
Workup as described for 6 and purification of the residue by column chromatography (60-
120 mesh Silica gel, 5% EtOAc in pet. ether) afforded azide 9 (0.350 g, 67%) in 1:1 ratio as a 
light yellow oil. IR (CHCl3): 2988, 2097, 1607, 1511, 1250, 1077, 1024, 958, 886, 756 cm
-1
;
 
1
H NMR (500 MHz, CDCl3):  7.74-7.70 (m, 2.3H, ArH), 7.66-7.61 (m, 1.7H, ArH), 7.47-
7.38 (m, 4.6 H, ArH), 7.37-7.32 (m, 1.7 H, ArH), 7.19-7.16 (m, 1.3H, ArH ), 7.10-7.04 (m, 
0.9H, ArH )6.79-6.74 (m,1.H, ArH), 6.73 (0.5 H, olefinic), 6.56 H (0.5 H, olefinic),  4.41 (m, 
1H, OCH2), 4.33 (m, 1H, OCH2),  4.06 (m, 1H, NCH2), ),  4.03 (m, 1H, NCH2), 3.83 (s, 2H, 
OMe), 3.79 (s, 1H, OMe),1.10 (s, 4.5H, 3 x CH3), 1.06 (s, 4.5H, 3 x CH3). 
13
C NMR (125 
MHz, CDCl3): δ 158.98, 135.63, 133.89, 133.35, 130.22, 130.11, 129.83, 128.50, 127.80, 
113.90, 66.58, 60.54, 55.27, 48.23, 26.88, 19.32. 
 
 
 
(E)-1-(3-Azidobut-1-en-1-yl)-4-methoxybenzene (12): To the stirred solution of 11 (0.50 g, 
2.8 mmol) in acetonitrile (3 mL) at 0 
o
C azidotrimethylsilane (0.90 mL, 7.0 mmol) followed 
by ZrCl4 (0.065mg) in portion wise was added and stirred for 2 h. Workup as described for 6  
and purification of the residue by column chromatography (60-120 mesh Silica gel, 5% 
EtOAc in pet. ether) afforded azide 12 as a yellow oil. (0.45 mg, 79%) IR (CHCl3): 2933, 
2100, 1662, 1607, 1512, 1250, 1175, 969, 831cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 7.32 (m, 
2H, ArH), 6.97-6.79 (m, 2H, ArH), 6.53 (d, J = 15.8 Hz, 1H, olefinic), 5.99 (dd, J = 15.8, 7.6 
Hz, 1H, olefinic), 4.13 (m, 1H, CH), 3.90-3.72 (m, 3H, OCH3), 1.34 (d, J = 6.6 Hz, 3H, CH3).
 
13
C NMR: (75 MHz, CDCl3) δ 159.72, 131.88, 128.89, 128.00, 126.22, 114.19, 60.07, 55.47, 
20.50 
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((3aR,5R,6S,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(4-
methoxyphenyl)methanol (14): To a suspension of Mg turnings (0.65 g, 27.39 mmol) in 
THF (10 mL), p-bromoanisole (5.1 g, 27.39 mmol) was added and stirred for 0.5 h. The 
mixture was cooled to 0 °C and a solution of 13 (2.5 g, 13.69 mmol) in THF (15 mL) was 
added and stirred for 0.5 h. Workup as described for 5 and purification of the residue by 
column chromatography (60-120 mesh Silica gel, 10% EtOAc in pet. ether) afforded  14 (6.1  
g, 80%) as a light yellow oil. Spectral details 
 
 
 
 
 
1-((3aR,5S,6S,6aR)-6-Methoxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)-1-(4-
methoxyphenyl)prop-2-en-1-ol (16):  
To a stirred solution of oxalyl chloride (0.75 mL, 8.8 mmol) in dry CH2Cl2 (10 mL), DMSO 
(1.2 mL, 17.7 mmol) was added at -78 
o
C and stirred at the same temperature for 0.5 h. A 
solution of 14 (2.5 g, 8.0 mmol) in CH2Cl2 (10 mL) was added at -78 
o
C and stirred for an 
additional 3 h at the same temperature. Et3N (5.6 mL, 40.3 mmol) was added at 0 
o
C and 
stirred for 15 min. The reaction mixture was diluted with water (30 mL) and extracted with 
CH2Cl2 (2 x 30 mL). The combined organic layers were washed with brine (30 mL), dried 
(Na2SO4), evaporated to give 15, which was used as such for the next reaction.  
 
To a solution of ketone 15 (2.5 g, 8.12 mmol) in THF (10 mL) at 0 
o
C, vinylmagnesium 
bromide (20.3 mL, 20.3 mmol, 1 M in THF) was added and stirred for 15 min.  Workup as 
described for 5purification of the residue by column chromatography (60-120 mesh Silica 
gel, 20% EtOAc in pet. ether) afforded 16 (2.14 g, 78%) as a light yellow oil.
 
IR (CHCl3): 
3454, 2925, 1611, 1604, 1511, 1375, 1177, 1027, 834 cm
-1
;
 1
H NMR (CDCl3, 300 MHz):  
7.31 (d, 2H, J = 8.5 Hz, ArH ), 6.85 (d, 2H, J = 8.6 Hz, ArH), 6.13-6.04 (dd, 1H, J = 17.2, 
10.6 Hz olefinic), 5.98 (d, 1H, J = 3.6 Hz, C1H), 5.27 (d, 1H, J = 17.2 Hz, olefinic), 5.08 (d, 
1H, J = 10.6 Hz, olefinic), 4.44 (d, 1H, J = 3.02 Hz, C2H), 4.37 (d, 1H, J = 3.7 Hz, C4H ), 
3.75 (s, 3H, OMe), 3.32 (d, 1H, J = 2.8 Hz, C3H), 3.05 (s, 3H, OMe), 1.45 (s, 3H, Me) 1.38 
(s, 3H, Me).
 13
C NMR (75 MHz, CDCl3): δ 158.71, 141.32, 136.02, 126.38, 114.08, 113.77, 
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111.74, 105.46, 86.00, 82.64, 81.02, 57.79, 55.38, 26.97, 26.30.HRMS (ESI+) m/z calcd for 
C18H24O6Na (M
+ 
+ Na) 359.1471, found 359.1467.  
 
 
 
 
 
 
(3aR,5R,6S,6aR)-5-((E)-3-Azido-1-(4-methoxyphenyl)prop-1-en-1-yl)-6-methoxy-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxole (17): To a solution of 16 (2.0 g, 5.95 mmol) in 
acetonitrile (10 mL) at 0 
o
C azidotrimethylsilane (2.3 mL, 17.85  mmol) followed by ZrCl4 
(0.180 mg)  portion wise was added and stirred for 2 h. Workup as described for 6 
purification of the residue by column chromatography (60-120 mesh Silica gel, 5% EtOAc in 
pet. ether) afforded 17 (1.6 g, 74%) in a mixture of diastereomers as a light yellow oil. IR 
(CHCl3): 2933, 2098, 1609, 1512, 1457, 1289, 1165, 1026, 836 cm
-1
;
 1
H NMR (CDCl3, 300 
MHz):  7.10 (m, 2H, ArH), 6.85-6.79 (m, 2H, ArH), 6.00-5.96 (m, 2H, C1H, olefinic),  4.87 
(s, 1H, C3H), 4.49 (d, 1H, J = 3.7Hz, C2H), 3.76 (s, 3.8 H, OMe, CH2), 3.62 (m, 1.2H, CH2), 
3.31 (d, 1H, J = 3.02 Hz, C4H), 3.19 (s, 3H, OMe), 1.44(s, 3H, Me) 1.27 (s, 3H, Me). 
13
C 
NMR (75 MHz, CDCl3): δ 159.21, 140.40, 129.91, 120.63, 113.9, 111.67, 104.80, 83.46, 
82.53, 81.14, 77.2, 57.61, 55.25, 48.63, 26.78, 26.16. HRMS (ESI+) m/z calcd for 
C18H23N3O5Na (M
+ 
+ Na) 384.1535, found 384.1565.  
 
 
 
 
 
2-((3aR,5R,6S,6aR)-6-Methoxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)-1-(4-
methoxyphenyl)prop-2-en-1-ol (20):  
To a stirred solution of oxalyl chloride (2.4 mL, 28.6 mmol) in dry CH2Cl2 (30 mL), DMSO 
(4.0 mL, 57.3 mmol) was added at -78 
o
C and stirred at the same temperature for 0.5 h. A 
solution of 19 (6 g, 26.0 mmol) in CH2Cl2 (30 mL) was added at -78 
o
C and stirred for an 
additional 2 h at the same temperature. Et3N (18.1  mL, 130.4 mmol) was added at 0 
o
C and 
stirred for 15 min. The reaction mixture was diluted with water (50 mL) and extracted with 
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CH2Cl2 (2 x 50 mL). The combined organic layers were washed with brine (50 mL), dried 
(Na2SO4), evaporated to give 19a, which was used as such for the next reaction.  
To a suspension of Mg turnings (2.1 g, 88.23 mmol) in THF (15 mL) at ambdient 
temperature, p-bromoanisole (11.2 mL, 88.23mmol) was added and stirred for 30 min. The 
mixture was cooled to 0 
o
C and a solution of aldehyde 19a (5.0 g, 29.41mmol) in THF (30 
mL) was added. Workup as described for 5 purification of the residue by column 
chromatography (60-120 mesh Silica gel, 20% EtOAc in pet. ether) afforded 20 (5.8  g, 72%) 
as a mixture of diastereo isomers in 2;3 ratio as a light yellow oil. IR (CHCl3): 2922,1632, 
1511, 1375, 1248, 1165, 832 cm
-1
;
1
H NMR (CDCl3, 300 MHz, ):  7.33-7.26 (m, 2H, ArH ), 
6.89-6.86 (m, 2H,  ArH), 5.95 (t, 1H, J = 3.4 Hz, C1H), 5.42 (s, 1H, ArCH) 5.38-5.22 (m, 2H, 
olefinic), 4.60 (m, 2H, C2H, C4H), 3.80 (s, 3H, OMe), 3.69 (d, 0.6 H, J = 3.4 Hz, C3H), 3.53 
(d, 0.4H, J = 3.4 Hz, C3H ), 3.30 (s, 3H, OMe), 1.39 (s, 3H, CH3), 1.31 (s, 3H, CH3).
 13
C 
NMR (75 MHz, CDCl3) δ 159.13, 145.37, 127.60, 115.38, 114.13, 113.78, 111.65, 104.15, 
85.20, 80.13, 79.72, 74.99, 57.46, 55.44, 26.81, 26.43. HRMS (ESI+) m/z calcd for 
C18H24O6Na (M
+ 
+ Na) 359.1471, found 359.1469.  
 
 
 
 
 
(3aR,5R,6S,6aR)-5-((Z)-3-Azido-1-(4-methoxyphenyl)prop-1-en-2-yl)-6-methoxy-2,2-
imethyltetrahydrofuro[2,3-d][1,3]dioxolen (21): To a mixture of  alcohol 20 (2.0 g, 5.95 
mmol)  and at 0 °C, azidotrimethylsilane (2.3 mL, 17.85 mmol) in acetonitrile (10 mL), 
cooled to 0 °C was added followed by ZrCl4 (0.180 mg) were added and stirred for 2 h. 
Workup as described for 6 purification of the residue by column chromatography (60-120 
mesh Silica gel, 5% EtOAc in pet. ether) afforded the azide compound 21 (1.6 g, 74%) as a 
mixture of diastereo isomers in 7:3  ratio as a light yellow oil. IR (CHCl3): 2986, 2929, 2852, 
2098, 1607, 1451, 1251, 1079, 1027, 860;
 1
H NMR (CDCl3, 300 MHz, 295 K):  7.24-7.14 
(m, 1H, ArH ), 6.90-6.75 (m, 4H, 3 x ArH, olefinic), 6.02 (d, 0.7H, J = 4.1 Hz, C1H) 5.94 (d, 
0.3H, J = 3.7 Hz, C1H), 5.18 (d, 0.3H, J = 3.0 Hz, C2H), 4.82 (d, 0.7H, J = 1.8 Hz, C2H), 
4.65 (d, 0.7H, J = 3.7 Hz, C4H), 4.57 (d, 0.3H, J = 3.7 Hz, C4H ), 4.12-3.96 (m, 2H, CH2), 
3.85(d, 0.7H, J = 3.02 Hz, C3H),3.82 (s, 3H, OMe), 3.75(d, 0.3H,  J = 3.39Hz, C3H), 1.38 (s, 
6H, 2 x CH3).
 13
C NMR (75 MHz, CDCl3) δ 158.74, 158.72, 145.14, 145.12, 133.42, 125.76, 
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125.74, 115.25, 114.34, 104.32, 104.30, 85.14, 85.12, 82.44, 82.42, 79.98, 74.62, 57.72, 
57.70, 55.92, 26.32, 26.30 HRMS (ESI+) m/z calcd for C18H23N3O5Na (M
+ 
+ Na) 384.1535, 
found 384.1539.  
 
 
 
 
 
 
(E)-3-((3aR,5R,6S,6aR)-6-Methoxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)-
1-(4-methoxyphenyl)prop-2-en-1-ol (24):  
 
To a stirred solution of oxalyl chloride (1.2 mL, 14.3 mmol) in dry CH2Cl2 (20 mL), DMSO 
(12.0 mL, 28.6 mmol) was added at -78 
o
C and stirred at the same temperature for 0.5 h. A 
solution of 23 (3.0 g, 13.0 mmol) in CH2Cl2 (10 mL) was added at -78 
o
C and stirred for an 
additional 2 h at the same temperature. Et3N (9  mL, 65.21 mmol) was added at 0 
o
C and 
stirred for 15 min. The reaction mixture was diluted with water (30 mL) and extracted with 
CH2Cl2 (2 x 30 mL). The combined organic layers were washed with brine (30 mL), dried 
(Na2SO4), evaporated to give 23a, which was used as such for the next reaction.  
 
To a suspension of Mg turnings (0.580 g, 24.13 mmol) in THF (15 mL) at room temperature, 
p-bromoanisole (3.0 mL, 24.13 mmol) was added and stirred for 30 min. The Grignard 
reagent was cooled to 0 
o
C and a solution of aldehyde 23a (2.2 g, 9.65 mmol) in THF (15 
mL) was slowly added. Workup as described for 5 purification of the residue by column 
chromatography (60-120 mesh Silica gel, 20% EtOAc in pet. ether) afforded 24 (2.5 g, 78%) 
as a diastereomeric mixture with 7:3 ratio as a light yellow oil. IR (CHCl3): 2932, 1607, 
1512, 1464, 1374, 1165, 1079, 1023, 854, 756 cm
-1
; 
1
H NMR (CDCl3, 300 MHz):  7.31 (m, 
2H, ArH ), 6.89-6.86 (m, 2H, ArH), 6.10-6.03 (m, 1H, olefin),  5.95-5.85 (m, 2H, olefin, 
C1H), 5.22 (m, 1H, C2H), 4.60-4.59 (m, 2H, C4H, C5H), 3.8 (s, 3H, OMe), 3.64 (m, 1H, 
C3H), 3.38 (s, 3H, OMe), 2.02(brs, 1H, OH), 1.49 (s, 3H, Me), 1.32 (s, 3H, Me).
 13
C NMR 
(75 MHz, CDCl3): δ 159.39, 132.00, 130.98, 129.49, 127.88, 126.69, 124.74, 114.02, 111.73, 
105.21, 85.30, 83.46, 81.73, 77.36, 70.81, 57.85, 55.36, 26.82, 26.29. HRMS (ESI+) m/z 
calcd for C18H24O6Na (M
+ 
+ Na) 359.1471, found 359.1470. 
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(3aR,5R,6S,6aR)-5-((E)-1-Azido-3-(4-methoxyphenyl)allyl)-6-methoxy-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxole (25a): A solution of alcohol 24 (2.0 g, 5.95 
mmol) in acetonitrile (10 mL) was cooled to 0 
o
C,  treated with azidotrimethylsilane(2.3 mL, 
17.85 mmol) and and ZrCl4 (0.18 mg) sequentially, and stirred at room temperature for 2 h.. 
Workup as described for 6 purification of the residue by column chromatography (60-120 
mesh Silica gel, 5% EtOAc in pet. ether) afforded 25a (1.2 g, 72%) as a light yellow oil. []D 
= -135.92 (c 0.38, CHCl3); IR (CHCl3): 2936, 2836, 2102, 1607, 1512, 1463, 1374, 1216, 
1114, 889, 852, 759 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 7.35 (d, J = 8.7 Hz, 2H, ArH), 6.89 
(t, J = 5.8 Hz, 2H, ArH), 6.70 (d, J = 15.8 Hz, 1H, olefinic), 5.97 (d, J = 3.8 Hz, 1H, C1H), 
5.91 (dd, J = 15.8, 8.0 Hz, 1H, olefinic), 4.58 (t, J = 5.5 Hz, 1H, C2H), 4.42 (t, J = 8.7 Hz, 
1H, C5H), 4.13 (dd, J = 9.4, 3.2 Hz, 1H, C4H), 3.82 (d, J = 3.4 Hz, 3H, OMe), 3.60 (d, J = 3.2 
Hz, 1H, C3H), 3.35 (s, 3H, OMe), 1.51 (s, 3H, Me), 1.33 (s, 3H, Me). 
13
C NMR (75 MHz, 
CDCl3) δ159.92, 134.57, 128.70, 128.02, 120.32, 114.21, 112.14, 105.44, 83.90, 82.35, 
81.34, 77.36, 63.66, 57.76, 55.42, 26.89, 26.36. 
 
 
 
 
(3aR,5R,6S,6aR)-5-((R,E)-1-Azido-3-(4-methoxyphenyl)allyl)-6-methoxy-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxole (25b): A yellow oil was obtained (0.40 g, 72%) 
[]D = +228.43 (c 0.22, CHCl3); IR (CHCl3): 2936, 2836, 2102, 1607, 1512, 1463, 1374, 1216, 
1114, 889, 852, 759 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.35 (d, J = 8.7 Hz, 2H, ArH), 6.86 
(t, J = 9.2 Hz, 2H, ArH), 6.67 (d, J = 15.8 Hz, 1H, olefinic), 6.10 (dd, J = 15.8, 7.6 Hz, 1H, 
olefinic), 5.89 (d, J = 3.7 Hz, 1H, C1H), 4.59 (d, J = 3.8 Hz, 1H, C2H ), 4.42-4.34 (m, 1H, 
C5H ), 4.05 (dd, J = 9.7, 3.1 Hz, 1H, C4H), 3.82 (m, 4H, OMe, C3H), 3.49 (s, 3H, OMe ), 
1.49 (s, 3H, Me), 1.30 (s, 3H, Me).
 13
C NMR (75 MHz, CDCl3): δ 159.75, 134.18, 128.95, 
128.31, 122.50, 114.05, 111.97, 105.46, 83.60, 81.67, 81.37, 77.58, 77.36, 77.16, 76.74, 
62.01, 57.92, 55.44, 26.92, 26.36 
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t-Butyl((S)-1-((3aR,5R,6S,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-
5-yl)-3-(4-methoxyphenyl)propyl)carbamate (26a):  A mixture of olefin 25a (0.5 g),  Pd-C 
(0.050 mg) and methanol (5 mL) was pressurised with 90-100 psi of hydrogen and was 
allowed to stir at room temperature for 6 h.  The reaction mixture was filtered through a 
Celite bed and washed with methanol (5 × 5 mL). The filtrate was dried (Na2SO4) and 
evaporated under reduced pressure afford amine.  
 
A stirred solution of above amine (0.3 g, 0.8 mmol) in dry CH2Cl2 (3 mL) was cooled to 0 °C, 
treated with Et3N (0.35 mL, 2.4 mmol) and (Boc)2O (0.46 mL, 2.0 mmol). The reaction 
mixture was stirred at room temperature for 2 h and evaporated the solvent. The residue was 
purified by column chromatography (60-120 mesh Silica gel, 15% EtOAc in pet. ether) to 
give 26a (0.31 g, 81%) as a yellow syrup. []D = -83.42 (c 0.22, CHCl3); IR (CHCl3): 2979, 
1713, 1523, 1366, 1247, 1167, 1079, 1016, 853 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 7.11 
(m, J = 9.8 Hz, 2H, ArH), 6.91-6.75 (m, 2H, ArH), 5.88 (d, J = 3.8 Hz, 1H, C1H), 4.70 (s, 
1H, NH), 4.55 (d, J = 3.8 Hz, 1H, C2H), 4.05 (dt, J = 15.8, 7.9 Hz, 1H, C5H), 3.95 (d, J = 3.2 
Hz, 1H, C4H), 3.78 (d, J = 3.6 Hz, 3H, OMe), 3.62 (t, J = 7.2 Hz, 1H, C3H), 3.39 - 3.28 (m, 
3H, OMe), 2.69 (dt, J = 15.2, 7.7 Hz, 1H, CH), 2.65-2.55 (m, 1H, CH), 1.84-1.70 (m, 2H, 
CH2), 1.46 (d, J = 7.8 Hz, 12H, Me, Boc-H), 1.31 (s, 3H, Me). 
13
C NMR (75 MHz, CDCl3): δ 
157.85, 156.04, 134.23, 129.45,113.89, 111.52, 104.82, 84.63, 81.51, 81.19, 57.79, 55.39, 
49.40, 35.24, 31.14, 28.55, 26.86, 26.30. HRMS (ESI+) m/z calcd for C23H36NO7Na (M
+ 
+ 
Na) 438.2492, found 438.2495.  
 
 
 
 
 
 
tert-Butyl((R)-1-((3aR,5R,6S,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[2,3-
d][1,3]dioxol-5-yl)-3-(4-methoxyphenyl)propyl)carbamate (26b): A mixture of olefin 25b 
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(0.4 g),  Pd-C (0.050 mg) and methanol (5 mL) was pressurised with 90-100 psi of hydrogen 
and was allowed to stir at room temperature for 6 h. The crude residue obtained as described 
for 26a was used  without  further purification. A stirred solution of the above amine (0.25 g, 
0.74 mmol) in dry CH2Cl2 (3 mL) was cooled to 0 C and treated with Et3N (0.28 mL, 2.23 
mmol) and (Boc)2O (0.45 mL, 2.20 mmol). Workup as described for 26a and purification of 
the residue by column chromatography (60-120 mesh Silica gel, 15% EtOAc in pet. ether) to 
give 26b (0.25 g, 79%) as a yellow syrup. []D = +48.76 (c 0.41, CHCl3); IR (CHCl3): 2933, 
1713, 1513, 1455, 1366, 1246, 1166, 1080, 1019, 889 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 
7.11 (d, J = 8.3 Hz, 2H, ArH), 6.82 (d, J = 8.5 Hz, 2H, ArH), 5.88 (d, J = 3.7 Hz, 1H, C1H), 
4.99 (m, 1H, C5H), 4.52 (d, J = 3.5 Hz, 1H, C2H), 4.18-3.99 (m, 2H, C4H, C3H), 3.78 (s,  3H, 
OMe), 3.69 (m, 1H, CH), 3.40 (s, 3H, OMe), 2.79-2.54 (m, 2H CH2),  1.97-1.62 (m, 2H, 
CH2), 1.46 (d, J = 7.8 Hz, 12H, Me, Boc-H), 1.31 (s, 3H, Me). 
13
C NMR (75 MHz, CDCl3): δ 
157.85, 156.04, 134.23, 129.45, 113.89, 111.52, 104.82, 84.63, 81.51, 81.19, 57.79, 55.39, 
49.40, 35.24, 31.14, 28.55, 26.86, 26.30. HRMS (ESI+) m/z calcd for C23H36NO7Na (M
+ 
+ 
Na) 438.2492, found 438.2497.  
 
 
 
 
 
Methyl(S)-4-((tert-butoxycarbonyl)amino)-4-((3aR,5R,6S,6aR)-6-methoxy-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)butanoate (27b): A solution of compound 
26a (0.25 g, 0.57 mmol) in CH3CN:H2O:CCl4 (1 mL:1 mL:1.5 mL) was treated with NaIO4 
(0.36g, 1.76 mmol) followed by catalytic amount of RuCl3(10 mg) and NaHCO3 (10 mg). 
The reaction mixture was stirred at room temperature for 8 h then treated with saturated. 
aqueous NaHCO3 (10 mL) and washed with CH2Cl2 (2 x 20 mL). The aqueous layer was 
cooled in an ice bath and acidified with 10% aq HCl to pH 2-3. The solution was extracted 
with EtOAc (4 x 20 mL). The organic layer was dried (Na2SO4) and evaporated in vacuo. The 
residue was purified by column chromatography (60-120 mesh Silica gel, 35% EtOAc in pet. 
ether) to afford acid 27a as a yellow syrup.  
 
A solution of acid 27a (0.01 g, 0.26 mmol) in MeOH (4 mL) was tretaed with ethereal 
diazomethane [prepared from 0.30 g of N-nitrosomethylurea and 20% KOH (10 mL) in 
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diethyl ether (15 mL)]. The reaction mixture was stirred at 0 
o
C for 12 h. Solvent was 
evaporated and purified the residue by chromatography (60-120 mesh Silica gel, 15% EtOAc 
in pet. ether) to give  27b (0.085 g, 79%) as a yellow syrup []D = -92.34 (c 1.0, CHCl3); IR 
(CHCl3):  2980, 2919, 2849, 1739, 1714, 1514, 1454, 1368, 1166, 1081, 1021, 885, 857 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 5.91 (d, 1H, J = 3.9 Hz, C1H), 4.65 (d, 1H, J = 8.2 Hz, NH), 
4.57 (d, 1H, J = 3.8 Hz, C2H), 4.04 (dd, J = 6.6, 3.3 Hz, C4H), 3.98 (m, 1H, C5H), 3.68 (s, 
3H, OMe), 3.66 (d, J  = 3.32, 1H, C3H), 3.38 (s, 3H, OMe), 2.45- 2.40 (m, 2H, CH2), 1.97-
1.72 (m, 2H, CH2), 1.47 (s, 3H, CH3), 1.44 (s, 9H, Boc-H), 1.35-1.26 (s, 3H, CH3). 
13
C NMR 
(126 MHz, CDCl3): δ 174.20, 156.05, 111.61, 104.87, 84.67, 81.52, 81.18, 57.85, 51.78, 
30.50, 28.52, 28.32, 26.87, 26.32. HRMS (ESI+) m/z calcd for C18H32NO8Na (M
+ 
+ Na) 
390.2128, found 390.2131.  
 
 
 
 
 
Methyl(R)-4-((t-butoxycarbonyl)amino)-4-((3aR,5R,6S,6aR)-6-methoxy-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)butanoate (27d): A solution of compound 
26b (0.25 g, 0.57 mmoL) in CH3CN:H2O:CCl4 (1 mL:1 mL:1.5 mL) was treated with NaIO4 
(0.36g, 1.76 mmoL) followed by a catalytic amount of RuCl3 (10 mg) and NaHCO3 (10 mg). 
The work-up described for 27a was implemented, and the residue was purified by column 
chromatography (60-120 mesh Silica gel; 35% EtOAc in pet. ether) to afford acid 27c as a 
yellow syrup.  
The treatment of acid 27c (0.010 g; 0.26 mmol) in MeOH (4 mL) was admixed with ethereal 
diazomethane [prepared from 0.30 g of N-nitrosomethylurea and 20% KOH (10 mL) in ether 
(15 mL), and the work-up described for 27b and purification of 27d by column 
chromatography (60-120 mesh Silica gel; 15% EtOAc in pet. ether)  gave 27d (0.08 g, 79%) 
as a yellow syrup with []D = +179.43 (c 0.53, CHCl3). IR (CHCl3):2978, 1713, 1524, 1456, 
1366, 1247, 1117, 1079, 1015, and 853 cm
-1
; 
1
H NMR (300 MHz, CDCl3): δ 5.91 (d, 1H, J = 
3.8 Hz, C1H), 4.96 (s, 1H, NH), 4.54 (d, 1H, J = 3.77 Hz, C2H), 4.06 (s, 1H, C4H), 3.76 (m, 
2H, C5H, C2H), 3.67 (s, 3H, OMe), 3.40 (s, 3H, OMe), 2.50-2.39 (m, 2H, CH2), 2.15-1.89(m, 
2H, CH2), 1.48 (s, 3H, CH3), 1.43 (s, 9H, Boc), 1.32 (s, 3H, CH3). 
13
C NMR (125 MHz, 
CDCl3): δ 174.20, 155.89, 111.66, 105.07, 84.93, 81.23, 80.80, 51.79, 49.39, 31.05, 28.51, 
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27.85, 26.89, and 26.35. HRMS (ESI+) m/z calculated for C18H32NO8Na (M
+ 
+ Na) 
390.2128: 390.2135.  
General synthetic procedure for azide and double-bond reduction (failed to synthesise 17 
to 18 as well as 21 to 22. Reagents and conditions are related to Table 4.1.) 
 
1. A mixture of azide (1.0 g) and 10% Pd/C (0.1g for 1.0 g) in methanol (5 mL) was 
pressurised at 90-100 psi of hydrogen at room temperature for 12 h. The starting 
material was consumed, and multiple spots were observed (TLC analysis). The 
reaction mixture was passed through the Celite bed, and the filtrate was evaporated 
under reduced pressure to give a crude residue as a yellow liquid.  
 
2. A mixture of azide (1.0 g), ammonium acetate (10 mmol) and 10% Pd/C (0.1 g for 1.0 
g) in methanol (5 mL) was stirred at reflux conditions for 8 h. The starting material 
was consumed, and multiple spots were observed (TLC analysis). The reaction 
mixture was passed through the Celite bed, and the filtrate was evaporated under 
reduced pressure to give a crude residue as a yellow liquid. A mixture of azide (1.0 
mmol), raney nickel (washed twice in ethanol) (0.1 g for 1.0 g) in ethanol (5 mL) was 
stirred at room temperature under a hydrogen atmosphere (1 atm) for 12 h. The 
starting material was completed, and multiple spots were observed (TLC analysis). 
The reaction mixture was passed through the Celite bed, and the filtrate was 
evaporated under reduced pressure to give a crude residue as a yellow liquid.  
 
3. A mixture of azide (1.0 g) and 10% Pd(OAc)2/Charcoal (0.1 g for 1.0 g) in methanol 
(5 mL) was pressurised at 90-100 psi of hydrogen at room temperature for 12 h. The 
starting material was consumed, and multiple spots were observed (TLC analysis). 
The reaction mixture was passed through the Celite bed, and the filtrate was 
evaporated under reduced pressure to give a crude residue as a yellow liquid.  
 
4. A mixture of the azide (1.0 g) and RhCl(PPh3)3, (0.1 g for 1.0 g) in toluene (5 mL) 
was pressurised at 90-100 psi of hydrogen at room temperature for 12 h. The starting 
material was consumed, and multiple spots were observed (TLC analysis). The 
reaction mixture was passed through the Celite bed, and the filtrate was evaporated 
under reduced pressure to give a crude residue as a yellow liquid.  
 
Chapter IV 
 
120 
 
5. A mixture of azide (1.0 g) and PtO2(0.1 g for 1.0 g) in methanol (5 mL) was 
pressurised at 90-100 psi of hydrogen at room temperature for 12 h. The starting 
material was consumed, and multiple spots were observed (TLC analysis). The 
reaction mixture was passed through the Celite bed, and the filtrate was evaporated 
under reduced pressure to give a crude residue as a yellow liquid.  
 
6. A mixture of azide (1.0 g), raney nickel (washed twice in ethanol; 0.1 g for 1.0 g) in 
ethanol (5 mL) was stirred at room temperature under hydrogen atmosphere (1 atm) 
for 12 h. The starting material was completed, and multiple spots were observed (TLC 
analysis). The reaction mixture was passed through the Celite bed, and the filtrate was 
evaporated under reduced pressure to give a crude residue as a yellow liquid.  
 
 
4.10
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The objective of the research performed in this chapter is to synthesise selected potent amine 
derivatives for potential use as TRPV3 agonists that overcome pain. 
 
5.1 Introduction 
 
The synthesis of novel compounds with potent Transient Receptor Potential Vanilloid 
(TRPV3) activity is a challenging task in medicinal chemistry. Transient receptor potential 
vanilloid is a sub-ion channel of the TRP channels1 family. The family of TRP ion channels 
have been divided into six trans-membrane domains based on their structural homology and 
cation permeability. However, TRP channels are important ion channels among all known ion 
channels because of their diversity in cation selectivity and activation mechanisms. Although 
mechanisms of the activation of each TRP channel are diverse, they share a common 
similarity in exhibiting the crucial roles in response to all major classes of external stimuli, 
including light, sound, chemicals, temperature and touch. Some TRP channels can also act as 
sensors2 for osmotic pressure, stretch, vibration and volume. In this chapter, novel amine 
derivatives are designed and synthesised as TRPV3 agonists. This chapter presents the 
classification of TRP channels and their descriptions as well as synthetic approaches of 
selective amine derivatives as TRPV3 agonists and evaluation of their functional activity.  
 
5.2 The TRP-ion channel family 
 
The TRP-ion channel family consists of 28 cation channels that are classified into six sub-
families: TRPV , TRP Ankyrin (TRPA), TRP Melastatin (TRPM), TRP Canonical (TRPC), 
TRP Polycystin (TRPP) and TRP Mucolipin (TRPML). These channels perform diverse 
biological functions3 such as absorption of calcium and magnesium, thermal sensation and 
pain relaxation. Each TRP-ion channel plays a specific role in the body, and its dysfunction 
causes various diseases.4 Additionally, these channels play a key role in overcoming diseases. 
Generally, chemical and physical stimuli, such as temperature, mechanical forces, ligand 
binding, cell volume and voltage factors involved to activate the TRP channels. Some of the 
channels are extremely developed chemical modulators5 based on their activity and 
selectivity. Those channels include TRPV1, TRPV3, TRPV4, TRPA1, and TRPM8  
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5.2.1 Transient Receptor Potential Vanilloid 1 
 
Transient Receptor Potential Vanilloid 1 (TRPV1) is a sub-cation channel of TRPV sub-
family member 1. It is also known as a capsaicin receptor. Ion channels of TRPV1 can be 
activated by vanilloids, protons/cations, and lipids at temperatures above 42 °C. Capsaicin 16 
and resiniferatoxin (RTX) 27 (Figure 5.1) are potent small-molecule TRPV1 agonists. The 
key chemical ingredient in ‘hot’ chilli peppers is capsaicin, which draws the burning pain 
sensation and communicates the message with the central nervous system by activating 
sensory neurons selectively. Purified capsaicin activates TRPV1 with an EC50 of 711.9 nM. 
Resiniferatoxin 2 is the most potent among all known natural and endogenous agonists of 
TRPV1. Purified RTX activates TRPV1 with an EC50 of 39.1 nM.
 In a recent analysis8, 
various TRPV1 antagonists were developed for the improvement of pain-relaxation therapy.  
 
 
 
 
 
 
 
 
Figure 5.1: TRPV1 channel modulators 
 
5.2.2 Transient Receptor Potential Vanilloid 2 
 
Transient Receptor Potential Vanilloid 2 is a sub-cation channel of TRPV sub-family member 
2. It is expressed in vascular smooth muscle cells and can be activated by membrane stretch9 
and temperatures above 52 °C. Previous reports suggest that a TRPV210 channel exhibits 
sensitivity to osmotic concentration, temperature and pressure. This channel is less likely to 
be developed as a therapeutic agent against pain. 
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5.2.3 Transient Receptor Potential Vanilloid 3 
 
Transient Receptor Potential Vanilloid 3 is a sub-cation channel of TRPV subfamily   
member 3. It is a calcium-permeable ion channel activated by warm temperatures11a (>31 °C) 
with localisation in keratinocytes11b (predominant cells in the outermost layer of the skin) and 
a sub-population of small-diameter dorsal root ganglia (DRG) neurons (a cluster of nerve-cell 
bodies in the spinal nerve).11c Transient Receptor Potential ion channels can also be activated 
by pH, osmolarity and its agonists. A chemical compound such as menthol 3 can make 
changes in the channels’ temperature sensitivity by activating and inhibiting particular TRP 
ion channels. Transient Receptor Potential Vanilloid 3 is a sensitising receptor,13 and natural 
compounds such as camphor 4 have the ability to activate it and regulate sensitisation of the 
body temperature of humans12. The 2-aminoethoxy diphenyl borate (2-APB) 5 is a synthetic 
agonist that activates significant currents upon first application at concentrations of 100-300 
mM, whereas camphor is a weak agonist that activates sizeable currents only at 
concentrations of 10 mM or higher on first exposure. Additionally, Thymol 6, Carvacrol 7 
and Eugenol 8 (Figure 5.2) have also been found to activate TRPV3.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: TRPV3 agonists 
 
Transient Receptor Potential Vanilloid 3 is mainly expressed in the skin, hair, brain and 
spinal cord. After nerve injury, TRPV3 expression increases considerably in human sensory 
neurons. Therefore, the TRPV3 channel is the ideal target for pain therapy. Another property 
of TRPV3 is that it is sensitive to repeated stimulation through modulation of the N-terminal 
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domain calmodulin binding site,14 whereas TRPV1 and TRPV4 are both desensitised upon 
repetitive stimulations. Transient Receptor Potential Vanilloid 3 activation of keratinocytes 
results in the release of Adenosine Triphosphate (ATP), which has been demonstrated to 
subsequently activate sensory neurons and thus act as a transducer15 of sensory inputs from 
the skin. In addition to the potential role in pain relaxation, modulation TRPV3 plays an 
essential role in skin keratinisation, hair growth and skin-related disorders such as the 
Olmsted syndrome.16 
 
Discovery of antagonists17a for TRPV3 has indicated a pathway to a preclinical investigation 
of pain therapy. In 2011, Glenmark17b reported that a Phase I study was successfully 
completed for the compound GRC15300 (structure unknown), which can inhibit complete 
Freund's adjuvant (CFA)-induced mechanical hyperalgesia. Subsequently, in 2012 an 
agreement was initiated with Sanofi-Aventis for a Phase II trial of studies of neuropathic 
pain.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Glenmark TRPV3 antagonists. 
Similarly, Glenmark generated a series of compounds, which include pyrido-pyrimidine 9, 
benzimidazole 10 and the spiro-chroman chemotype 11 (Figure 5.3). Furthermore, Hydra 
Biosciences and AbbVie are also involved in opening patent applications for TRPV3 
inhibitors. Hydra Biosciences reported the analogues of substituted thio-dihydroisoquinolone 
ethones (12 and 13) and a series of quinazolinones 14 with similarity in structure to the 
Glenmark compounds. AbbVie also reported compounds with substitutions around a pyridine 
ring, such as 15 and 16 (Figure 5.4).  
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Figure 5.4: Hydra and AbbVie TRPV3 antagonists. 
 
5.2.4 Transient Receptor Potential Vanilloid 4 
 
Transient Receptor Potential Vanilloid 4 is a sub-cation channel of TRPV subfamily member 
4. It can be activated by a temperature ranging from 27 to 34 °C and small chemical 
compounds such as anandamide (ANA 17) and GSK 106790A 18 (Figure 5.5). 
 
 
 
 
 
 
 
 
 
  
 
Figure 5.5: TRPV4 channel modulators 
 
Compound 18, a highly potent TRPV4 agonist has been found to activate a Ca2+ influx in 
human embryonic kidney (HEK) cells18 that express human and mouse TRPV4 cells with 
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EC50 values of 2.1 and 18 nM, respectively. The TRPV4 channel plays a vital role in 
physiological processes such as osmoregulation, thermal changes and hearing. It also plays a 
key role in urinary bladder functions and is able to contract urinary bladders.19. Hydra 
revealed a TRPV4 antagonist pyrrole HC-067047 1920, which has proven to be effective 
against bladder cystitis in clinical trials. 
 
5.2.5 Transient Receptor Potential Ankyrin 1 
 
Transient Receptor Potential Ankyrin 1 is a sub-ion channel of TRPA subfamily member 1. 
Sensory neurons mediate potentially damaged responses to the spinal cord and the brain 
through pain signals. Transient Receptor Potential Ankyrin 121 is expressed in sensory 
neurons. It is activated by a variety of noxious stimuli that include low temperature (<17 °C), 
environmental irritants and unpleasant chemical compounds. Reports have indicated that 
TRPV1 can be activated through reactive chemicals.22    Chemicals such as cinnamaldehyde, 
hydroxylnonenal, formalin, acrolein can activate TRPV1 whereas compounds such as 
nicotine is unreactive.23 However, Hydra Biosciences 3 revealed some TRPA1 channel 
modulators that include compound HC-030031 20 with IC50 = 6.2 μM and the other analogue 
TRPA1 ligand HC-068559 21 as effective TRPA1 inhibitors (Figure 5.6).  
 
 
 
 
 
 
Figure 5.6: TRPA1 channel modulators. 
 
 5.2.6 Transient Receptor Potential Melastatin 8 
 
Transient Receptor Potential Melastatin 8 is a sub-cation channel of TRPM subfamily 
member 8 and is also known as a cold menthol receptor. It is activated by chemical cooling 
agents such as icilin 22 and menthol 3 in a temperature range of 10-23 °C. Transient Receptor 
Potential Melastatin 8 plays a role in mediating painful signals24 that are associated with low 
temperatures. It is well known that cold temperatures can be utilised to cause pain relaxation, 
which suggests that TPRM8 can be considered to be a drug target for analgesics.25 Borneol 
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23 has the medicinal property of the TRPM8 channel and also mediates this channel’s 
therapeutic effect in the eyes. In 2009, the Dendreon Corporation presented D-3263 24 as a 
good TRPM8 agonist under clinical trials. (Figure 5.7).  
 
 
 
 
 
 
 
Figure 5.7: TRPM8 channel modulators. 
  
5.3 Drug targets that are required in future for TRPV3 
 
Although TRP channels are available as drug targets,26 there are still some questions 
concerning whether TRPV3 is a good target for therapy. First, the usage of the TRP channel 
as well as related compounds for the treatment of chronic pain has not been studied so far and 
is a potentially exciting research field. Similarly, the efficacy of TRPV3 antagonists in 
patients who suffer from pain has not been studied in detail. The pharmaceutical field is 
waiting for the results of the Phase 2 trial of Glenmark-Sanofi's TRPV3 antagonist GRC 
15300. Although some chronic pain model exists for TRPV3 as an antagonist, much research 
still needs to be conducted on TRPV3 for it to be regarded as a good drug target for better 
results.  
 
Second, the potentially different expression profile of TRPV3 between humans and rodents 
might complicate preclinical/clinical translation into a human-accurate prediction of effective 
therapeutic doses. Furthermore, activity results of TRPV3 that indicate towards hair growth, 
inflammation and skin-related problems suggest that enhancement in the activity of TRPV3 
certainly has an effect on skin biology. Over-activity28 of TRPV3 is the cause of skin diseases 
such as the Olmsted syndrome and has an effect in increased skin inflammation. This 
signifies the importance of TRPV3 antagonists.  
 
Moreover, there is a need of gaining complete knowledge about the role of TRPV3 in the 
physiological process and studying the mechanism involved in the pathology and specific 
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modulation of TRPV3 to determine detailed functions of TRPV3 agonists and antagonists. 
Thus, it makes it easy to focus on the particular target of analgesic effects29 and to reduce the 
side effects related to TRPV3’s non-sensory functions. The focus of the present study is on 
designing and synthesising various novel amine derivatives to test as TPRV3 agonists. 
 
5.4 Results and discussion 
 
The present study was initiated to screen a small compound library in search of more potent 
and selective agonists for TRPV3. It was aimed at characterising TRPV3, to define its role in 
pain and itch and may form the basis of new antagonist compounds that target TRPV3. It was 
also aimed at publishing the TRPV3-activity results on selected compounds. Four agonists 
(Figure 5.7), namely two natural products camphor 4 and thymol 6 as well as two synthetic 
compounds 2-APB30 5 and the N,N-dibenzyltryptamine 25, were identified from the 
screening of a 290-compound library at Royal Melbourne Institute of Technology (RMIT) 
University. 2-APB is synthetic organic compound, which is an important activator of TRPV3, 
that regulates the activity of several TRP ion channels. In addition, it activates TRPV1, 
TRPV2 and TRPV3 but not TRPV4, TRPV5 and TRPV6. Furthermore, 2-APB activates 
TRPA1 and TRPM6 and inhibits some of the sub-ion channels of TRPM and TRPC, which 
include TRPM8, TRPC4, TRPC5, and TRPC6. However, the exact mechanism that is 
involved in the sensitivity of chemical compounds such as 2-APB and camphor towards the 
domains of TRPV3 have not been studied so far. It is necessary to determine the specific 
location of the binding site, which is responsible for the activation of diverse stimuli. 
 
5.4.1 Design strategy for the compounds of interest 
 
Currently, there is not a wide range of existing drugs and lead molecules that improve 
TRPV3 agonists’ activity. The design strategy comprised including the steric interactions and 
modifying the hydrophobic nature of the lead compound N,N-dibenzyltryptamine 25 (Figure 
5.8). Compounds were designed with the addition of various substituents on the alkyl side 
chain to determine if these structural changes had resulted in discovering more potent and 
more selective agonists. The objective is to synthesise a small library of N,N-
dibenzyltryptamine with the aim of finding more potent agonists. The research plan was to 
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synthesise a diverse range of potential second-generation TRPV3 agonists using diverse β-
nitrostyrenes and Michael adducts, as outlined in the following Scheme 5.1.  
 
 
 
 
 
 
 
Figure 5.8: Active agonists for TRPV3 
 
5.4.2 Synthesis of β-nitrostyrenes using the Henry reaction 
 
Some of the selected aldehydes were converted into nitrostyrenes using the Henry reaction 
conditions. Nitrostyrenes were further converted to Michael adducts using indoles in water 
under reflux conditions; subsequently, Michael adducts were reduced to corresponding 
amines using Zn and acetic acid. Thereafter, the amines were protected with benzyl groups, 
and further amine derivatives were oxidised to oxy indoles using dimethyl sulfoxide (DMSO) 
and concentrated HCl in acetic acid. 
 
The reaction of p-chloro benzaldehyde (A) with ammonium acetate and acetic acid in 
nitromethane under reflux conditions afforded the corresponding known β-nitrostyrene32 26a 
in 82% yield (Scheme 5.1). The 1H NMR spectrum of 26a indicated that the olefinic protons 
resonated at  7.97 and  7.56 as doublets that integrated to one proton each, and the 13.7 Hz 
coupling constant of the olefinic protons indicates the formation of trans configuaration. Aryl 
protons that resonated at  7.40 as a multiplet that integrated to four protons indicates the 
formation of β- nitrostyrenes 26a. X-ray crystallographic data of 26a further supported the 
formation of the desired structure. 
 
Scheme 5.1 
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5.4.3 Reaction of indoles with nitroalkenes 
 
Acid-catalysed reactions of indoles with nitroalkenes can be considered to be Michael 
addition reactions. Acidic agents,33 in homogeneous or heterogeneous conditions may be 
employed in these reactions, whereas the use of chiral acid catalysts allows asymmetric 
syntheses of 3-(2-nitroalkyl) indoles. Activation of the indole ring towards reaction with 
nitroalkenes can also be achieved by the removal of the acidic proton from the nitrogen atom 
under basic conditions. This process involves the generation of a stabilised indolyl anion, 
which reacts with a nitroalkene through a conjugate addition reaction followed by a 
tautomerisation that restores the indole’s aromatic character. The powerful electron-
withdrawing effect exerted by the nitro group makes nitroalkenes strong electrophilic 
reactants.34 This high reactivity of nitro alkene usually requires moderate activation to react 
with indoles, as proved by the catalytic effect exerted by n-tetrabutylammonium bromide in 
this reaction.35 Physical activation by ultrasound irradiation or simple heating of the reaction 
mixture is often enough to provide a successful reaction of indoles with nitroalkenes. 
Interestingly, indoles and nitroalkenes can react under solvent-free conditions36 when heated 
at 100 °C. 
  
Scheme 5.2 
 
 
 
 
 
Table 5.1: Various reagent conditions for the synthesis of Michael adducts 
 
Entry Compound Conditions 26b Product % Reference 
1 26a (indole) CeCl3·7H2O-NaI (30 mol%)  
on Silica gel, Acetonitrile (MeCN), 
overnight 
52 37 
2 26a (indole) Zn(OAc)2 (5  mol%), EtOH, 4h, rt 48 38 
3 26a (indole) I2 (30  mol%), Et2O, 5h, rt 59 39 
4 26a (indole) H2O, reflux, overnight 87 40 
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The treatment of compound 26a (Scheme 5. 2) with Silica-supported CeCl3·7H2O-NaI in 
MeCN gave compound 26b in 52% yield, whereas the treatment of compound 26a with 
Zn(OAc)2 in ethanol and I2 (30 mol %) in Et2O
 gave 26b in lower yields. However, when the 
mixture of 26a and indole was suspended in water and allowed to stir under reflux conditions 
overnight, it afforded the desired product 26b in 87% yield (Table 5.1).  
 
The 1H NMR spectrum of 26b indicated that  the NH proton resonated at  7.91 as a singlet, 
and the indole proton resonated at  7.25 as a doublet that integrated to one proton. Aryl 
protons resonated at  7.10 as a multiplet that integrated to six protons, whereas other aryl 
protons resonated at  6.94 and  6.75 as a triplet and a singlet that integrated to one proton 
each. Benzylic protons resonated at  4.98 as a triplet, CH2 protons that resonated at  4.84 
and  4.69 as a doublet of doublets that integrated to one proton each indicated the formation 
of 26b. HRMS further confirmed the formation of product 26b, as (M+ + H) was found to be 
at m/z of 301.0728. 
 
5.5 Suggested mechanism for the Michael addition reaction 
 
Scheme 5.3 
 
 
 
 
 
 
 
Based on the literature,36 it was assumed that the formation of the Michael adducts takes 
place through the formation of the intermediate σ-complex (A-B). The lone pair of electrons 
in indole A makes the compound to facilitate the reaction. By contrast, the strong electron-
withdrawing group in the nitroalkene B makes the compound electron-deficient, which 
requires a moderate activation to participate in the reaction progress. These reaction 
conditions causes indole A to attack nitrostyrene B and form the intermediate σ-complex (A-
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B). Thereafter, σ-complex undergoes immediate transformation to form Michael adduct C 
(Scheme 5.3). 
 
Similarly, piperonal (B) reacted with ammonium acetate and acetic acid in nitromethane 
under reflux conditions to afford corresponding the known β-nitrostyrene32 27a in 73% yield. 
The 1H NMR spectrum of 27a indicated that the olefinic protons resonated at  7.93 and  
7.47 as doublets that integrated to one proton each. The 13.6 Hz coupling constant of the 
olefinic protons indicates the formation of  trans configuaration. Aryl protons resonated at  
7.04 as a multiplet that integrated to two protons, whereas other aryl protons resonated at  
6.87 as a doublet and integrated to one proton. CH2 protons that resonated at  6.06 as a 
singlet indicated the formation of β-nitrostyrene 27a. HRMS further confirmed the formation 
of product 27a, as (M+ + H) was found to be at m/z of 194.0464 (Scheme 5.4.1). 
 
Scheme 5.4.1 
 
 
 
 
 
The treatment of 27a with indole in water under reflux conditions for 16 h afforded the 
desired product 27b in 84% yield. In the 1H NMR spectrum of Michael adduct 27b, NH 
protons resonated at δ 8.02 as a singlet, and aryl protons resonated at δ 7.33, δ 7.15, δ 7.02 
and δ 6.71 as multiplets that integrated to two, one, two and three protons, respectively. 
OCH2 protons resonated at 5.84 as a doublet, and NCH2 protons resonated at 5.84 as a 
multiplet. Benzylic proton that resonated at δ 4.79 indicated the formation of the product 27b. 
HRMS further confirmed the formation of the product 27b, as (M+ + H) was found to be at 
m/z of 311.1030 
 
Similarly, vanillin (C) reacted with ammonium acetate and acetic acid in nitromethane under 
reflux conditions to afford the corresponding known β-nitrostyrene32 28a in 78% yield. The 
1H NMR spectrum of 28a indicated that the hydroxy proton resonated at δ 8.57 as a broad 
singlet, and olefinic protons resonated at  7.83 and  7.44 as doublets that integrated to one 
proton each. The 13.5 Hz coupling constant of the olefinic protons indicated the trans 
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formation. Aryl protons resonating at  6.98 and  6.65 as doublets and at  6.95 as a singlet 
that integrated to one proton each. Methoxy protons observed at δ 3.81 indicated the 
formation of β-nitrostyrenes 28a. HRMS further confirmed the formation of the product 28a, 
as (M+ + H) was found to be at m/z of 196.0614 (Scheme 5.4.2). 
 
Scheme 5.4.2 
 
The treatment of 28a with indole in water under reflux conditions for 16 h afforded the 
desired product 28b in 92% yield. In the 1H NMR spectrum of Michael adduct 28b, NH 
protons resonated at δ 7.97 as a singlet, and aryl protons resonated at δ 7.31, δ 7.15, δ 6.80 
and δ 6.71 as multiplets that integrated to one, three, one and three protons, respectively. 
Benzylic protons resonated at δ 4.97 as a triplet, whereas NCH2 protons that resonated at δ 
4.86 and δ 4.72 as singlets that integrated to one proton each indicated the formation of the 
product 28b. HRMS further confirmed the formation of the product, as (M+ + H) was found 
to be at m/z of  313.12030 
 
Similarly, p-chloro benzaldehyde (A) reacted with ammonium acetate, acetic acid in 
nitroethane under reflux conditions to afford the corresponding known β-nitrostyrenes32 29a 
in 73% yield. In the 1H NMR spectrum of 29a, the olefinic protons resonated at  8.03 as a 
singlet, and aryl protons resonated at  7.40 as a multiplet that integrated to four protons. 
Methyl protons that resonated at  2.44 as a singlet indicated the formation of β-nitrostyrenes 
29a. HRMS further confirmed the formation of the product 29a, as (M+ + H) was found to be 
at m/z of 198.0334 (Scheme 5.4.3). X-ray crystallographic data of 29a further supported the 
formation of the desired structure. 
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Scheme 5.4.3 
 
Treatment of 29a with indole in water under reflux conditions for 16 h afforded the desired 
product 29b in inseparable diastereomer mixture on column chromatography in (3:2) ratio 
with 82% yield. The ratio was identified based on 1H NMR Spectrum. In the 1H NMR 
spectrum of Michael adduct 29b, NH proton resonated at δ 8.07- 7.99 as singlets, aryl protons 
resonating in the region δ 7.31-6.71 as multiplets integrating to nine protons. Methyl protons 
appeared at δ 1.56 to 1.42 as doublets, while, rest of the proton signals appeared at the 
expected chemical shifts indicates the formation of products 29b. HRMS further confirmed 
the product 29b, (M+ + H) found to be at m/z  315.0900 
 
Similarly, piperonal (B) on reaction with ammonium acetate, acetic acid in nitroethane under 
reflux conditions afforded corresponding known β-nitrostyrene32 30a in 71% yield. In the 1H 
NMR spectrum of 30a, showed the olefinic protons resonated at  8.01 as a singlet 
integrating to one proton. Aryl protons resonating at  6.95 as a multiplet integrating to three 
protons, while, OCH2 protons appear at  6.04 as a singlet integrating to two and methyl 
protons resonating at  2.46 as singlet indicates the formation of β-nitrostyrene 30a. HRMS 
further confirmed the product 30a, (M+ + H) found to be at m/z  208.0609 (Scheme 5.4.4) 
 
Scheme 5.4.4 
 
 
 
 
 
Treatment of 30a with indole in water under reflux conditions for 16 h afforded the desired 
product 30b in inseparable diastereomer mixture (1:1) ratio with 82% yield. The ratio was 
identified based on 1H NMR Spectrum. In the 1H NMR spectrum of Michael adduct 30b, NH 
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proton resonated at δ 7.98-7.78 as singlets, aryl protons resonating in the region δ 7.53-6.50 
as multiplets integrating to eight protons. Methyl protons appeared in the region δ 1.45 to 
1.32 as doublets, while, the rest of the proton signals appeared at the expected chemical shifts 
indicates the formation of products 30b. HRMS further confirmed the product 30b, (M+ + H) 
found to be at m/z  325.1200 
 
When the Michael adducts had been prepared, corresponding amines were reduced, and 
amine derivatives were prepared. Michael adducts 26b were reduced with Zinc and acetic 
acid in dry THF at room temperature (RT) for 2 h to afford corresponding amines 26c in 
optimum yield, which were used to prepare the next-step product without any further 
purification. The treatment of amines 26c with benzyl bromide in the presence of sodium 
hydride (NaH) in dry Dimethylformamide (DMF) at RT for 2 h afforded benzyl derivative 
compound 26d in 91% yield as a yellow solid (Scheme 5.5.1). 
 
Scheme 5.5.1 
 
 
 
In the 1H NMR spectrum of Michael adduct 26d, aryl protons resonated at δ 7.32-7.17, δ 7.13 
and δ 6.90 as multiplets that integrated to six, eight and one protons, respectively. Other aryl 
protons resonated at δ 7.06 as a doublet, δ 7.00 as a doublet of a triplet, δ 6.67 as a singlet, 
and they integrate to four, four and one protons, respectively. Benzylic CH2 protons appeared 
at δ 5.15 as a doublet that integrated to two protons , whereas other benzylic protons appeared 
at δ 3.65-3.44 as an AB quartet that integrated to four protons. The rest of the proton signals 
that appeared at the expected chemical shifts indicated the formation of products 26d. HRMS 
further confirmed the formation of the product, as (M+ + H) was found to be at m/z of 
541.2287 
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Similarly, Michael adducts 27b were reducted with Zinc and acetic acid in dry THF at RT for 
2 h to afford corresponding amines 27c in optimum yield, which was used to prepare the 
next-step product without any further purification. The treatment of amines 27c with benzyl 
bromide in the presence of NaH in dry DMF at RT for 2 h afforded benzyl derivative 
compounds 27d  in 89% yield as a white solid (Scheme 5.5.2). 
 
Scheme 5.5.2 
 
 
 
 
 
 
 
 
In the 1H NMR spectrum of Michael adduct 27d, aryl protons resonated at δ 7.19, δ 7.14-
7.02, and δ 6.97 as multiplets that integrate to four, eleven and three protons, respectively. 
Other aryl protons resonated at δ 6.86 and δ 6.61 as triplets that integrate to one and three 
protons, respectively, and aromatic protons also resonated at δ 6.48 as a singlet that integrated 
to one proton. OCH2 protons appeared at δ 5.75 as a doublet that integrated to two protons. 
Benzylic protons resonated at δ 5.08 as a doublet, whereas other benzylic protons appeared at 
δ 3.50 as an AB quartet that integrated to four protons. The rest of the proton signals that 
appeared at the expected chemical shifts indicates the formation of the product 27d. HRMS 
further confirmed the formation of the product 27d, and (M+ + H) was found to be at m/z of 
551.2710 
 
Likewise, Michael adducts 28b were reduced with Zinc and acetic acid in dry THF at RT for 
2 h to afford corresponding amines 28c in optimum yield, which was used to prepare the 
next-step product without any further purification. The treatment of amines 28c with benzyl 
bromide in the presence of NaH in dry DMF at RT for 2 h afforded the benzyl derivative 
compound 28d  in 93% yield as a white solid (Scheme 5.5.3). 
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Scheme 5.5.3 
 
 
 
 
 
 
 
 
 
In the 1H NMR spectrum of Michael adduct 28d, aryl protons resonating at δ 7.36 as a 
doublet integrating to two protons, while, other aryl protons resonating at δ 7.31-7.12, 7.11-
6.81, and 6.65 integrating to seven, fifteen and four protons respectively. Benzylic protons 
resonated at δ 5.08, 5.12 as singlets, while other benzylic protons appeared at δ 3.63-3.32 as 
ABquartet integrating to four protons and methoxy protons resonated at δ 3.62 as a singlet, 
while, the rest of the proton signals appeared at the expected chemical shifts indicates the 
formation of products 28d. HRMS further confirmed the product 28d (M+ + H) found to be at 
m/z  643.3362 
 
Michael adducts 29b on reduction with Zinc and acetic acid in dry THF at rt for 2 h afforded 
corresponding amines 29c in optimum yield, which was used to prepare next step product 
without any further purification. Treatment of amines 29c with benzyl bromide in the 
presence of NaH in dry DMF at RT for 2 h afforded benzyl derivative compounds in  29d  an 
inseparable mixture of diastereomers in 1:1 ratio with 87% yield as a yellow solid (Scheme 
5.5.4).   
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Scheme 5.5.4 
 
 
 
 
 
 
 
 
In the 1H NMR spectrum of Michael adduct 29d, some of the protons showed spltting in the 
raio of 1:1 ratio. Aryl protons resonating in the downfield region and methyl protons 
appeared in the up field region and rest of the proton signals appeared at the expected 
chemical shifts indicates the formation of products 29d. HRMS further confirmed the product 
29d (M+ + H) found to be at m/z  556.2599. 
 
Scheme 5.5.5 
 
 
 
 
 
 
 
 
Michael adducts 30b on reduction with Zinc and acetic acid in dry THF at rt for 2 h afforded 
corresponding amines 30c in optimum yield, which was used to prepare next step product 
without any further purification. Treatment of amines 30c with benzyl bromide in the 
presence of NaH in dry DMF at RT for 2 h afforded benzyl derivative compounds in 30d  an 
inseparable mixture of diastereomers in 1:1 ratio with 82% yield as a yellow solid (Scheme 
5.5.5). 
 
In the 1H NMR spectrum of Michael adduct 30d, some of the protons showed splitting in 1:1 
ratio. Aryl protons resonating in the downfield region and methyl protons appeared in the 
pfield region and rest of the proton signals appeared at the expected chemical shifts indicates 
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the formation of products 30d. HRMS further confirmed the product 30d (M+ + H) found to 
be at m/z  565.2865. 
 
Benzyl protected compound 26d on oxidation with DMSO, Conc. HCl in acetic acid 
furnished the corresponding oxy indole 26e in 87% yield as a mixture of inseparable 
diastereomers in 7:3 ratio. The ratio of the isomers was calculated based on the 1H NMR 
spectrum of isolated compound (Scheme 5.6.1). 
 
Scheme 5.6.1 
 
 
 
 
 
 
 
In the 1H NMR spectrum of 26e, aryl protons resonated at down field region, Benzyl CH2 
proton resonated at the upfield region and rest of the protons appeared in the expected 
chemical shifts indicates the formation of 26e. The 13C NMR of 26e resonating at δ 177.05, 
175.92 confirms the presence of carbonyl group in the compound. Further, HRMS showing 
(M+ + H) peak at m/z 557.2356 supports the formation of the product 
 
Benzyl protected compound 27d on oxidation with DMSO, Conc. HCl in acetic acid 
furnished the corresponding oxy indole 27e in 82% yield as a mixture of inseparable 
diastereomers in 7:3 ratio. The ratio of the isomers was calculated based on the 1H NMR 
spectrum of isolated compound (Scheme 5.6.2). 
 
Scheme 5.6.2 
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In the 1H NMR spectrum of 27e, aryl protons resonated at down field region, Benzyl CH2 
proton resonated at the upfield regio and rest of the protons appeared in the expected 
chemical shifts indicates the formation of 27e. The 13C NMR of 27e resonating at δ 177.26, 
confirms the presence of carbonyl group in the compound. Further, HRMS showing (M+ + H) 
peak at m/z 567.2681 supports the formation of the product 
Benzyl protected compound 28d on oxidation with DMSO, Conc. HCl in acetic acid 
furnished the corresponding oxy indole 28e in 84% yield as a mixture of inseparable 
diasteromers in 4:1 ratio. The ratio of the isomers were calculated based on the 1H NMR 
spectrum of isolated compound (Scheme 5.6.3). 
 
Scheme 5.6.3 
 
 
 
 
 
 
 
 
In the 1H NMR spectrum of 28e, aryl protons resonated at down field region, Benzyl CH2 
proton resonated at the upfield region and rest of the protons appeared in the expected 
chemical shifts indicates the formation of 28e. The 13C NMR of 28e resonating at δ 177.36, 
176.38 confirms the presence of carbonyl group in the compound. Further, HRMS showing 
(M+ + H) peak at m/z 659.3262 supports the formation of the product 
Similarly, commercially available tryptamine 31c on reaction with NaH and benzyl bromide 
in the presence of dry DMF afforded (Scheme 5.7) 31d in 83% yield. In the 1H NMR 
spectrum of 31d, Aryl protons resonated at δ 7.38 as a doublet of doublet integrating to six 
protons, while, other aryl protons resonated at δ 7.33-7.17, 7.11 integrating to ten, three 
protons respectively and also aryl protons resonated at δ 7.02 as a triplet, δ 6.83 as a singlet 
integrating to one proton each. Benzylic protons appeared at δ 3.68 as a singlet, δ 3.05-2.91 
as a multiplet integrating to four protons and two protons respectively and rest of the protons 
appeared at the expected chemical shifts indicates the formation of product 31d. Further, 
HRMS showing (M+ + H) peak at m/z 431.2487  
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Scheme 5.7 
 
 
 
 
 
 
 
Benzyl-protected compound 31d was oxidised with DMSO and concentrated HCl in acetic 
acid afforded the corresponding oxyindole 31e in 78% yield. In the 1H NMR spectrum of 31e, 
aryl protons resonated at δ 7.32-7.09, δ 7.07-6.91 and δ 6.67-6.63 as multiplets that integrated 
to fifteen, one and one proton each respectively, whereas other aryl protons resonated at δ 
6.55 as a triplet that integrated to two protons. Benzyl CH2 protons resonated at δ 3.79-3.50 
as an AB quartet and at δ 3.68 as a doublet of a doublet that integrated to four and two 
protons, respectively. The rest of the protons that appeared in the expected chemical shifts 
indicated the formation of 31e. The 13C NMR of 31e that resonated at δ 178.10 confirms the 
presence of the carbonyl group in the compound. Furthermore, HRMS that indicates the (M+ 
+ H) peak at m/z 447.2400 supported the formation of the product. 
 
5.6 Screening assay of TRPV3 compounds 
 
All 25 synthesised compounds were examined for TRPV3 activity. A calcium assay was 
chosen to identify the activity of the compounds, and the aim of this assay was to investigate 
the effect of 25 modified compounds on HEK293 that expresses TRPV3. The analysis of 
TRPV compounds includes several steps.  
 
5.6.1 Plating cells 
 
The method of plating cells includes resuspension of HEK293 cells and HEK293 that is 
transfected with TRPV3 from frozen stocks, which are about 0.5 mL of 8 × 106 cells in 24.5 
mL of the medium (DMEM; 10% FBS), followed by the addition of 50 µL of cells per well 
in a 384-well plate of desired layout and incubation for 48 h at 37 °C in 5% CO2. 
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5.6.2 Overnight induction  
 
Tetracycline was diluted to 0.5 µg/mL in DMEM (10% FBS; 5 µg/mL of blasticidin). This is 
a 1 in 2000 dilution of stock (1 mg/mL). Subsequently, 12.5 µL of the solution was added to 
each well 16 h before the intended assay.  
 
Constituents of pH 7.4 assay buffer 
 
HEPES pH 7.4    100 mM           11.915 g/500 mL (SIGMA; H-3375) 
KCl                        1M                  14.91 g/200 mL (SIGMA); P-9333) 
NaCl                       1M                  23.38 g/400 mL (Fosher-Scientific; S/3160/53) 
MgCl2                      1M                 (Standard solution from Fluka; 63020) 
CaCl2                       1M                 (Standard solution from Fluka; 21114) 
D-(+)-Glucose                                 (SIGMA; G-7528) 
Probenecid                                     (SIGMA; P-8761) 
 
Table 5.2: Ingredients for 400 mL of pH 7.4 assay buffer 
 
 
 
 
 
 
 
 
 
 
 
 
5.6.3 Loading cells with Fura-2AM 
 
The assay buffer has to be warmed to 37 °C about 30 min before cells are loaded. A Fura-
2AM aliquot (50 µg; molecular probes; F-1221) was dissolved in DMSO (11 µL) and then 
mixed with 3.5 µL of FURA-2, 3.5 µL of Pluronic F-127 (20% in DMSO; Molecular probes; 
Constituents Amount of working 
solution added to a total 
volume of 400 mL 
(final concentration) 
constituent 
100 mM HEPES 40 mL HEPES (10mM) 
1M KCl 2 mL KCl (5 mM) 
1M NaCl 56 mL NaCl  (140 mM) 
1M MgCl2 400 µL MgCl2 (1 mM) 
1M CaCl2 800 µL CaCl2 (2 mM) 
Glucose 0.8 g Glucose (11 mM) 
****Probenecid 1mL ****Probenecid (2 mM) 
 Balance H2O to 400 mL  
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P-3000), 7.5 mL of a HEPES buffer and vortex (enough for one 384-well plate) to make a 
FURA buffer mix for each plate. Subsequently, the medium was removed from the 384-well 
plate and washed with 15 µL of the hepes buffer in the assay buffer. The buffer was removed 
from the 384-well plate, and 15µL of the FURA-2 buffer mix was added to the 384-well plate 
and incubated for 30-40 min at 37 °C in the dark (wrapped in aluminium foil; the drug plate 
was prepared during incubation time) and then washed with 15 µL of the HEPES buffer at 
pH 7.4. Then, cells were loaded with 20 µL of the final buffer solutions, and the cell plate 
was incubated at 37 °C in the dark for 20 min. 
 
5.6.4 Preparation of drug plates 
 
A 100 mM stock concentration of 2-APB (#100065 Calbiochem, 100 mg) was made up in 
vehicle 0.1% DMSO (#76-68-5, Astral Scientific) for the assay. The concentration for all 25 
compounds used in the assay was 100 µM (1% DMSO) stock concentration 10 Mm. 
Concentrations of agonists in the drug plate were loaded into the Flex station and then 
injected into the assay plate (cell plate).  For drug additions, the drug plate should contain   a 
3 × the stock, as the best injection for mixing and accuracy is injecting 10 µL into the 20 µL 
already loaded in wells. 
 
5.6.5 Flex setting on Softmax Pro 
 
Fluorescence (RFU) was selected, wavelengths were then chosen to adjust fluorescence 
accordingly. For FURA-2, Lm1 excitation was 340 nM, Lm2 excitation was 380 nM, and 
emission is 520 nM for both. For increased accuracy, the plate type must be changed to a 
specific brand. 
 
5.6.6 Injection setting 
 
The desired number was adjusted to the transfer option, and the initial volume in assay plate 
was inputted. The level in the plate was calibrated to pipette height (this is where the pipette 
head injected from). The volume is tuned on and a time point has to be selected to inject the 
drug. 20 µL of the compound from each well in the drug plate was injected into the final 80 
µL buffer solution in each well of the cell plate 
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5.7 TRPV3-activity results of synthesised compounds   
 
The results from the 25 compounds suggested that the compounds have no agonistic effect. 
Obtained results were compared with the agonist 2-APB activity and found that synthesised 
compounds have no  agonist activity of TRPV3 receptor expressed in HEK293 
 
Table 5.3: Activity results of synthesised compounds against HEK293 cells (non-
transfected cells) 
         [Ca2+]i,                                   
                            (F340/F380) 
Compound 
I II III Average 
26a 2.139 1.676 1.676 1.830 
27a 1.632 1.521 2.466 1.873 
28a 1.673 1.515 1.494 1.561 
29a 1.720 1.563 1.401 1.561 
30a 1.397 1.817 1.470 1.561 
26b 1.615 1.571 1.345 1.510 
27b 1.634 1.530 1.497 1.554 
28b 1.778 1.566 1.455 1.600 
29b 1.546 1.558 1.712 1.605 
30b 1.477 1.688 1.522 1.562 
26c 1.481 1.659 1.530 1.557 
27c 1.521 1.530 1.603 1.551 
28c 1.585 1.717 1.666 1.656 
29c 1.632 1.724 1.789 1.715 
30c 1.773 1.761 1.654 1.729 
26d 1.610 1.680 1.735 1.675 
27d 1.587 1.468 1.695 1.583 
28d 1.571 1.741 1.605 1.639 
29d 1.419 1.771 1.505 1.565 
30d 1.631 1.463 1.629 1.574 
26e 1.594 1.652 1.269 1.505 
27e 1.628 1.501 1.473 1.534 
28e 1.604 1.585 1.641 1.610 
31d 1.59 1.532 1.736 1.619 
31e 1.725 1.440 1.527 1.564 
Buffer (HEPES) 1.830 1.753 2.269 1.950 
DMSO 1.849 1.761 1.917 1.842 
2-APB (50µM) 1.816 1.561 1.648 1.675 
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However, the investigation of the agonist-activity effect of compounds 27d, 28d, 30d, 28e 
and 31d suggested that more research is needed. 
 
Table 5.4: Activity results of synthesised compounds against TRPV3 HEK293 cells  
         [Ca2+]i, 
                     (F340/F380)                
                           
Compound 
I II III Average 
26a 1.809 1.590 1.507 1.635 
27a 1.698 1.631 1.726 1.685 
28a 1.538 1.537 1.539 1.538 
29a 1.589 1.472 1.481 1.514 
30a 1.508 1.579 1.466 1.517 
26b 1.611 1.575 1.565 1.583 
27b 1.794 1.556 1.502 1.617 
28b 1.847 1.563 1.573 1.661 
29b 1.638 1.792 1.569 1.666 
30b 1.569 1.543 1.531 1.547 
26c 1.711 1.628 1.745 1.695 
27c 1.648 1.576 1.033 1.419 
28c 1.696 1.689 1.765 1.716 
29c 1.707 1.685 1.707 1.700 
30c 1.679 1.780 1.669 1.709 
26d 1.596 1.607 1.681 1.628 
27d 1.646 1.514 1.674 1.611 
28d 1.622 1.666 1.618 1.635 
29d 1.535 1.496 1.568 1.533 
30d 1.454 1.561 1.460 1.491 
26e 1.621 1.462 1.531 1.538 
27e 1.576 1.561 1.576 1.571 
28e 1.528 1.623 1.572 1.574 
31d 1.560 1.519 1.604 1.561 
31e 1.561 1.639 1.643 1.614 
buffer(HEPES) 1.850 1.784 1.830 1.821 
DMSO 1.788 1.730 1.777 1.765 
2-APB (50µM) 5.568 4.390 4.259 4.739 
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5.8 Conclusion 
 
 An efficient method has been established for synthesising benzyl-protected oxyindoles from 
nitrostyrenes that were converted into Michael adducts by the treatment of indoles in aqueous 
media, further reduced to amines and then benzylated. These benzylated amine derivatives 
oxidised to oxyindoles. These compounds were assayed to evaluate their TRPV3 agonist 
activity, and the results suggested that these compounds have no agonistic activity, and only a 
few compounds have mild TRPV3 agonist activity. 
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5.10 Experimental section 
 
5.10.1 Typical synthetic procedure for β-nitrostyrene (26a) 
 
To a stirred solution of NH4OAc (6.8 g; 89.25mmol) in AcOH (50 mL) under Ar atmosphere 
CH3NO2 (13.4 mL, 250.0 mmol) was added, followed by the p-chloro benzaldehyde (35.7 
mmol) at room temperature. The light-yellow solution was then heated to 100 °C for 8 h. The 
temperature of the reaction was reduced to room temperature, and the resulting mixture was 
poured into water (200 mL). The pH was adjusted to 7 using a 2M NaOH solution, and the 
resulting aqueous phase was extracted with EtOAc (4 × 100 mL). The combined organic 
layers were dried (Na2SO4), filtered and concentrated under vacuum to give a crude residue 
as a brown solid. To get a pure (E)-nitroalkene, the crude residue was further crystallised 
using 10% EtOAc in hexane as a solvent and filtered at its boiling-point temperature to 
remove brown oily impurities, thus affording the desired compound as pale yellow needles 
26a. Same procedure was followed for the synthesis of compounds 27a-30a. 
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5.10.2 Typical synthetic procedure for compound 26b 
 
To a stirred suspension of nitrostyrene 26a (1.0 g, 5.46 mmol) in water (10.0 mL), indole 
(0.639 g, 5.46 mmol) was added, and the mixture was allowed to stir under reflux conditions 
for 16 h. The mixture was cooled to room temperature, and the organic compound was 
extracted with ethyl acetate (3 × 15 mL). Combined organic layers were washed with brine 
and dried (Na2SO4). The solvent was evaporated under reduced pressure to get a crude 
residue, which was further purified by column chromatography (60-120 mesh Silica gel, 30% 
EtOAc in pet. ether) to afford 26b. A similar procedure was followed for the synthesis of 
compounds 27b-30b. 
 
5.10.3 Typical synthetic procedure for compound 26c 
 
To the stirred solution of compound 26b (0.50 g, 1.66 mmol) in dry THF (5.0 mL), Zn dust 
(1.62 g, 25.00 mmol) and acetic acid (5.0 mL) were successively added under N2 atmosphere 
at 0°C.The mixture was allowed to stir at room temperature for 1.5 h, filtered through a Celite 
bed, and the filtrate was evaporated to remove acetic acid. Thereafter, the reaction mixture 
was neutralised with saturated NaHCO3 and extracted with ethyl acetate (3 × 50 mL). 
Combined organic layers were washed with water and brine solution and dried (Na2SO4). The 
solvent was evaporated under reduced pressure, and the residue was purified by column 
chromatography (60-120 mesh Silica gel; 5% MeOH in CH2Cl2) to afford 26c. A similar 
procedure was followed for the synthesis of compounds 27c-30c. 
 
5.10.4 Typical synthetic procedure for compound 26d 
 
To a cold solution of 26c (200 mg; 0.74 mmol) in dry DMF (5 mL), sodium hydride (58 mg; 
2.44 mmol) was added and stirred at 0 °C for 15 min. Benzyl bromide (0.4 mL; 2.44 mmol) 
was added to the reaction mixture, and the mixture was allowed to stir at room temperature 
for 2 h. The mixture was quenched with water (15 mL) and extracted with ethyl acetate (2 × 
15 mL). Organic extracts were washed with water (10 mL) and brine (10 mL) and dried 
(Na2SO4). The organic extracts were filtered, and the filtrate was concentrated under vacuum 
and at 30 °C. The resulting crude product was purified by Silica gel column chromatography 
to give 23d. A similar procedure was followed for the synthesis of compounds 27d-30d. 
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5.10.5 Typical  synthetic procedure for compound 26e 
 
To a solution of 26d (0.10 g; 40. 9 mmol) in acetic acid (1 mL), a solution of DMSO (0.2 
mL) and 37% concentrated hydrochloric acid (0.2 mL) were added, and the mixture was 
stirred for 9 h.  The reaction mixture was diluted with water and extracted with ether. The 
organic phase was washed with saturated aqueous NaHCO3 and brine and dried (Na2SO4). 
The solvent was evaporated under reduced pressure to give a crude residue, which was 
further crystallised using 10% EtOAc in hexane as a solvent and filtered at its boiling-point 
temperature to remove impurities and thus afford the desired compound as white crystals 26e. 
A similar procedure was followed for the synthesis of compounds 27e-30e. 
 
5.11 Spectral data of compounds 
 
 
 
 
(E)-5-(2-nitrovinyl)benzo[d][1,3]dioxole (27a): A yellow gummy liquid was obtained in 
73% yield. 1H NMR (300 MHz, CDCl3) δ 7.93 (d, J = 13.6 Hz, 1H), 7.47 (d, J = 13.6 Hz, 
1H), 7.13-6.96 (m, 2H), 6.87 (d, J = 8.0 Hz, 1H), 6.06 (s, 2H) ppm. 13C NMR (75 MHz, 
CDCl3) δ 151.53, 148.91, 139.27, 135.53, 126.80, 124.33, 109.22, 107.13, and 102.21 HRMS 
(ESI): calculated for C9H8NO4 [M + H]+ 194.0453; found 194.0464. 
 
 
 
(E)-2-methoxy-4-(2-nitrovinyl) phenol (28a): A yellow gummy liquid was obtained in 78% 
yield.1H NMR (300 MHz, CDCl3) δ 8.57 (s, 1H), 7.83 (d, J = 13.5 Hz, 1H), 7.44 (d, J = 13.5 
Hz, 1H),, 7.03-6.88 (m, 2H), 6.83 (d, J = 8.2 Hz, 1H), 3.81 (s, 3H), 13C NMR (75 MHz, 
CDCl3) δ 151.0, 148.0, 139.9, 134.4, 124.9, 121.7, 115.9, 110.9, and 55.9 HRMS (ESI): 
calculated for C9H10NO4 [M + H]+ 196.0610; found 196.0614 
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(E)-5-(2-nitroprop-1-en-1-yl)benzo[d][1,3]dioxole (30a) : A yellow gummy liquid was 
obtained in 71% yield. 1H NMR (300 MHz, CDCl3) δ 8.01 (s, 1H), 6.95 (m, 3H), 6.04 (s, 
2H), 2.46 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 149.43, 148.40, 146.31, 133.77, 126.38, 
126.06, 109.66, 109.00, 101.91, and 14.29. HRMS (ESI): calculated for C10H10NO4[M + H]+ 
208.0610; found 208.0609. 
 
 
 
 
 
3-(1-(4-Chlorophenyl)-2-nitroethyl)-1H-indole (26b): A yellow solid was obtained in 87% 
yield; mp 112-116 oC; IR (KBr): 3391, 3136, 3050, 2906, 2517, 1906, 1785, 1545, 1379, 
1093, 859, 756, 716 cm-1;  1H NMR (300 MHz, CDCl3) δ 7.91 (s, 1H, NH), 7.25 (d, 1H, J = 
7.9 Hz, ArH), 7.20-6.99 (m, 6H, ArH), 6.94 (t, 1H,  J = 7.4 Hz, ArH), 6.75 (s, 1H, ArH), 4.98 
(t, 1H, J = 7.9 Hz, CH), 4.84 (dd, 1H, J = 12.4, 7.5 Hz, CH), 4.69 (dd, 1H, J = 12.3, 8.7 Hz, 
CH). 13C NMR (75 MHz, CDCl3) δ 137.86, 136.65, 133.59, 129.29, 129.26, 126.04, 123.05, 
121.64, 120.28, 118.96, 114.16, 111.60, 79.43, 77.58, 77.16, 76.74, 41.11.  HRMS (ESI): 
calcd. for C16H14ClN2O2   (M
+ + H) 301.0744 found 301.0728. 
 
 
 
 
 
 
 
3-(1-(Benzo[d][1,3]dioxol-5-yl)-2-nitroethyl)-1H-indole (27b): A white solid was obtained 
in 84% yield; mp 132-136 oC; IR (KBr):3404, 2985, 2904, 2515, 1833, 1549, 1502, 1376, 
1260, 1040, 920, 874, 659 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.02 (s, 1H, NH), 7.33 (m, 
2H, ArH), 7.22-7.07 (m, 1H, ArH), 7.07-6.88 (m, 2H, ArH), 6.80-6.63 (m, 3H, ArH), 5.84 (d, 
2H, J = 5.1, Hz, CH2), 5.09-4.87 (m, 2H, 2 x CH), 4.79 (m, 1H, CH). 
 13C NMR (75 MHz, 
CDCl3) δ 148.21, 147.12, 136.63, 133.15, 126.20, 122.91, 121.36, 121.17, 120.13, 119.12, 
114.69, 111.50, 108.64, 108.31, 101.29, 79.86 41.46. HRMS (ESI): calcd. for C17H15N2O4 
(M+ + H) 311.1032; found 311.1030 
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4-(1-(1H-Indol-3-yl)-2-nitroethyl)-2-methoxyphenol (28b): A brown solid was obtained in 
92% yield; mp 114-118 oC; IR (KBr): 3406, 2967, 2932, 2846, 1616, 1550, 1270, 1212, 1038, 
806, 752 cm-1;   1H NMR (300 MHz, CDCl3) δ 7.97 (s, 1H, NH), 7.31 (m, 1H, ArH), 7.21-
6.90 (m, 3H, ArH), 6.85 (m, 1H, ArH), 6.74-6.67 (m, 3H, ArH), 4.97 (t, 1H, J = 8.0 Hz, CH), 
4.86 (m, 1H, CH), 4.78-4.65 (m, 1H, CH), 3.57 (s, 3H, OMe). 13C NMR (75 MHz, CDCl3) δ 
146.90, 144.94, 136.54, 131.26, 126.14, 122.64, 121.70, 120.33, 119.89, 118.92, 114.72, 
114.46, 111.55, 110.69, 79.81, 55.88, 41.39. HRMS (ESI): calcd. for C17H15ClN2O4 (M
+ + H) 
313.1188; found313.1203.   
 
 
 
 
 
 
3-(1-(4-Chlorophenyl)-2-nitropropyl)-1H-indole (29b): A yellow solid was obtained in 
82% yield; mp 120-124 oC; IR (KBr): 2097, 2755, 1904, 1540, 1540, 1414, 1207, 1095, 1058, 
932, 712, 677 cm-1;  1H NMR (300 MHz, CDCl3) δ 8.03 (s, 1H, NH), 7.52 (s, 1H, ArH), 7.34-
7.20 (m, 3H, ArH), 7.20-7.15 (m, 2H, ArH), 7.15-7.05 (m, 2H, ArH), 7.05-6.90 (m, 1H, 
ArH), 5.42- 5.14 (m, 1H, CH), 4.71 (m, 1H, CH), 1.55-1.43 (d, 3H, J = 6.6 Hz, CH3).  HRMS 
(ESI): calcd. for C17H16ClN2O2 (M
+ + H) 315.0900; found 315.0893. 
 
 
 
 
 
3-(1-(Benzo[d][1,3]dioxol-5-yl)-2-nitropropyl)-1H-indole (30b): A white solid was 
obtained in 78% yield; mp 138-142 oC; IR (KBr): 3414, 2995, 2363, 2341, 1929, 1553, 1475, 
1460, 1417, 1038, 929, 869, 712 cm-1;  1H NMR (300 MHz, CDCl3) δ 7.83 (m, 1H, NH), 7.39 
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(m, 1H, ArH), 7.20 -6.86 (m, 4H, ArH), 6.83 -6.64 (m, 2H, ArH), 6.57 (m, 1H, ArH), 5.79 -
5.58 (m, 2H, CH2), 5.27 -5.04 (m, 1H, CH), 4.59 (m, 1H, CH), 1.38 (d, 3H, J = 8.2 Hz 
CH3).HRMS (ESI): calcd. for C18H17N2O4 (M
+ + H) 325.1188; found 325.1200.  
 
 
 
 
 
 
N,N-Dibenzyl-2-(1-benzyl-1H-indol-3-yl)-2-(4-chlorophenyl)ethan-1-amine (26d): A 
yellow solid was obtained in 91% yield; mp 112-116 oC; IR (KBr): 3086, 3060, 3030, 2795, 
2341, 1492, 1452, 1384, 1197, 975, 816, 732, 699 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.32-
7.17 (m, 6H, ArH), 7.13 (m, 8H, ArH), 7.06 (d, J = 6.7, 2.9 Hz, 4H), 7.00 (dt, J = 7.5, 2.9 Hz, 
4H, ArH), 6.90 (m, 1H, ArH), 6.67 (s, 1H, ArH), 5.15 (d, J = 3.6 Hz, 2H, CH2), 4.51-4.36 (m, 
1H, CH), 3.65 (m, 2H, CH2), 3.44 (s, 2H, CH2 ), 3.13 -2.85 (m, 2H, CH2). 
13C NMR (75 
MHz, CDCl3) δ 142.79, 139.60, 137.88, 136.84, 131.73, 129.98, 129.08, 128.88, 128.72, 
128.41, 128.31, 128.25, 127.76, 127.66, 126.96, 126.69, 125.93, 121.94, 119.59, 119.18, 
117.00, 109.79, 77.58, 77.36, 77.16, 76.74, 59.56, 59.06, 50.06, 40.87. HRMS (ESI): calcd. 
for C37H34ClN2 (M
+ + H) 541.2411; found 541.2287. 
 
 
 
 
 
 
 
2-(Benzo[d][1,3]dioxol-5-yl)-N,N-dibenzyl-2-(1-benzyl-1H-indol-3-yl)ethan-1-amine 
(27d): A white solid was obtained in 89% yield; mp 135-139 oC; IR (KBr): 2992, 2927, 2369, 
1914, 1836, 1505, 1109, 1043, 937, 896, 710, 646, 614 cm-1; 1H NMR (300 MHz, CDCl3) δ 
7.19 (m, 4H, ArH), 7.14-7.02 (m, 11H, ArH), 6.97 (m, 3H, ArH), 6.86 (t, J = 7.4 Hz, 1H, 
ArH), 6.61 (t, J = 6.8 Hz, 3H, ArH), 6.48 (s, 1H, ArH), 5.84-5.68 (m, 2H, CH2), 5.16-4.97 
(m, 2H, CH2), 4.37 (t, J = 7.4 Hz, 1H, CH), 3.50 (m, 4H, CH2), 3.03 (m, 1H, CH), 2.84 (m, 
1H, CH); 13C NMR (75 MHz, CDCl3) δ 147.53, 145.86, 139.73, 138.35, 137.97, 136.80, 
129.51, 129.16, 128.82, 128.18, 127.93, 127.56, 126.89, 126.65, 125.93, 121.77, 121.64, 
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119.71, 119.04, 117.38, 109.67, 108.86, 107.90, 100.80, 77.58, 77.36, 77.16, 76.74, 59.77, 
59.00, 49.96, 41.17, 29.83, 1.17. HRMS (ESI): calcd. for C38H33N2O2 (M
+ + H) 551.2699; 
found 551.2710. 
 
 
 
 
 
 
 
 
N,N-Dibenzyl-2-(1-benzyl-1H-indol-3-yl)-2-(3-methoxy-4-phenoxyphenyl)ethan-1-amine 
(28d): A brown solid was obtained in 93% yield; mp 143-147 oC; IR (KBr): 2992, 2863, 
2376, 1836, 1510, 1462, 1159, 896, 788 cm-1;  H NMR (300 MHz, CDCl3) δ 7.36 (d, J = 7.3 
Hz, 2H, ArH), 7.31-7.12 (m, 7H, ArH), 7.11-6.81 (m, 15H, ArH), 6.65 (m, 4H, ArH), 5.07 
(m, 4H, CH2), 4.38 (t, J = 7.2 Hz, 1H, CH), 3.63 (s, 5H, CH3, CH2), 3.41 (s, 2H, CH2), 2.97 
(m, 2H, CH2).
13C NMR (75 MHz, CDCl3) δ 149.43, 146.54, 139.83, 137.98, 137.67, 137.58, 
136.81, 129.03, 128.79, 128.66, 128.60, 128.37, 128.15, 127.93, 127.83, 127.56, 127.43, 
127.07, 126.83, 126.63, 125.75, 121.78, 120.59, 119.78, 119.02, 117.64, 114.04, 112.40, 
109.65, 59.80, 58.96, 55.90, 49.93, 41.12, 29.81. HRMS (ESI): calcd. for C45H43N2O2 (M
+ + 
H) 643.3325; found 643.3362. 
 
 
 
 
 
 
N,N-Dibenzyl-2-(1-benzyl-1H-indol-3-yl)ethan-1-amine (31d): A yellow syrup was 
obtained in 82% yield; IR (KBr): 3086, 3060, 3030, 2795, 2341, 1492, 1452, 1384, 1197, 
975, 816, 732, 699 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.38 (dd, J = 7.2, 4.6 Hz, 6H, ArH), 
7.33-7.17 (m, 10H, ArH), 7.11 (m, 3H, ArH), 7.02 (t, J = 7.4 Hz, 1H, ArH), 6.83 (s, 1H, 
ArH), 5.23 (s, 2H, CH2), 3.68 (s, 4H, CH2), 3.05-2.91 (m, 2H, CH2), 2.82 (dd, J = 8.8, 6.0 Hz, 
2H, CH2). 
13C NMR (75 MHz, CDCl3) δ 140.07, 137.96, 136.70, 128.93, 128.84, 128.56, 
128.40, 128.29, 127.94, 127.79, 127.62, 126.90, 126.89, 125.88, 121.70, 119.21, 118.91, 
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113.90, 109.63, 72.27, 58.52, 54.13, 49.95, 23.25. HRMS (ESI): calcd. for C30H30N2 (M
+ + 
H) 431.2487; found 431.2487. 
 
 
 
 
 
 
 
 
1-Benzyl-3-(2-(dibenzylamino)ethyl)indolin-2-one (31e): A yellow solid was obtained in 
87% yield; mp 112-116 oC; IR (KBr): 2959, 2924, 2371, 1906, 1785, 1545, 1379, 1093, 859, 
756, 716 cm-1;  1H NMR (300 MHz, CDCl3) δ 7.32 - 7.09 (m, 15H, ArH), 7.07 - 6.91 (m, 1H, 
ArH), 6.76 - 6.63 (m, 1H, ArH), 6.55 (t, J = 8.5 Hz, 2H, ArH), 4.87 - 4.68 (m, 2H, CH2), 3.68 
(m, 2H, CH2), 3.56 (dd, J = 7.7, 5.1 Hz, 1H, CH), 3.40 (m, 2H, CH2), 2.73 - 2.48 (m, 2H, 
CH2), 2.26 (m, 1H, CH), 1.97 - 1.74 (m, 1H, CH). 
13C NMR (75 MHz, CDCl3) δ 178.10, 
143.15, 136.01, 129.21, 129.07, 128.67, 128.21, 127.47, 127.26, 126.91, 123.95, 122.11, 
108.73, 58.17, 49.91, 43.61, 43.03, 28.90. HRMS (ESI): calcd. for C31H30N2O (M
+ + H) 
447.2436; found 447.2400. 
 
 
 
 
 
 
 
N,N-Dibenzyl-1-(1-benzyl-1H-indol-3-yl)-1-(4-chlorophenyl)propan-2-amine (29d): A 
yellow syrup was obtained in 87% yield as a mixture of diastereomers (1:1) ratio; IR (KBr): 
2967, 2813, 2341, 1949, 1548, 1472, 1401, 1348, 1149, 1003, 954, 838 cm-1;  mp 165-170 
oC;HRMS (ESI): calcd. for C38H36ClN2 (M
+ + H) 555.2567; found 556.2599. 
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1-(Benzo[d][1,3]dioxol-5-yl)-N,N-dibenzyl-1-(1-benzyl-1H-indol-3-yl)propan-2-amine 
(30d):  A white solid was obtained in 82% yield as a mixture of diastereomers; mp 125-130 
oC; IR (KBr): 2967, 2876, 2916, 2765, 1601, 1500, 1487, 1227, 952, 859, 780 cm-1; HRMS 
(ESI): calcd. for C39H37N2O2 (M
+ + H) 565.2855; found 565.2865. 
 
 
 
 
 
 
 
1-Benzyl-3-(1-(4-chlorophenyl)-2-(dibenzylamino) ethyl)indolin-2-one (26e): A yellow 
solid was obtained in 87% yield as a mixture of (7:3) ratio diastereomers; mp 174-178 oC; IR 
(KBr): 2959, 2924, 2371, 1906, 1704, 1906, 1704, 1265, 1162, 1058, 929, 755, 677 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 7.35-7.13 (m, 10.3H), 7.15-7.00 (m, 3H), 6.99-6.78 (m, 3.5H), 
6.61 (m, 3.2H), 6.51-6.37 (m, 1.39H), 6.36-6.09 (m, 1.6H), 4.96 (m, 1H), 4.18 (m, 2H), 3.84 
(m, 2.7H), 3.69-3.50 (m, 0.8H), 3.41 (d, 1.4H), 3.19 (m, 1H), 2.99 (m, 0.3H), 2.71 (m, 0.7H); 
13C NMR (75 MHz, CDCl3) δ 177.05, 175.92, 143.60, 139.66, 138.93, 136.98, 135.09, 
132.71, 130.35, 129.51, 129.22, 128.49, 128.33, 128.03, 127.84, 127.25, 126.72, 126.47, 
126.23, 125.00, 121.88, 59.90, 58.67, 55.46, 48.11, 45.02, 43.20;  HRMS (ESI): calcd. For  
C37H33ClN2O (M
+ + H) 557.2360; found 557.2356. 
 
 
 
 
 
 
 
3-(1-(Benzo[d][1,3]dioxol-5-yl)-2-(dibenzylamino)ethyl)-1-benzylindolin-2-one (27e): A 
yellow solid was obtained in 82% yield as a mixture of (7:3) ratio of enantiomers; mp 185-
188 oC; IR (KBr): 2959, 2924, 2851, 2371, 1906, 1704, 1609, 929, 755, 652cm-1; 1H NMR 
(300 MHz, CDCl3) δ 7.34-7.18 (m, 9.7H), 7.15-6.99 (m, 3.1H), 6.99-6.68 (m, 2.2H), 6.56 (m, 
2.15H), 6.43 (m, 1.0H), 6.40-6.17 (m, 2.2H), 6.09 (m, 1.4H), 5.73 (m,1.9H), 5.00 (m, 1.H), 
4.37 (m, 0.3H), 4.20 (m, 1H), 4.12-4.00 (m, 0.9H), 4.00-3.74 (m, 2.7H), 3.74-3.51 (m, 1H), 
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3.38 (m, 1.4H), 3.28-3.09 (m, 1H), 2.89 (m, 0.3H), 2.65 (m, 0.7H);  13C NMR (75 MHz, 
CDCl3) δ 177.26, 146.99, 146.43, 143.59, 139.74, 139.05, 135.46, 132.36, 129.57, 129.24, 
128.43, 128.37, 128.30, 127.69, 127.21, 127.12, 126.87, 126.63, 124.98, 122.51, 121.86, 
109.10, 108.89, 107.77, 100.69, 59.86, 58.52, 55.87, 48.20, 45.21, 43.28; HRMS (ESI): 
calcd. for C38H34N2O3 (M
+ + H) 567.2648; found 567.2681. 
 
 
 
 
 
 
 
3-(1-(Benzo[d][1,3]dioxol-5-yl)-2-(dibenzylamino)ethyl)-1-benzylindolin-2-one(28e):       
A yellow solid was obtained in 84% yield as a mixture of (8:2) ratio of enantiomers; mp 140-
144 oC; IR (KBr): 2964, 2927, 2343, 1710, 1611, 1515, 1265, 1220, 1035, 924, 790, 752, 614 
cm-1;  1H NMR (300 MHz, CDCl3) δ 7.32 (d, J = 7.4 Hz, 2H), 7.29-7.15 (m, 10.2H), 7.14 
(s,.8H), 7.11-6.92 (m, 3.3H), 6.95-6.78 (m, 1.5H), 6.68-6.61 (m, 0.5H), 6.61-6.47 (m, 1.8H), 
6.47-6.38 (m, 1.5H), 6.38-6.25 (m, 1.3H), 6.21 (m, 1.8H), 6.00 (m, 0.8H), 5.05-4.90 (m, 
2.7H), 4.84 (d, 0.3H), 4.35 (m, 0.2H), 4.19 (m, 1H), 4.04 (m, 0.8H), 3.92-3.71 (m, 2.7H), 
3.72-3.51 (m, 0.8H), 3.49-3.29 (m, 2.3H), 3.26-3.08 (m, 3.3H), 2.96 (m, 0.2H), 2.79-2.62 (m, 
0.8H); 13C NMR (75 MHz, CDCl3) δ 177.36, 176.38, 148.77, 147.28, 143.86, 139.86, 139.16, 
137.32, 135.24, 131.50, 129.54, 129.23, 128.47, 128.30, 127.85, 127.36, 127.18, 127.06, 
126.69, 126.45, 124.96, 121.70, 121.59, 113.05, 112.17, 70.84, 58.62, 56.12, 55.55, 48.33, 
45.30, 43.25. HRMS (ESI): calcd. for C45H43N2O3 (M
+ + H)659.3274; found 659.3262. 
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6.1 Concluding statements 
 
The present stufy has found a novel ZrCl4-catalysed method for the conversion of diverse 
benzyl carbinols into the corresponding azides using TMSN3 as an azide source. This is an 
advantageous and attractive strategy for the direct preparation of azides from alcohols. 
Synthesised azides were further converted into 1,2,3-triazole derivatives using Click 
chemistry (Chapter 2).  
 
Triazoles are five-membered aromatic rings that contain three nitrogen atoms in it. They 
display diverse biological activities by binding with a variety of receptors and enzymes in a 
biological system through non-covalent interactions. Triazole compounds are more potent 
and less toxic in nature. The present study was initiated for the synthesis of novel triazole 
derivatives for the treatment of various diseases. Thus, diverse azide scaffolds were 
synthesised and converted into various triazole analogues using different acetylenes. 
Thereafter, antimicrobial properties of the synthesised azides and triazole analogues were 
investigated, and interesting results were found about these compounds.  
 
 In view of the above results, the research continued to evaluate more potent triazole 
analogues with a rational approach. Therefore, rolipram was chosen as a basic skeleton to 
prepare various triazole analogues (Chapter 3). Rolipram is a PDE4 drug that has many 
biological properties such as anti-inflammatory and anti-tumour properties. To synthesise 
rolipram-based triazole analogues, vanillin and isovanillin were selected as starting materials. 
Thus, the triazole scaffolds were designed, synthesised and screened for anticancer activity 
against several human cancer cell lines, of which two exhibited significant anticancer activity 
against breast-cancer cell lines.  
 
For further development of the aforementioned methodology, aryl vinyl cabinols were 
investigated for direct azidation using ZrCl4 as a Lewis acid catalyst. Azide synthesis from 
aryl vinyl carbinols was found to occur through a novel rearrangement of the double bond to 
produce allyl azides.  The synthetic strategy was utilised to prepare sugar allyl azides from 
corresponding sugar aryl vinyl carbinols, for the reason that the non-natural amino acids are 
of great potential in the drug discovery. (Chapter 4). Thus, the synthesised allyl azides were 
converted into a rare class of non-natural γ4-amino acids, and attempts were made to prepare 
γ2- and γ3-amino acids.  
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The last section of the research involved the preparation of selective tryptamine derivatives 
that were screened for TRPV3 agonist activity (Chapter 5). For this study, N,N-dibenzyl 
tryptamine was chosen as a model structure for preparing analogues. The synthesis was 
initiated with nitrostyrenes as starting materials. Nitrostyrenes were converted to Michael 
adducts using indoles in aqueous media. Michael adducts were reduced to amines using Zinc 
metal as a reducing agent. Thereafter, they were benzylated with NaH and benzyl bromide, 
which were further oxidised to prepare oxyindoles. The synthesised compounds were 
investigated for TRPV3 agonist activity, and the results indicated that the compouds were 
less potent in TRPV3 agonist activity and suggested that activity can be improved further by 
making some other changes in the five synthesised compounds. 
 
6.2 Future work 
 
The alcohol functionality is an important precursor of electrophile for the generation of 
diverse-bond formations. From the advantage of the developed methodology, i.e. ZrCl4-
catalysed direct formation of the C-N bond from the C-O bond, generation of C-C and C-S 
bonds from alcohols was proposed. In the preparation of more potent compounds, the 
developed synthetic methodology could be extended to the preparation of novel dissimilar 
bis-triazole products and the study of their anti-microbial and anti-cancer properties. 
 
Peptides have gained significant applications in the medicinal field. Thus, the design and 
synthesis of non-natural oligomers and their biological evaluation along with the study of 
novel secondary structures are of great interest in the field. The coupling of non-natural γ-
amino acids to homo-oligomers by iterative coupling could generate di, tri-, tetra-, penta- and 
hexapeptides. This approach could be extended to prepare hybrid and cyclic peptides. NMR 
studies could enable other structural features such as helices, sheets and ribbons in the novel 
peptides. 
 
The present study provides the groundwork for the synthesis of natural poly-hydroxylated 
pyrrolidine alkaloids that contain various substituents such as (-)-codonopsinine and (-)-
codonopsine. These natural products display antibiotic and hypotensive activities without 
affecting the central nervous system in animal studies.
 
 Similarly, (+) radicamine A and (+) 
radicamine B are other synthetic targets. These compounds can be synthesised through a 
novel synthetic approach using benzyl azides as key intermediates. The research on TRPV3 is 
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still required to make them as good targets for pain thrapy. Diverse substituents on indole and 
benzyl ring in N, N - benzyl tryptamine can be synthesised and their properties studied as a 
TRPV3 agonist. 
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Appendix 
 
 
General experimental conditions 
1. Nuclear Magnetic Resonance spectra were recorded on Bruker Avance-600 MHz,  
Varian Unity Inova-500 MHz, Bruker Avance-300 MHz and Varian-200 MHz spectrometer using 
tetramethylsilane (TMS) as the internal standard. Chemical shifts have been expressed in (δ) ppm 
units downfield from TMS. Selected data are reported as follows. Chemical shifts, multiplicity (s 
= singlet, d = doublet, t = triplet, q = quartet,   m = multiplet, br = broadened, dd = doublet of 
doublet, dt = doublet of triplet, td = triplet of doublet), coupling constants (J in Hz) and 
assignments. 
 
2 Liquid Secondary Ion Mass Spectra (LSIMS/FABMS) were recorded with a VG   AUTOSPEC-M 
mass spectrometer at an acceleration voltage of 7 kV. Meta-Nitro benzyl alcohol (MNBA) was 
used as matrix. 
 
3. Infra-red spectroscopy was recorded on a Perkin-Elmer Instrument. 
4. Optical rotations were measured using a Jasco Dip 300 digital polarimeter at 20-27 °C. 
5. Melting points were determined using a Fisher-Johns melting point apparatus and are uncorrected. 
 
7. All evaporations were carried out under reduced pressure on Buchi rotary evaporator or Heidolph 
rotary evaporator at below 45 °C. 
 
8. All solvents and reagents were purified and dried by standard techniques. 
10. All non-aqueous reactions were carried out under nitrogen (N2) atmosphere using dry, freshly 
distilled solvents unless otherwise noted. Yields refer to chromatographically and 
spectroscopically homogeneous materials isolated unless otherwise stated. 
 
11. Nomenclature mentioned in the experimental section was adopted from Chem office  
 Ultra-Cambridge software/ Name version 10.0, Cambridge software, UK. 
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NMR and HRMS Spectra of selected compounds  
 
(Page number from 167 to 295) 
12. Room temperature = 25-27 °C. 
 
13. Petroleum ether boiling point is 65-70 °C. 
14. ‘Brine’means saturated aqueous NaCl solution. 
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                        1
H NMR Spectrum of 6 (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 6(75 MHz, CDCl3, 295K). 
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5060708090100110120130140
                           1
H NMR Spectrum of 6a (500 MHz, CDCl3, 295K). 
                   
13
C NMR  Spectrum of 6a (75 MHz, CDCl3, 295K). 
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HRMS Spectrum of compound 6a 
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0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
                      1
H NMR Spectrum of 6b (300 MHz, CDCl3, 295K). 
                
13
C NMR  Spectrum of 6b (75 MHz, CDCl3, 295K). 
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HRMS Spectrum of compound 6b 
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Figure S1: 
1
H NMR Spectrum of 9 (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 9 (75 MHz, CDCl3, 295K). 
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Figure S2: 
1
H NMR Spectrum of 11 (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 11 (75 MHz, CDCl3, 295K). 
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Figure S3: 
1
H NMR Spectrum of 13a (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 13a (75 MHz, CDCl3, 295K). 
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Figure S4: 
1
H NMR Spectrum of 8b (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 8b (75 MHz, CDCl3, 295K). 
 
213 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
2030405060708090100110120130140150
Figure S5: 
1
H NMR Spectrum of 5 (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 5 (75 MHz, CDCl3, 295K). 
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Figure S6: 
1
H NMR Spectrum of 7 (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 7 (75 MHz, CDCl3, 295K). 
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Figure S7: 
1
H NMR Spectrum of 13a (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 13a (75 MHz, CDCl3, 295K). 
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Figure S8: 
1
H NMR Spectrum of 13b (300 MHz, CDCl3, 295K). 
                  
13
C NMR Spectrum of 13b (125 MHz, CDCl3, 295K). 
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Figure S9: 
1
H NMR Spectrum of 9a (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 9a (75 MHz, CDCl3, 295K). 
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Figure S10: 
1
H NMR Spectrum of 11a (500 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 11a (75 MHz, CDCl3, 295K). 
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Figure S11: 
1
H NMR Spectrum of 15a (500 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 15a (75 MHz, CDCl3, 295K). 
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Figure S12: 
1
H NMR Spectrum of 15b (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 15b (75 MHz, CDCl3, 295K). 
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Figure S13: 
1
H NMR Spectrum of 10a (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 10a (75 MHz, CDCl3, 295K). 
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Figure S14: 
1
H NMR Spectrum of 12a (500 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 12a (75 MHz, CDCl3, 295K). 
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Figure S15: 
1
H NMR Spectrum of 15a (300 MHz, CDCl3, 295K). 
                   
13
C NMR Spectrum of 15a (75 MHz, CDCl3, 295K). 
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Figure S16: 
1
H NMR Spectrum of 15b (300 MHz, CDCl3, 295K). 
                  
13
C NMR Spectrum of 15b (125 MHz, CDCl3, 295K). 
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X-Ray crystagraphy data for 29a 
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X-Ray crystagraphy data for 27b 
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Activity results of synthesized compounds against HEK293 cells (non-transfected cells) 
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Activity results of synthesized compounds against TRPV3 HEK293 cells 
 
 
 
 
 
 
 
